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Abstract 
The aim of this work is to further understanding into the biological bases of 
human executive control through an integration of neuropsychology, 
psychopharmacology and functional imaging. Executive control includes the 
prototypical executive functions of response inhibition and error awareness. 
Response inhibition can be further divided into action cancellation and action 
restraint, which were assayed with the stop signal (SST) and Error Awareness 
(EAT) tasks, respectively. The EAT, which is a modified go-no go paradigm, 
was also used to measure error awareness behaviour. Monoamine 
neurotransmitters, specifically dopamine, noradrenaline and serotonin, were 
modulated during task performance with acute doses of methylphenidate (a 
dopamine and noradrenaline reuptake inhibitor), atomoxetine (a noradrenaline 
reuptake inhibitor), citalopram (a serotonin reuptake inhibitor) and cabergoline 
(a D2 agonist). The pharmacoimaging correlates of task performance were 
also examined with functional magnetic resonance imaging (fMRI). All 
experiments adhered to a randomised, double blind, placebo-controlled, 
crossover design and were limited to 18-35 year old healthy right-handed 
male participants. 
 
In Chapter 1, twenty-four (24) participants received acute doses of 
methylphenidate (30mg), atomoxetine (60mg), citalopram (30mg) and placebo 
and performed the SST. Methylphenidate, but not atomoxetine or citalopram, 
led to a reduction in response time variability and stop-signal reaction time 
indicating enhanced action cancellation compared with the other drug 
conditions. This enhancement occurred without change to overall response 
speed suggesting that methylphenidate was modulating core response 
inhibition processes rather than simply augmenting overall processing speed. 
This result argued for the prominence of dopaminergic, rather than adrenergic 
or serotonergic, mechanisms in action cancellation.  
 
 In Chapter 2, the pharmacoimaging correlates of action restraint aspect were 
explored. Twenty-seven (27) males received acute doses of methylphenidate 
(30mg), atomoxetine (60mg), citalopram (30mg) and placebo whilst 
undertaking the EAT during fMRI. No-go related BOLD activations were then 
correlated for each of the drug conditions. Although Inhibitory performance 
under methylphenidate was numerically superior to the other drug conditions, 
this difference did not achieve statistical significance. On fMRI, 
methylphenidate activated, versus placebo, the anterior cingulate cortex, right 
inferior frontal, left middle frontal, left angular and right superior temporal gyri 
and right caudate. Atomoxetine activated a broad network of cortical regions. 
Both methylphenidate and atomoxetine, but not citalopram, activated superior 
temporal, right inferior frontal and left middle frontal clusters. Citalopram only 
activated the left inferior occipital lobe. Taking each condition’s activations as 
functionally defined regions of interest, the specificity of no-go related activity 
was compared across the four conditions. Only methylphenidate 
demonstrated drug specific effects through increased activation of the anterior 
cingulate and decreased activation of the caudate. A direct comparison of 
methylphenidate and atomoxetine showed a similar recruitment in prefrontal 
regions but specific effects of methylphenidate in the anterior cingulate and 
caudate. This further supported the notion that dopaminergic processes were 
making a specific and dissociable contribution during response inhibition.  
 
In Chapter 3 the pharmacoimaging correlates of error awareness were 
examined using the EAT. This study examined the fMRI data obtained whilst 
testing the cohort described in Chapter 2. Methylphenidate, but not 
atomoxetine or citalopram, significantly improved error awareness behaviour 
during the EAT. Methylphenidate, versus the other drug conditions, was also 
associated with specific BOLD activation differences in the dorsal anterior 
cingulate cortex and inferior parietal lobe for errors made with versus without 
awareness. These findings suggested that dopaminergic, rather than 
noradrenergic or serotonergic, mechanisms might also be important during 
error awareness. Accordingly, the final experiment in this thesis sought to 
examine specific dopamine receptor mechanisms of executive control.  
 
 In Chapter 4 the role of the D2 receptor during response inhibition and error 
awareness was explored. Twenty-five (25) males received acute doses of 
cabergoline (1.25mg) and placebo before undertaking the SST and EAT. 
During the SST cabergoline was able to selectively reduce stop signal 
reaction time without a concomitant effect on reaction time variability or 
overall response speed. Cabergoline was, however, unable to improve action 
restraint in the go no-go component of the EAT. This suggested a specific and 
dissociable role for the D2 receptor in the action cancellation but not action 
restraint, which was consistent with the findings of Chapters 1 and 2. 
Cabergoline was also able to enhance the conscious perception of errors 
during the EAT, suggesting D2 mechanisms during error awareness, which 
was supportive of the findings in Chapter 3.  
 
In summary, this series of experiments showed that dopaminergic, and 
potentially D2, mechanisms are specifically implicated in the neurobiology of 
human executive control. Further experiments with more specific D2 agents, 
combined imaging paradigms and refined task design would extend these 
findings. 
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Introduction!!
Executive control: an overview  
 
Executive control, also referred to as cognitive control, is the ‘supervisory function’ that 
maintains goal-focused behaviour when one is faced with competing or ambiguous 
choices (1). Executive control likely evolved in response to the large amounts of sensory 
and cognitive data generated by rapidly changing environments that present many options 
for potential courses of action (1). Although a wealth of data allows for great flexibility in 
responding, it also carries the risk of confusion and loss of overall purpose. Executive 
control guards against this. The evolutionary advantage conferred by executive control is 
evidenced by its functional and neurobiological conservation across a broad range of 
species, including humans (2). Acknowledging its fundamental importance to purposeful 
behaviour, scholars have studied its underlying mechanisms from ancient times to the 
present.  
 
Plato, using the allegory of a charioteer’s final destination being determined by the pulling 
of two horses of different character (3), anticipated one contemporary notion of executive 
control, “Processing in the brain is competitive… different pathways, carrying different 
sources of information, compete for expression in behaviour with the winner being that 
with the strongest support” (1). Executive control is not, therefore, a singular neurological 
mechanism but several, at times competitive, processes that include inhibition, attention, 
selection, set shifting, performance monitoring and working memory (4). Yet to execute 
goals these processes must also sometimes work in concert. For example, monitoring for 
changes in the environment might cue the inhibition of one set of responses and prompt 
switching to a more appropriate set. This repeated interaction of attention, inhibition and 
cognitive flexibility could then generate external and internal feedback to facilitate 
performance monitoring so that the alignment of goals with changing environmental 
conditions is continually optimised. Executive control can therefore be described as a ‘top 
down’ form of processing, in that a consciously held goal continually drives and refines 
behaviour via loosely mapped feedback relationships between sensory data, executive 
processes and motor responses (1). The flexibility of this mapping confers the critical 
advantage of executive control, that is, the ability to consciously select a ‘weaker’ goal-
relevant response in the face of unconscious bias towards a ‘stronger’ but goal-irrelevant 
choice (5, 6).  
 
This thesis examines two components of the executive control process -response 
inhibition and error awareness, which, conceptually, can both be thought of as facilitating 
goal-focused behaviour via ‘threshold’ models but at differing time points (3, 7). In the case 
of response inhibition, motor responses that are irrelevant to the goal are kept at a state of 
elevated threshold for activation, whilst the threshold for goal relevant responses is 
lowered to increase the likelihood of success (3). With error awareness, when 
accumulating external and internal cues regarding performance reach a given threshold a 
conscious perception that prior behaviour has not met goals can emerge (8). In both cases 
an event that is consistent with overall goal, that is salient, triggers the response after 
meeting specific criteria. Yet response inhibition and error awareness necessarily occur at 
differing time points during executive control behaviour. For example, it is only after a 
failure of response inhibition that there is a requirement for error detection and awareness 
of that error, , which in turn informs future inhibitory responses. This thesis sought to 
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examine how these two conceptually comparable but temporally dissociable components 
map to neurochemical signalling and neuroanatomical networks, and whether their 
theoretical similarities and differences are recapitulated in underlying neurobiology. 
Accordingly, this Introduction first surveya the respective neuropsychology, 
neurochemistry, functional imaging and clinical relevance of response inhibition and error 
awareness as prelude to the experiments that probed these questions.  
  
The neuropsychology of response inhibition 
 
Response inhibition can be defined as the ability to stop a pre-potent, observable, motor 
behaviour in response to a stop stimulus (3). Choice is central to this notion, in that one 
behaviour can be chosen over another, such as stopping instead of going, when there are 
conflicting options. The timing of when the behaviour needs to be stopped, however, 
relative to the stop stimulus, allows response inhibition to be divided into two 
subcategories -action cancellation and action restraint (9). Alternative names for Eagle et 
al.’s subcategorisations have included stopping versus waiting (10), hot versus cool 
inhibition (11) and motor versus choice inhibition (12). Regardless of name, a range of 
human and animal experimental studies now support the validity of distinguishing between 
action cancellation and restraint behaviour (13-15). In these experiments action 
cancellation and action restraint have frequently been assayed with two classic 
neuropsychological paradigms –the stop signal task (SST) and go no-go task (GNG) task, 
respectively (9).  
 
In both the SST and GNG the pre-potency, or dominance, of ‘go’ behaviour is established 
by presenting many more ‘go’ stimuli than ‘stop’ stimuli. The essential difference between 
the two tasks, however, is the timing of when the stop stimulus is presented. In the GNG 
task the stop stimulus is presented, unexpectedly, instead of the prepotent go stimulus. 
Accordingly, an action ‘restraint’ is required because the subject must immediately restrain 
the behavioural response (’no-go’) before commencing with the established tendency to 
‘go’. In the SST, however, the stop stimulus is presented only after the subject has 
commenced the ‘go’ action necessitating a ‘cancellation’. Hence both tasks assay 
response inhibition but at differing time points relative to their respective stop stimuli (2, 9). 
Another way of conceptualising these differences is that in the GNG task the stop stimulus 
is an alternative to the go stimulus, whereas in the SST the stop stimulus is an additional 
requirement to the go stimulus. Thus the GNG task can be said to measure the inhibition 
of a prepotent response that requires rapid decision making between opposing actions, 
whereas the SST measures the inhibition of a commenced action without a comparable 
decision as the go stimulus is always initiated (3). Accordingly, we used variants of the 
both the SST and GNG to probe the neurobiology of response inhibition, which are 
detailed further in the ‘General Methods’ appendix.  
 
The usage of tasks such as the SST and GNG is appealing due to their relative ease of 
application, objectivity and quantitative data outputs (16, 17). The availability of analogous 
tasks for laboratory animals has also allowed modulations that would not otherwise be 
available in humans (2). In support of the evolutionary conservation of response inhibition, 
humans and laboratory animals show similar brain area activation and behavioural effects 
following pharmacological manipulation, suggesting that such assays are valid biological 
models (2). One of the problems with the SST and GNG, however -though equally 
applicable to all tasks in cognitive neuroscience, is that for successful task completion a 
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broad range of ancillary cognitive processes must be intact beyond that which is being 
studied (18). For example, the SST requires both sustained attention and action 
cancellation to successfully complete a stop trial, and in the EAT working memory is 
required to successfully inhibit during repeat no-go. It has been argued, however, that 
rather than invalidating its theoretical components this reflects the multidimensional and 
interdependent nature of executive control (3).  
 
Behavioural tasks are not the only method of assessing response inhibition, or its 
antithesis, impulsivity. Several questionnaires have been developed for assessing 
impulsivity that are used in both research and clinical environments. In this thesis the 
Barrett Impulsiveness Scale (BIS and Connors’ Adult ADHD Rating Scale Self Report 
Long version (CAARS–S:L) were employed to assess trait impulsivity (19, 20). Trait 
impulsivity refers to that driven by pre-existing personality characteristics, as opposed to 
state impulsivity, which is driven by environmental conditions (3). Questionnaires, 
however, remain problematic due to recall bias, poor cross cultural applicability and 
questionnaire words having different meanings to different people (3). There is also only a 
low correlation between the results of self-report impulsivity questionnaires and response 
inhibition behavioural tasks (14, 18, 21-26), however, there is a study showing an 
association between BIS and a GNG task and another showing linkage between the SST 
and the BIS motor subscale (27, 28). Nonetheless, the generally low correlation might be 
because impulsive tendencies are inherently unpredictable and often driven by the 
subject’s anxiety, anger or desire state (29). To monitor this potential confound we 
measured our subjects’ emotional states during behavioural testing with the Visual 
Analogue Scale, a 16-item rating battery measuring alertness, contentedness, and 
calmness (30). We also excluded subjects that had a history of psychiatric disorder. This 
was an essential consideration because since at least the 19th century a higher incidence 
of response inhibition deficits has been known to occur in psychiatric populations.  
 
Disordered response inhibition in clinical populations 
 
In 1876, David Ferrier, a pioneering neurologist at the West Riding Lunatic Asylum, 
observed response inhibition failure in his patients and concluded, “If the centres of 
inhibition are weak, or present impulses unusually strong, volition is impulsive rather than 
deliberate in nature” (3). It has since been demonstrated that impulsive behaviour is 
indeed present across a range of psychiatric populations including those with 
schizophrenia (31), substance dependence (32), personality disorder (33), major 
depression (34), obsessive-compulsive disorder (OCD) (35) and attention deficit 
hyperactivity disorder (ADHD) (36). Response inhibition impairments are not benign and 
have been associated with higher rates of violence, drug addiction and suicide (37, 38),  
 
ADHD has been of particular interest in the study of response inhibition as impulsivity is a 
core feature of the condition (36). Indeed response inhibition neurobiology is thought to 
represent an endophenotype, or proxy, for understanding the mechanisms that underlie 
ADHD (39) as ADHD patients show deficits of both action cancellation and action restraint 
behavioural tasks (9). In addition, relatives of ADHD patients also perform more poorly 
than controls on the SST and GNG suggesting that response inhibition deficits are 
heritable traits with shared genetic precursors (40, 41). Importantly, these deficits can be 
ameliorated with ADHD medications in both ADHD patients and healthy controls (42). 
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Similar observations have been made for medications used in schizophrenia and major 
depression (34, 43), suggesting a broad range of compounds that could be used as 
neurochemical probes for exploring response inhibition neurobiology. Many of these 
compounds can also be used in both animals and humans and because the SST and 
GNG translate well between species (2) there have been a range of cross-species studies 
that correlate behavioural performance, neurochemical modulation and imaging. Following 
in this tradition, the roles of the neurotransmitters dopamine, noradrenaline and serotonin 
in human response inhibition neurobiology are discussed below. 
 
The neuropharmacology of response inhibition 
 
The noradrenaline and dopamine reuptake inhibitors methylphenidate and amphetamine, 
which are established treatments for ADHD (2), have frequently been combined with the 
GNG and SST to probe response inhibition (3). These stimulant drugs consistently 
modulate performance across a diverse range of species and populations (44-49). For 
example, methylphenidate improves SST performance in rodents (50), healthy adults (51), 
children with ADHD (49) and adult ADHD populations (52). Results from these studies 
may, however, depend upon an individual’s genetic background and baseline inhibitory 
performance as those with lower baselines generally experience the largest performance 
gains (2, 53). Methylphenidate and amphetamine are known to increase extracellular 
concentrations of both dopamine and noradrenaline (54, 55), which has driven interest in 
how these two catecholamines might differentially influence action cancellation and action 
restraint, and what specific receptors might be involved. 
 
Increasing overall dopamine levels in humans through administration of L-dopa does not 
affect SST behaviour (56), a measure of action cancellation. The dopamine reuptake 
inhibitor bupropion also had no effect on SST behaviour in humans (57). Rodent studies 
using the dopamine reuptake inhibitor GBR-12909, vanoxerine, and the non-specific 
dopamine receptor antagonist flupenthixol both failed to influence SST (50). Later work 
showed, however, that infusion of a selective dopamine D1 receptor (D1) antagonist, SCH 
23390, into the rat striatum improved SSRT, whilst infusion of a selective D2 antagonist, 
sulpiride, impaired SSRT (58). These findings suggested that modulation of specific 
dopamine receptors in subcortical regions, rather than global manipulations of dopamine, 
might have specific behavioural effects during action cancellation (58). 
 
With respect to GNG, a measure of action restraint, neither L-dopa administration nor 
phenylalanine depletion influenced behaviour in healthy adults (59, 60). Frank and O’Reilly 
administered cabergoline (a non-specific D2 agonist) or haloperidol (a selective D2 
antagonist) to healthy adults and proposed that action restraint was controlled via phasic 
and tonic modulation of D1 and D2 receptors within the direct and indirect pathways of the 
striatum (43). Eagle, Bari and Robbins challenged this, noting that what had been defined 
as improved action restraint was likely only a negative modulation of the go pathway rather 
than a positive modulation of the no-go pathway (2). The argument against a role for 
dopamine in action restraint received further support when D1 and D2 manipulations were 
unable to influence GNG behaviour in either rats or monkeys (58, 61). Hence, in contrast 
to the SST and action cancellation, evidence for dopaminergic modulation of action 
restraint via GNG paradigms remains equivocal. It is noteworthy, however, that there is 
support for dopaminergic mechanisms in other impulse control, or ‘waiting’ paradigms, 
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such as in the rodent five-choice serial reaction time task (62, 63). In humans, 
dopaminergic pathways involving medial prefrontal, orbitofrontal and ventral striatal 
projections also appear to be relevant to choice impulsivity (64-66).  
  
The role of noradrenaline in response inhibition has been investigated with the non-
selective noradrenaline reuptake inhibitor atomoxetine, a treatment for childhood and adult 
ADHD (67, 68). Atomoxetine improved SST performance in rodents and healthy adults 
(69, 70), although negative studies do exist (51). Atomoxetine may not, however, be an 
ideal compound for differentiating the effects of catecholamines during response inhibition 
because of its ability to increase both noradrenaline and dopamine in the prefrontal cortex 
(PFC) (71). Attempts to resolve this confound suggest, however, that atomoxetine’s 
noradrenergic activity is likely pre-eminent over any dopaminergic activity (72). Modafinil, 
an atypical stimulant with noradrenergic and dopaminergic properties (73), improves SST 
but not GNG performance in rodents and healthy adults (50, 73). In rodents modafinil’s 
augmentation of action cancellation could not be blocked by the mixed D1/D2 receptor 
antagonist flupenthixol suggesting that its noradrenergic mechanism might be dominant 
(50). Paralleling the studies in dopamine, there has also been interest as to which 
noradrenergic receptors might be implicated in response inhibition, with considerable focus 
placed on the α2A class.  
 
Guanfacine, an α2A receptor agonist that decreases ascending noradrenergic activity (74), 
impaired SST performance in rodents and slowed reaction times in healthy adults (75, 76). 
Guanfacine’s slowing of SST reaction times suggests a sedating effect, potentially through 
inhibition of noradrenaline release via stimulation of presynaptic α2A autoreceptors (76). 
Conversely, the α2A receptor antagonist atipamezole improved SST performance in 
rodents (77), presumably by preventing pre-synaptic autoreceptor activation that would 
inhibit noradrenaline release(77). The non-selective α2A receptor agonist clonidine has 
been shown to enhance neuronal activity, but not performance, during GNG studies in 
primates (78). Complimentarily, the non-selective α2 receptor antagonist yohimbine caused 
impairment of GNG performance in primates (79). Hence there is also some support for a 
role of the α2A receptor during action restraint. The apparently contradictory results 
between α2 antagonists in rodent response inhibition, that is, atipamezole improved SST 
performance whereas yohimbine impaired GNG performance might be due to atipamezole 
antagonism being specific to the α2A receptor or its ability to improve attention (77). It is, 
however, noteworthy that both atipamezole and yohimbine have dopaminergic effects and 
their apparently contradictory α2 effects on response inhibition must be interpreted with 
caution (77).  
 
The serotonergic system appears to be implicated in action restraint and to a lesser 
degree action cancellation (2). In rodents, global serotonin depletion led to marked 
impairment in a GNG task whilst sparing SST performance (80). Selective serotonin 
reuptake inhibitors (SSRIs), though efficacious in the treatment of OCD, have been unable 
to affect SST performance across a number of studies (51, 56, 70, 75, 81) with the 
exception of a beneficial effect of citalopram in Parkinson’s disease (82). Subjects carrying 
a low expression variant of the serotonin transporter had poorer SST performance 
compared to high expression carriers (83), however, an earlier study failed to find any 
association between allelic variation in this serotonin transporter polymorphism and SST 
performance (84). The latter study also failed to find any effect of acute tryptophan 
depletion on SST performance, regardless of genotype (84), and in rodents serotonin 
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depletion does not appear to affect SSRT (85). With respect to specific serotonin 
receptors, the serotonin-2C receptor antagonist SB242084 improved SST performance in 
a mouse model, which also demonstrated improved SST performance using 
methylphenidate and atomoxetine (86). In alcohol dependent individuals, who are thought 
to show increased trait impulsivity, there is an association between impaired performance 
on the SST and a serotonin-2A receptor gene polymorphism (87). Furthermore, the 
serotoninergic system’s continued implication in other behaviours linked to impulsivity such 
as delayed gratification (88), aggression (89) and suicidal behaviour (90) ensures that 
despite the mixed results of pharmacological manipulations it continues to be of interest in 
the study of response inhibition. 
 
Functional imaging, lesion studies and response inhibition neurocircuitry 
 
In 1966 Luria noted that patients with damage to their frontal lobes were unable to inhibit 
behavioural responses despite understanding instructions requesting them to do so (3). In 
1970, building on Luria’s observations, primate lesion studies showed that damage to the 
inferior convexity, a homologue of the right inferior frontal gyrus in humans, caused 
impaired GNG performance (91). In the fifty years that followed a host of studies have 
shown that the integrity of the prefrontal cortex (PFC) is essential for response inhibition 
(3, 5).  
 
Further work has shown how specific subdivisions of the PFC, including inferior, 
dorsomedial, ventrolateral and orbitofrontal areas, are implicated during response 
inhibition. Decreased activation of the orbitofrontal cortex appears to be related to 
impulsive behaviour in adolescents (92) and was associated with reduced activation 
without behavioural change following tryptophan depletion (93). The dorsolateral PFC has 
been repeatedly implicated during response inhibition tasks (94, 95), though this may be 
due to it role in maintaining task rules rather than inhibitory behaviour as similar activations 
occur during tasks that progressively increase working memory load (96). In contrast, 
inferior frontal cortex activations, and in particular those of the right inferior frontal gyrus 
are thought to be specific to response inhibition (97-99). This is supported by the finding 
that right inferior frontal cortex damage is associated with poorer SSRTs, whereas no such 
association was found with left sided lesions (44). In addition, temporary lesions of the 
right inferior frontal gyrus, achieved via transcranial magnetic stimulation (TMS), are 
associated with longer SSRTs indicative of poorer performance (100). The PFC is thought 
to act in a ‘top down’ manner to control and co-ordinate other structures so that subsidiary 
executive processes, such as sustained attention and error awareness, can be recruited 
as necessary during response inhibition (3).  
 
fMRI and lesion studies have implicated a number of such areas in the cortex including the 
pre-supplementary motor area (pre-SMA) and SMA (96, 101), pre-motor cortex (102, 103), 
parietal cortex (98, 104), anterior cingulate cortex (ACC) (105, 106) and insula (107, 108). 
In the context of response inhibition task behaviour, a range of functions has subsequently 
been ascribed to these areas. For example, the SMA and pre-SMA activations are thought 
to be specific to motor stopping as the degree of BOLD activation has been shown to be 
proportionate to SSRT (109). The SMA and pre-SMA may, however, also be involved in 
the initiation (110) and selection (111) of motor responses. The ACC is thought to be 
responsible for several ancillary functions that support response inhibition including 
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attention (112), error detection (113), conflict monitoring (114), working memory (115) and 
task switching in fast changing environments (116). The ACC also has direct connections 
to both frontal areas (117) and the basal ganglia (118), making it an important facilitator of 
fronto-subcortical circuits (3). 
 
In addition to being connected via the ACC, the subthalamic nucleus (STN) is directly 
connected to the pre-SMA (119) and IFG (120) as part of the so-called ‘hyperdirect’ 
pathway, one of several proposed fronto-subcortical circuits thought to be relevant to 
response inhibition (119). STN involvement during response inhibition has been 
empirically demonstrated following studies in Parkinson’s disease patients (121). Striatal 
regions, which contribute to the so-called ‘direct’ and indirect’ pathways, have also been 
implicated in response inhibition behaviour via imaging studies (49, 122, 123). For 
example, patients with ADHD exhibited less striatal activation than controls during a GNG 
task (49). Although GNG and SST tasks generally share overlapping areas of cortical and 
subcortical activation (124), there are significant differences (124) suggesting potentially 
distinct neurocircuitry for action restraint and action cancellation. GNG inhibition was 
distinguishable from SST inhibition by greater activation of the right middle frontal gyrus, 
right inferior parietal lobule/precuneus and the right inferior frontal gyrus (124). Activation 
patterns tended to be bilateral for the GNG and predominantly confined to the right 
hemisphere for SST (124).  
 
The relationship of these cortical and subcortical areas and their neurochemical 
intermediaries has produced a number of theoretical models of the neurobiology of 
response inhibition. These, in light of our own results, will be elaborated upon in the 
Discussion. 
 
 
The neuropsychology of error awareness 
 
In order to remain aligned with an overarching goal, a subject must be able to monitor and 
appraise performance against a foreseeable succession of events (7). Yet in complex and 
changing environments outcomes often fail to meet expectations and the subject must 
then assess the impact of errors, initiate remedial action and once again appraise 
performance. Such feedback loops can be implemented on many levels, from simple 
spinal circuits through to complex systems that involve multiple higher structures. Here we 
focus on the latter process, collectively termed ‘performance monitoring’, which constitutes 
a second essential component of the executive control system (8).  
 
A dividing line within performance monitoring is whether the subject is aware or unaware 
of a given error. In this thesis, ‘awareness’ of an error denotes a state that is known as 
‘access consciousness’ (125). A state is defined as access consciousness when “the 
content of that state is available for verbal report, rational inference and the deliberate 
control of behaviour” (126). Hence, in experimental terms, what distinguishes error 
awareness from unawareness is reportability (8). Although such a dichotomy is practical it 
appears far more likely that the subjective awareness of errors lies on a continuum from 
unperceived, to phenomenological (‘the redness of red’), to reflexive (‘gut feeling’) and 
then, finally, access consciousness (8). Indeed there have been a handful of experimental 
studies that have attempted to measure these more subtle forms of error awareness with 
varying success (127, 128). Nonetheless, the vast majority of behavioural studies 
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concerning ‘error awareness’ remain specifically limited to measuring only those errors 
which present to access consciousness (8).  
 
One of the earliest examples of this was in the 1960s when Rabbitt asked subjects to 
make a specific button press during a speeded choice reaction time task to indicate their 
awareness of commission errors (129). Since Rabbitt’s work a range of behavioural 
paradigms has emerged to detect error awareness, with only a limited consensus as to 
which are most appropriate or generalisable (8). Areas of divergence include how error 
awareness is quantified (binary vs. parametric), how error awareness is reported (e.g. by 
specific button press), the presence of an ‘unsure’ option, the presence of a time limit to 
assess performance, and the primary task itself (8). There are also indirect methods for 
inferring error awareness, the validity of which remains unclear, such calculating post error 
slowing and rapid error correction (130, 131).  
 
In this thesis the Error Awareness Task (EAT) was used to detect error awareness at the 
level of access consciousness (132). As described in the ‘General Methods’ appendix, the 
EAT is a modified GNG task that has two no-go conditions. The first is associated with a 
Stroop effect (colour no-go) and the other with working memory (repeat no-go). The 
presence of two relatively complex no-go conditions was designed to increase the 
probability of errors, which then may, or may not, become apparent to the subject. Error 
awareness was reported by pressing a specific button, instead of the usual go response 
button, during the trial after the error was detected [see Figure 1]. Accordingly, the 
reporting of errors was binary and time limited, in that, unless the subject pressed the 
awareness button before the next trial commenced, it was assumed that they had been 
unaware of an error.  
 
 
Figure 1 The EAT with undetected (unaware), detected (aware) errors and correct no-go responses  
 
 
Since its inception the EAT has been examined with a number of modalities, including 
event related potentials (ERP) and fMRI, in an attempt to probe the specific neurobiology 
of error awareness (133, 134). Nonetheless, this investigation remains critically informed 
by and situated within its larger context, the neurobiology of human performance 
monitoring. The following survey will emphasise human performance monitoring studies 
due to the inherent difficulties in operationalising error awareness in animals.  
Orr and Hester Error awareness in dACC
FIGURE 1 | The Error Awareness Task (EAT). The EAT presents a serial
stream of single color words in colored fonts. Participants were trained to
respond to each of the words with a single “Go trial” button press, and to
withhold this response when either of two different circumstances arose. The
first was if the same word was presented on two consecutive trials (Repeat
No-go), and the second was if the word and font of the word matched (Color
No-go). To indicate “error awareness” participants were trained to forego the
regular go trial button response and instead to execute the alternative “error
awareness” response following any commission error. Past studies have
demonstrated that error-related BOLD signal is uninfluenced by the
awareness response itself (Hester et al., 2005). Although levels of awareness
undoubtedly vary on a continuum, we made a qualitative distinction between
“Aware” and “Unaware” errors to facilitate our event-related fMRI analysis.
Figure reproduced from Hester and colleagues (2012).
Color names, printed in colored font, were presented in a serial
stream. The three samples completed versions of the task that
differed slightly in the stimulus presentation and inter-stimulus
interval duration, 900/600ms (Hester et al., 2005, 2009a) or
800/700ms (Hester et al., 2012). Participants were instructed
to respond to the presentation of each stimulus with a but-
ton press (a “Go” response) unless the stimulus was a “lure,”
in which case they were to withhold their response (“No-go”
response). Lures could take two forms: a “Repeat lure” in which
the same word was presented on two consecutive trials; and a
“Color lure” defined by the congruence of the color name and
the font color. Color lures were defined by incongruence between
the color word and the font in the two earlier studies (Hester
et al., 2005, 2009a); and by congruence in the third study (Hester
et al., 2012). Adopting competing inhibition rules exploits the
different strengths of the stimulus-response relationships such
that the overlearned behavior of reading a word would make the
Repeat rule more salient than the Color rule. Previous research
has suggested that this may cause the Color rule to be sup-
pressed, producing more Color errors than Repeat errors and
potentially affecting participants’ awareness of the errors (Hester
et al., 2005, 2009a). Participants were instructed to execute an
alternative “error awareness” response on the “Go” trial following
an error.
The 2005 and 2009 studies presented five blocks of 225 trials
during fMRI data acquisition with lure trials pseudo randomly
distributed across the 1125 experimental trials. The 2012 study
presented six blocks of 225 trials. There were minor differences to
the ratio of No-go: Go trials across the three experiments, with
128 lures presented in the earlier study (Hester et al., 2005) and
125 and 150, respectively, in the two later studies (Hester et al.,
2009a, 2012). On average, a lure was presented every 8.95 trials,
corresponding to an average inter-lure interval of 13.42 s. While
some other variations in the design of these tasks existed, only
the commission errors made during the aforementioned design
were considered, with the assumptionmade that the event-related
analysis would minimize the influence of unrelated task variance.
SCANNING PARAMETERS AND DATA ANALYSES
Scanning for the original study (Hester et al., 2005) was con-
ducted using contiguous 5mm sagittal slices covering the entire
brain from a 1.5 T Siemens Vision scanner using a single
shot, T2*-weighted echo-planar pulse sequence (TE = 50ms;
TR = 2000ms; FOV = 256mm; 64× 64 matrix). High resolu-
tion T1-weighted structural MPRAGE images (FOV = 256mm,
thickness = 1.0mm isotropic with no gap) were acquired prior
to functional imaging to allow subsequent activation localization
and for spatial normalization. Stimuli were delivered using an
IFIS-SA stimulus-delivery system (MRIDevices Corp.,Waukesha,
Wisconsin), which was equipped with a head-coil-mounted
640× 480 LCD panel. This shielded LCD screen is mounted
on the head-coil, directly in the subjects’ line of vision. Foam
padding was used to limit head movements within the coil.
Scanning for the second study (Hester et al., 2009a) was con-
ducted using a 3T Philips Achieva scanner in which foam padding
was used to restrict head movements. Contiguous 3.5mm
sagittal slices covering the entire brain were collected using a
gradient-echo echo-planar imaging (EPI) sequence (TE = 35ms;
TR = 2000ms; FOV = 224mm). High resolution T1-weighted
structural MPRAGE images (FOV = 256mm, isotropic 0.9mm
voxels) were acquired following functional imaging to allow sub-
sequent activation localization and spatial normalization. Stimuli
Frontiers in Human Neuroscience www.frontiersin.org June 2012 | Volume 6 | Article 177 | 3
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Imaging, lesion studies and error awareness neurocircuitry 
 
In the 1960s the first neurobiological evidence of a performance monitoring system in the 
human brain was reported after implanted electrodes showed increased neuronal activity 
in the putamen and caudate after errors on a psychological test (135). Studies in 
psychiatric patients undergoing cingulotomy then showed that neurons in the anterior 
medial cingulate cortex (aMCC) were sensitive to tasks that induced response conflict, that 
is, when two contradictory responses are invoked by a single stimuli (136). Further 
intraoperative studies in epilepsy patients implicated the dorsal anterior cingulate cortex 
(dACC), lateral frontal, and mesial frontal cortices, suggesting that performance monitoring 
occurs across a distributed brain network rather than being constrained to a specific 
neuroanatomical locus (137).  
 
In the 1990s, the study of human performance monitoring was significantly advanced by 
Falkenstein’s discovery of an ERP whose amplitude was dependent on the success or 
failure of an action (138). This ‘error-related negativity’ (ERN) consisted of a frontocentrally 
distributed negative deflection that started around the time of the erroneous response and 
reached its peak 50 to 100 milliseconds later (8). The ERN is followed by a complex set of 
positive deflections, collectively termed the error positivity (Pe), which emerge 200-400 
milliseconds after the error (139) (see Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 ERN and Pe waveforms elicited during the Error Awareness Task 
[A] The ERN is present during errors, irrespective of awareness. [B] The Pe is only present on trials for which 
awareness of errors is consciously indicated. 
 
In 2000, almost a decade after the discovery of the ERN, a flanker task was combined with 
a parametric measure of error awareness that asked subjects to rate the accuracy of their 
responses on a five-point scale, without time limit, before the commencement of the next 
trial (140). Analysis showed that ERN amplitudes rose proportionally with confidence in 
having detected an error (140). One year later, however, in an eye movement paradigm 
that required subjects to give a time limited binary response, error awareness could not be 
correlated with ERN amplitude (131). Since then there have been multiple studies, using a 
range of behavioural paradigms, that have sought to define the relationship between the 
ERN and error awareness yet the issue remains unresolved (130, 131, 140-148). 
Unfortunately, the discrepancy between studies cannot easily be explained by differing 
primary task type or error awareness reporting method (8). The functional significance of 
the Pe during error awareness has received less empirical investigation, however, on the 
basis of the limited evidence available there is cautious support for an association (139, 
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146, 149). Of specific interest here, during the EAT there does not appear to be a 
relationship between ERN and error awareness, however, for the Pe there does (144).  
 
Several fMRI studies have implicated the PFC and ACC in performance monitoring (150, 
151). Decreased activation of these areas has also been seen in psychiatric populations 
that display performance-monitoring deficits (150, 151). fMRI studies using the EAT, in the 
absence of pharmacological modulation, have shown associations between error 
awareness and activation in the dACC, insula, bilateral inferior parietal and bilateral mid 
frontal cortices (132, 152, 153). The association between the dACC and error awareness 
is particularly significant as the dACC is thought to be the cortical generator of the ERN 
(8). The association between error awareness and the insula has been replicated using an 
eye movement paradigm (154). Activation of the insula is of interest due to its role in 
awareness of the autonomic nervous system (ANS) and the finding that heart rate 
deceleration, pupil dilation and increased skin conduction occur during error awareness 
(144, 147, 155). Subcortical regions also appear to be involved as patients with thalamic 
lesions show decreased error awareness compared to healthy controls (156).  
 
Taken together, lesion, ERP and imaging data strongly suggest that fronto-subcortical 
circuits are active during error awareness. This has led to attempts to better understand 
and modulate these circuits via pharmacological and pharmacogenetic studies of targeted 
neurotransmitter systems.  
 
 
The neuropharmacology of error awareness 
 
As previously, understanding the neurochemical bases of error awareness is informed 
through studies of performance monitoring more generally. Here we survey human 
experimental data on the role of dopamine, noradrenaline and serotonin.  
 
Dopaminergic neurons of the substantia nigra project to the frontal cortex with the 
cingulate cortex, in particular, receiving prominent innervation (157). Several studies have 
looked at the effects of dopamine modulation on performance monitoring in healthy 
volunteers. Amphetamine, a mixed dopamine and noradrenaline reuptake inhibitor, 
increased ERN but not Pe amplitude during a flanker task without behavioural effects 
(158). Haloperidol, a D2 antagonist, decreased ERN amplitude during flanker tasks with 
inconsistent effects on behaviour (159, 160). Sulpiride, another D2 antagonist, was able to 
modulate ERN and post error slowing, again during a flanker task, dependent on subject 
COMT genotype (161). In an fMRI study, methylphenidate, a mixed dopamine and 
noradrenaline reuptake inhibitor, reduced activity in the ventral putamen during reversal 
learning, a behavioural paradigm that requires intact performance monitoring (162). In the 
same study, methylphenidate also enhanced ACC activity in response to positive 
feedback(162). To compliment the above, there have also been performance-monitoring 
studies on clinical populations with dopaminergic pathology.  
 
The depletion of striatal dopamine in Parkinson’s disease (PD) causes deficits in reversal 
learning that can be remediated with L-DOPA, a dopamine precursor (163-165). During a 
variety of performance monitoring tasks, PD patients showed variation in ERN amplitude, 
both on and off dopamine enhancing medication (166). Patients with ADHD, schizophrenia 
and Tourette’s syndrome also had deficits of performance monitoring that were reversible 
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with dopamine modulating treatment (167-169). Individuals addicted to cocaine, a mixed 
dopamine and noradrenaline reuptake inhibitor, displayed decreased error awareness on 
the EAT (170).  
 
Dopamine modulation during performance monitoring produces complex and, at times, 
seemingly contradictory results that often reflect variance in dosing amount and duration 
(7, 166). For example, pramipexole and ropinirole, D2 agonists, given chronically in PD 
improve reward learning, whereas pramipexole and cabergoline, also a D2 agonist, given 
acutely impair it (43, 171, 172). Similarly difficult to interpret results have been noted 
regarding high versus low dose D2 antagonists (173). In summary, the existent data 
suggests that dopamine has a significant, but as yet undefined, role during performance 
monitoring. Dopamine’s contribution during error awareness, however, remains limited to 
inference with few studies examining its specific effects.  
 
Noradrenergic neurons project from the brain stem to the forebrain in tangentially 
orientated fibres that allow for the synchronous modulation of activity across large cortical 
areas (174). There have been few studies that have sought to assess noradrenergic 
function during performance monitoring; notwithstanding the psychostimulant data 
mentioned above whose results are, at least in part, plausibly attributed to noradrenaline 
(166). Yohimbine, a non-selective α2 antagonist, was given to subjects performing a 
flanker task and was found to increase ERN amplitude whilst decreasing commission 
errors (175). Despite the lack of data in humans, primate studies have led to complex 
mechanistic theories of noradrenaline’s role during performance monitoring (176). In 
contrast to the limited amount of data regarding noradrenaline, there is a significant body 
of work on the role of serotonin in human performance monitoring.  
 
Serotonergic neurons, originating in the raphe nuclei of the brainstem, project to most of 
the forebrain and affect at least 14 different serotonin receptor subtypes, with additional 
indirect effects on dopaminergic neurons (177-179). Studies attempting to modulate 
serotonin during performance monitoring have used selective serotonin reuptake inhibitors 
(SSRI) and acute tryptophan depletion (ATD). These probes have, however, added 
confounds to what is already a complex neurobiology due to differential effects between 
species, differing effects of acute versus chronic dosing and problems correlating serum 
and central serotonin levels (166). With these caveats, in healthy volunteers an acute dose 
of citalopram, an SSRI, impaired probabilistic learning (70). In contrast, an acute dose of 
the SSRI paroxetine was unable to affect behaviour or ERN amplitude during a flanker 
task (159). Acute doses of mirtazapine, an antidepressant with serotonergic, 
noradrenergic, histaminergic and muscarinic effects, did not affect behavioural or ERP 
measures during a flanker task (180). ATD In healthy volunteers impaired reward-based 
learning and caused erroneous choice perseveration (181). During a reversal-learning 
task, ATD caused increased fMRI activation in the dmPFC in response to errors (182). 
Another method for studying the role of serotonin in human performance monitoring and 
has been to examine the effect of genetic polymorphisms. Variations in the serotonin-
transporter-linked polymorphic region (5-HTTLPR) have been associated with enhanced 
post error adjustment, increased accuracy and decreased ERN amplitudes during the 
flanker task (183, 184). A polymorphism associated with 5-HT1A receptors, which 
decreases net serotonin release, is associated with reduced post error slowing and ERN 
amplitude (185).  
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There are several complex theoretical models as to how dopamine, noradrenaline and 
serotonin modulate performance motoring, and error awareness, behaviour. Accumulating 
experimental data, including our own, challenges these models and they will be examined 
in the Discussion. What follows next, however, is a brief synopsis of the rationale 
underlying the experiments contained in this thesis and how they sought to address some 
of the questions raised in the Introduction.  
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The rationale underlying the experiments in this thesis 
 
Chapter 1 sought to isolate the relative contributions of dopamine, noradrenaline and 
serotonin to human action cancellation. We did this by giving acute doses of 
methylphenidate (a dopamine and noradrenaline reuptake inhibitor), atomoxetine (a 
predominantly noradrenergic reuptake inhibitor) and citalopram (a serotonin reuptake 
inhibitor) to healthy, Caucasian males who then undertook a stop signal task in a within-
subjects placebo controlled design. 
 
Chapter 2 sought to explore the neurochemical and neuroanatomical correlates of human 
action restraint using fMRI. Acute doses of methylphenidate, atomoxetine and serotonin 
were given to healthy, Caucasian males, in a within-subjects placebo controlled design, 
who then undertook the EAT. GNG behaviour was correlated with BOLD activity as a 
function of the three drug conditions and placebo.  
 
Chapter 3 examined the neurochemical and neuroanatomical bases of error awareness 
using fMRI. Using the same cohort as Chapters 1 and 2, error awareness behaviour was 
correlated with BOLD activity as a function of the three drug conditions and placebo. 
 
Chapter 4 sought to examine whether D2 receptor modulation could influence action 
cancellation, action restraint or error awareness behaviour. An acute dose of cabergoline, 
a D2 receptor agonist, was given to healthy, Caucasian males in a within-subjects placebo 
controlled design, who then undertook the stop signal task and EAT.  
 
All experiments tested only healthy Caucasian males to avoid ethnic differences in drug 
metabolism, menstrual cycle effects, medical conditions that may affect cognition and drug 
side effects. Methylphenidate, atomoxetine, citalopram and cabergoline were used due to 
their relatively high selectivity for the target neurotransmitter systems, safety profile in 
humans and evidence of cognitive effects from earlier studies. A within-subject placebo-
controlled design provided increased statistical power and confidence to attribute results to 
pharmacological modulation. The SST and EAT allowed examination of action 
cancellation, action restraint and error awareness, as detailed in the Introduction, and 
comparison to earlier work that used these paradigms. Our fMRI protocol allowed 
synchronisation of imaging and behavioural stimuli.  
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Chapters!
 
  
Methylphenidate But Not Atomoxetine or Citalopram
Modulates Inhibitory Control and Response Time
Variability
L. Sanjay Nandam, Robert Hester, Joe Wagner, Tarrant D.R. Cummins, Kelly Garner, Angela J. Dean,
Bung Nyun Kim, Pradeep J. Nathan, Jason B. Mattingley, and Mark A. Bellgrove
Background: Response inhibition is a prototypical executive function of considerable clinical relevance to psychiatry. Nevertheless, our
understanding of its pharmacological modulation remains incomplete.
Methods: We used a randomized, double-blind, placebo-controlled, crossover design to examine the effect of an acute dose of methyl-
phenidate (MPH) (30mg), atomoxetine (ATM) (60mg), citalopram (CIT) (30mg), and placebo (PLAC) (dextrose) on the stop signal inhibition
task in 24 healthy, right-handedmen 18–35 years of age. Participants performed the task under each of the four drug conditions across four
consecutive sessions.
Results: Methylphenidate led to a reduction in both response time variability and stop-signal reaction time (SSRT), indicating enhanced
response inhibition compared with all other drug conditions. Crucially, the enhancement of response inhibition by MPH occurred without
concomitant changes in overall response speed, arguing against a simple enhancement of processing speed. We found no significant
differences between ATM and PLAC, CIT and PLAC, or ATM and CIT for either response time variability or SSRT.
Conclusions: An acute dose of MPH but not ATM or CIT was able to improve SSRT and reduce response time variability in nonclinical
participants. Improvements in response inhibition and response variabilitymight underlie the reported clinical benefits ofMPH in disorders
such as attention-deficit/hyperactivity disorder.
Key Words: Atomoxetine, citalopram, methylphenidate, response
inhibition, stop signal, variability
T he processes that inhibit unwanted behavior and maintainconsistent task performance are impaired in several psychiat-ric conditions, including schizophrenia (1), obsessive compul-
sive disorder (2), and attention-deficit/hyperactivity disorder
(ADHD) (3). Significant controversy exists regarding their precise
neurochemical basis, despite the relevance of response inhibition
andvariability topsychiatry and their potential for pharmacological
treatment. Here we used a within-subjects design to examine the
influence of an acute dose ofmethylphenidate (MPH), atomoxetine
(ATM), citalopram (CIT), or PLAC on measures of inhibitory control
and response variability.
Response inhibition has been studied in cognitive neuroscience
with paradigms such as the stop-signal task. This task requires the
countermanding or cancelation of a prepotent “go” response upon
presentation of an infrequent “stop” signal. Stop-signal inhibition
can be viewed as a race between two competing “go” and “stop”
processes. By introducing a delay between the presentation of the
goandany subsequent stop signal, one canbias theoutcomeof the
race. When the theoretical assumptions underlying this racemodel
are respected, an index of the speed of inhibition can be calculated,
the stop-signal reaction time (SSRT) (4).
Reaction time tasks, including the stop-signal task, also allow
measurement of behavioral variability, measured as the SD of reac-
tion times to the go signal. Increased variability is thought to arise
from both moment-to-moment fluctuations in attentional control
and frommore gradual drifts in performance thatmight result from
diminished arousal (5,6).
Here we sought to determine the influence of three agents that
are used in the management of ADHD (MPH, ATM) and obsessive
compulsive disorder (CIT) on behavioralmeasures of response inhi-
bition. A randomized, double-blind, placebo-controlled, crossover
design was used to study the effects of an acute dose of MPH (30
mg), ATM (60 mg), CIT (30 mg), and PLAC (dextrose) on SSRT and
behavioral variability in healthy subjects.
Methods andMaterials
Participants
Twenty-four healthy right-handed, nonclinical Caucasian male
participants, 18–35 years of age, were recruited. Additional details
regarding the recruitment and screening procedures can be found
in Supplement 1.
Drug Administration
Participants were tested on the same day and time across 4
consecutive weeks in a double-blind manner. On each occasion a
singlebluegelatine capsule containingMPH30mg,ATM60mg, CIT
30 mg, or PLAC (dextrose) was ingested with water. Participants
performed the stop-signal reaction time task from min !150 to
!180 after drug administration. There was no significant drug "
time interactions for either blood pressure or subjective side effect
ratings (Supplement 1).
Stop-Signal Paradigm
The SSRT was derived as the mean reaction time to go-stimuli
(mean reaction time [MRT]) minus the stop signal delay for the 50%
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inhibition threshold (SSRT ! MRT " stop-signal delay) (4). The
intraindividual coefficient of variation [ICV: SDGo RT/MRT] was also
calculated, which provides a measure of response variability, ad-
justed for the influence of response speed (5).
Results
There was a significant effect of drug condition on SSRT
[F (3,66) ! 5.83, p # .01]. Methylphenidate led to a reduction in
SSRTs, indicating enhanced response inhibition compared with all
other drug conditions. Post hoc least significant difference tests
revealed significant differences between MPH and PLAC (p# .001;
d! .65) and MPH and CIT (p# .01; d! .62) and between MPH and
ATM (p ! .05, d ! .42) (Table 1). There were no significant differ-
ences betweenATMandPLAC (p! .1;d! .32) or betweenATMand
CIT (p! .2; d! .26).
Crucially, the selective enhancement of response inhibition by
MPH occurred without concomitant changes in response speed,
because there was no main effect of drug condition on MRT
[F (3,66)! .54, p! .65]. This suggests that MPH was able to specifi-
cally improve action cancelation without simply increasing overall
motor speed.Aconservative reanalysis of theSSRTdatawithMRTas
a covariate confirmed the significant effect of drug condition on
SSRT [p ! .002]. There was no main effect of drug condition on
stop-signal accuracy [F (3,66)! 1.35, p! .27] (Table 1).
Significant main effects of drug condition were found for the
intraindividual coefficient of variation [F (3,66) ! 5.76, p ! .001].
Methylphenidate led to a reduction in response timevariability that
was significantly different from all other conditions (all p values#
.05, corrected) (Table 1). No other drug comparisons of variability
were significant.
Because MPH enhanced both SSRT and response time variabil-
ity, we sought to understand the relationship between these vari-
ables with correlation. No significant correlations were found be-
tween SSRT and response time variability in any of the drug
conditions, suggesting that these processes are largely indepen-
dent (MPH: r! .08,p$ .05; ATM: r! .02,p$ .05; CIT: r! .27,p$ .05;
PLAC: r! .32, p$ .05).
Discussion
This study demonstrated that clinically relevant doses of MPH
were able to reduce SSRT and behavioral variability without con-
comitant changes in response speed or accuracy of responding.
The inability of CIT to facilitate action cancelation is consistent with
otherhumanstudies (7). However, the failure to confirmabeneficial
effect of ATM compared with PLAC on SSRT contrasts with other
work in humans and rodents (7–9). Our results challenge the view
that stimulant medications act to solely speed motoric processes
without specific effects on action cancelation (10).
Methylphenidate is a widely used stimulant medication for the
treatment of ADHD, with clinical response rates of approximately
70%. Although MPH is often viewed as a dopaminergic agent, its
pharmacology suggests effects on both dopamine (DA) and nor-
adrenaline (NA). Within the striatum, MPH acts to inhibit the re-
uptake of DA by blockade of the dopamine transporter (DAT) (11).
The increase in DA occasioned by DAT blockade likely modulates
activity within the circuits of the basal ganglia, particularly via D2
and D1 receptors within the indirect and direct pathways, respec-
tively. However, MPH increases both DA and NA at doses that en-
hance prefrontally dependent executive functions such as working
memory (12). This effect is likely mediated via blockade of the
noradrenaline transporter (NET), because DAT is sparse in prefron-
tal cortex (13). At the receptor level, the cognitive enhancing effects
ofMPH in rat prefrontal cortex seemtobemediatedby its effects on
%-2 adrenoreceptors and D1 receptors (14).
Pharmacological work in rodents has shown that, althoughATM
selectively inhibits NET in prefrontal cortex, there is a resultant
threefold increase in both NA and DA levels, without any concomi-
tant change in serotonin (13). However, within the striatum NET is
sparse, and ATM has only a limited ability to modulate catechol-
amine levels. Although ATM and MPH have similar effects on both
DA and NA in prefrontal cortex, a key difference is conferred by the
ability of MPH to selectively increase DA within the striatum (13).
Current models of behavioral inhibition emphasize the interac-
tion of prefrontal and basal ganglia circuits (15,16). Specifically,
prefrontal circuitsmight provide a top-down, stimulus-driven input
to the basal ganglia, signaling the need for enhanced behavioral
control. Both MPH and ATM are well-placed to exert a neuromodu-
latory influence over the prefrontal cortex, and indeed functional
magnetic resonance imaging studies of response inhibition dem-
onstrate effects of both drugs on prefrontal activity (9,17). Dopa-
mine, however, might play an important neuromodulatory role
within the basal ganglia, acting to transform the top-down inputs
into a focused, context-dependent signal that is able to suppress or
facilitate behavior via the appropriate balance of activity within the
indirect or direct pathways, respectively (18). Future studies should
attempt to modulate SSRT with selective D1/D2 agonists or antag-
onists as well as with a broader range of cognitive tasks to accu-
rately reflect the complexity and breadth of the construct of inhibi-
tion.
Recent evidence from ADHD suggests that response time vari-
ability and inhibition load onto distinct, familial cognitive factors
(19), with the former potentially linked to diminished arousal and
drifting attention (6) and the latter linked to executive processes.
Interestingly, although both stop-signal reaction time and re-
sponse time variability were robustly improved by MPH in the cur-
rent study, thesemeasures were largely uncorrelated in each of the
Table 1. Mean SSRT and MRT and Stop-Signal Accuracy as a Function of Drug Condition
MPH ATM CIT PLAC
M SD M SD M SD M SD
SSRT (msec) 252 30 264 26 272 34 275 39
MRT (msec) 392 56 399 54 401 63 400 51
% stop 48 3 48 3 46 7 45 9
SD of MRT 64 13.6 74 14.8 78 17.6 79 23.8
ICV .16 .03 .18 .03 .19 .04 .19 .04
Methylphenidate 30 mg (MPH); atomoxetine 60 mg (ATM); citalopram 30 mg (CIT); placebo (PLAC). SSRT, stop-
signal reaction time (msec); MRT,mean correct “go” reaction time (msec); % stop, percentage of successful inhibitions
on stop trials; ICV, intra-individual coefficient of variation (SD of MRT/MRT).
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drug conditions, providing further evidence that they are poten-
tially dissociable.
Chamberlain et al. (9) reported that an acute dose of ATM 40mg
reduced SSRT comparedwith PLAC. A comparison of the effect size
associated with the ATM versus PLAC difference in Chamberlain et
al. and the current study revealed Cohen’s d effect sizes of .37 and
.32, respectively. Because these effect sizes are modest, non-repli-
cations are likely. It is also notable that the PLAC condition of the
current study yielded comparable results (Chamberlain: SSRT: 278
msec; Nandam et al.: SSRT: 275 msec), suggesting that baseline
differences between the studies are unlikely to account for this
non-replication. Participant factors suchasDNAvariation in theNET
genes (20) might also account for the weaker effect of ATM in the
present study.
Although we found strong evidence that MPH specifically im-
proved response inhibition and response time variability, we found
no significant change compared with PLAC for ATM. Our results
provide foundational data that might help to explain why acute
doses of MPH have therapeutic value in disorders such as ADHD.
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Supplemental Information 
 
Supplemental Methods & Materials 
Participant Screening 
Twenty-four non-clinical Caucasian male participants were recruited for this study via 
advertisements at The University of Queensland, Queensland, Australia. All participants were 
right handed and aged from 18-35 years. Participants were excluded if they reported any 
history of psychiatric or neurological illness including head injury, previous usage of 
psychotropic medication, or significant drug use [significant was defined as: (i) use of any 
illicit substances within the last month; (ii) >5 lifetime intake of any illicit drug except 
cannabis; (iii) more than monthly cannabis intake, smoking (>5 cigarettes/week), alcohol 
dependence (<24 units/week). Before commencing all participants were screened by a 
consultant psychiatrist who also administered the M.I.N.I. Screen (1) and the Kessler K10 
(2).  
All participants were recruited according to the principles of the Declaration of Helsinki and 
in accordance with the ethical guidelines of The University of Queensland and the Wesley 
Hospital, Brisbane, Australia. 
Drug Administration 
Participants were tested on the same day and at the same time for four (4) consecutive weeks. 
Overall, the study consisted of 96 individual drug testing sessions. On each occasion the 
participant ingested with water (in a randomized order) a single blue gelatin capsule 
containing either methylphenidate 30 mg, atomoxetine 60 mg, citalopram 30 mg or placebo 
(dextrose). Dosage selection was based on clinically relevant doses for ADHD (3, 4) and 
depression, as well as on data from previous acute challenge studies which have 
demonstrated neurocognitive effects of these drugs (5-7). 
All participants were required to fast for at least one hour before drug administration. 
Caffeine was not to be consumed on test days. After drug administration, subjects rested in a 
quiet waiting room for 90 minutes before commencing. From minutes +90 to +150 (post 
administration) subjects undertook an fMRI experiment testing error awareness, the results of 
which will be reported separately. Participants subsequently performed the stop-signal 
reaction time (SSRT) task from minutes +150 to +180. Task timing was based on the region 
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of concomitant peak plasma levels for the three study drugs (approximately 90-180 minutes 
after oral ingestion in adults) (8-10), and on findings from earlier neurocognitive studies (5, 
6).   
Participants completed visual analogue scales (11, 12) in order to assess possible drug effects 
on subjective alertness, contentedness and calmness. Sixteen opposing subjective states were 
rated at baseline, +90 and +180 minutes after capsule administration. In accordance with 
Bond and Lader (11), a log transformation was applied to the items. Factors of ‘alertness’, 
‘contentedness’ and ‘calmness’ were calculated by taking the mean transformed score across 
loading items for each time point. Each factor was then subject to a 4(drug) by 3(time) 
repeated measures ANOVA. Crucially, there were no significant drug × time interactions 
[alertness: F(6,132) = 1.65, p > 0.05; contentedness: F(6,132) = 1.62, p > 0.05; calmness: 
F(6,132) = 1.82, p > 0.05].  
Blood pressure was also recorded at baseline and then again at time-points +60 and +180 
minutes. There were no significant drug by time-point interactions for either systolic 
(drug×time: F(6,132) = 2.00, p > 0.05) or diastolic (drug×time: F(6,132) = 1.18, p > 0.05) 
blood pressure measurements.  
Stop-Signal Paradigm 
Participants performed 512 trials of the stop-signal paradigm, in which the go-stimuli were 
the letters O and X mapped to left and right button press responses, respectively. The stop-
signal was a red box that surrounded the go-stimulus on 25% of trials. The delay between the 
onset of the go-stimulus and the onset of the stop-signal (stop-signal delay, SSD), was 
initially set to 250 ms and thereafter was adjusted dynamically in increments of 50 ms 
contingent upon the performance of the participant. Successful inhibitions resulted in an 
increase of the SSD whereas failed inhibitions resulted in a reduction of the SSD, thereby 
facilitating inhibitory success. This procedure ensured that on average each participant in 
each session had a probability of successful inhibition approaching 50%. SSRT was derived 
as the mean reaction time to go-stimuli (MRT) minus the SSD for the 50% inhibition 
threshold (SSRT = MRT - SSD) (13). To assess drug effects on intra-individual response 
time variability the intra-individual coefficient of variation [ICV: SD Go RT/ MRT] was 
calculated which provides a measures of variability, adjusted for the influence of response 
speed (14). 
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Preliminary inspection of the data revealed that the stop-signal task had not run correctly for 
one participant leading to spurious estimates of SSRT. The data from this participant was 
therefore excluded. The derivation of SSRT according to the race model requires that certain 
assumptions underpinning the data are satisfied. Namely, MRT should not correlate 
significantly with SSRT and the average of reaction times to failed inhibition trials should be 
faster than average MRT. Both of these assumptions were tested for each of the drug 
conditions (MPH, ATM, CIT, PLAC) and were satisfied in the remaining sample of 23 
participants (data available from authors).   
 
1. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998): 
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and 
validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J 
Clin Psychiatry. 59 Suppl 20:22-33;quiz 34-57. 
2. Kessler RC, Barker PR, Colpe LJ, Epstein JF, Gfroerer JC, Hiripi E, et al. (2003): 
Screening for serious mental illness in the general population. Arch Gen Psychiatry. 
60:184-189. 
3. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, et al. (1998): 
Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity 
disorder. Am J Psychiatry. 155:693-695. 
4. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, et al. (2003): 
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol 
Psychiatry. 53:112-120. 
5. Chamberlain SR, Muller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ (2006): 
Neurochemical modulation of response inhibition and probabilistic learning in humans. 
Science. 311:861-863. 
6. Aron AR, Dowson JH, Sahakian BJ, Robbins TW (2003): Methylphenidate improves 
response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 
54:1465-1468. 
7. Nathan PJ, Sitaram G, Stough C, Silberstein RB, Sali A (2000): Serotonin, noradrenaline 
and cognitive function: a preliminary investigation of the acute pharmacodynamic effects 
of a serotonin versus a serotonin and noradrenaline reuptake inhibitor. Behav Pharmacol. 
11:639-642. 
8. Henning J, Netter P (2002): Oral application of citalopram (20 mg) and its usefulness for 
neuroendocrine challenge tests. Int J Neuropsychopharmacol. 5:67-71. 
9. Kragh-Sorensen P, Overo KF, Petersen OL, Jensen K, Parnas W (1981): The kinetics of 
citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol (Copenh). 
48:53-60. 
10. Sauer JM, Ring BJ, Witcher JW (2005): Clinical pharmacokinetics of atomoxetine. Clin 
Pharmacokinet. 44:571-590. 
11. Bond A, Lader M (1974): The use of analogue scales in rating subjective feelings. Br J 
Med Psychol. 47:211-218. 
12. Norris H (1971): The action of sedatives on brain stem oculomotor systems in man. 
Neuropharmacology. 10:181-191. 
Nandam et al. 
 4 
13. Logan GD, Schachar RJ, Tannock R (1997): Impulsivity and Inhibitory Control. Psychol 
Sci. 8:60-64. 
14. Stuss DT, Murphy KJ, Binns MA, Alexander MP (2003): Staying on the job: the frontal 
lobes control individual performance variability. Brain. 126:2363-2380. 
 
 
 
Supplemental Data for CONSORT Checklist 
 
 
3a. Allocation ratio 
There is no allocation ratio in a full cross over design. Every participant received every 
intervention.  
 
7a. How sample size was determined? 
Power analysis indicated that a sample size of 24 will have 81% power to test drug effects (d 
= 0.65) using an F test and an alpha of 0.05. 
 
8a. Method used to generate the random allocation sequence 
Balanced Latin square 
 
8b. Type of randomisation; details of any restriction (such as blocking and block size) 
Randomization was not restricted.  
 
9. Mechanism used to implement the random allocation sequence (such as sequentially 
numbered containers), describing any steps taken to conceal the sequence until interventions 
were assigned 
Randomization order was given to the pharmacist preparing the drugs. The pharmacist then 
prepared the appropriate drug for that session using identical blue gelatin capsules. The 
capsule was then placed in a container that indicated the session number and participant’s 
name.   
 
The container was subsequently given to an investigator (L.S.N.), who then transported it to 
an external site for the testing session. The pharmacist was not present at the testing session.  
The investigators were blinded as to drug order and allocation. 
 
10. Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions? 
An external site colleague with experience in designing randomization for trials (Dr A. Dean) 
and not involved in this project generated the random allocation sequence. See 
Acknowledgements. 
 
13a. For each group, the numbers of participants who were randomly assigned, received 
intended treatment, and were analysed for the primary outcome 
In our cross over design 24 participants were randomly assigned and received all treatments. 
23 participants were analyzed, as described in the text. 
 
14a. Dates defining the periods of recruitment and follow-up 
Recruitment commenced on 15 July 2008 and the final session was on 23 June 2009. Follow 
up was included within this period. 
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15. A table showing baseline demographic and clinical characteristics for each group 
 Mean SD 
Age  23 5.5 
Conners Adult ADHD Rating Scale   
Conners subscale DSM-IV Inattentive 53.5 8.2 
Conners subscale DSM-IV Hyperactive Impulsive 46.6 8.6 
Conners subscale DSM-IV ADHD total symptoms 50.4 8.9 
 
16. For each group, number of participants (denominator) included in each analysis and 
whether the analysis was by original assigned groups 
23 contributed outcome data (eg SSRT) in each of the four conditions (three drugs and 
placebo). 
 
23. Registration number and name of trial registry 
The present study has not been registered at a trial registry because it does meet the definition 
of a clinical trial. Specifically,  
1) The study is conducted in a non-clinical sample rather than a patient group 
2)  The motivation of the study is not to affect clinical practice 
3) We are not administering drugs in order to influence a health outcome. 
 
The motivation for our study is to understand the neurochemical bases of aspects of cognitive 
control that are clinically relevant and the drugs that we have chosen to use are the vehicle 
used to achieve this aim.   
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CONSORT Flow Diagram 
 
Assessed for eligibility (n = 30) 
Excluded (n = 5) 
   Not meeting inclusion criteria 
(n = 5) 
 
Allocated to intervention (n = 25) 
 Received allocated intervention (n = 24) 
 Did not receive complete allocated 
intervention (wished to discontinue) (n = 1) 
Analysed (n = 23) 
 Excluded from analysis (n = 1) The stop-
signal task had not run correctly for one 
participant leading to spurious estimates of 
SSRT.  The data from this participant was 
therefore excluded.   
Allocation 
Analysis 
Follow-Up 
24 participants received a single dose of 
methylphenidate 30 mg, atomoxetine 60 mg, 
citalopram 30 mg and placebo in a 
randomized crossover design. Each 
administration was separated by 1 week for a 
total of 96 sessions (4 drug conditions by 24 
participants). 
Enrollment 
No losses to follow up  
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a b s t r a c t
Response inhibition is an executive function that allows the detection and modiﬁcation of unwanted
actions. Its underlying neurochemistry and neurobiology have been explored by combining classic
neuropsychological paradigms, such as the go/no-go task (GNG), with targeted pharmacology and
functional neuroimaging. We sought to further this literature by using single doses of methylphenidate
(30 mg), atomoxetine (60 mg), citalopram (30 mg) and placebo to probe dopaminergic, noradrenergic
and serotonergic aspects of response inhibition. Twenty-seven (27) healthy, right-handed males
participated in a randomised, double blind, placebo-controlled, within subject, crossover fMRI study to
examine stop-related BOLD activation correlates of a modiﬁed GNG task.
Methylphenidate demonstrated activation versus placebo in the pregenual cingulate (dorsal anterior
cingulate), right inferior frontal, left middle frontal, left angular and right superior temporal gyri and
right caudate. Atomoxetine demonstrated activation versus placebo across a broad network of cortical
regions. Both methylphenidate and atomoxetine, but not citalopram, activated superior temporal, right
inferior frontal and left middle frontal clusters. Citalopram only activated the left inferior occipital lobe.
Taking the above as functionally deﬁned regions of interest, we examined the speciﬁcity of stop-
related drug activity by comparing mean activations across the four conditions. Only methylphenidate
demonstrated drug-speciﬁc effects with increased activation of the pregenual cingulate and decreased
activation of the caudate.
Direct comparison of methylphenidate and atomoxetine showed broad recruitment of prefrontal
regions but speciﬁc effects of methylphenidate in the pregenual cingulate and caudate revealing
dissociable modulations of response inhibition networks.
& 2014 Elsevier Ltd. All rights reserved.
1. Introduction
Methylphenidate and atomoxetine are two of the most widely
prescribed and efﬁcacious treatments for attention deﬁcit hyper-
activity disorder (ADHD). Both medications also ameliorate deﬁcits
of response inhibition, an executive function that modiﬁes the
automatic tendency to act in a given situation, in both adult and
child ADHD populations (Aron, Dowson, Sahakian, & Robbins,
2003; Chamberlain, Del Campo et al., 2007; Gau & Shang, 2010;
Overtoom et al., 2003). These clinical ﬁndings have provided
impetus for investigating the underlying neurobiology of response
inhibition, especially when response inhibition deﬁcits are
thought to be prototypical of ADHD (Crosbie & Schachar, 2001).
Importantly, methylphenidate and atomoxetine have also been
shown to augment response inhibition in wild-type animals
(Eagle, Tufft, Goodchild, & Robbins, 2007; Robinson et al., 2008)
and healthy adults (Chamberlain, Muller, Cleary, Robbins, &
Sahakian, 2007; Nandam et al., 2011), suggesting that these agents
are modulating evolutionarily conserved, and therefore funda-
mental, response inhibition neurobiology. This work has been
driven by the clinical need for a robust foundational model of
response inhibition, not least because inhibitory impairments
extend beyond ADHD. Indeed response inhibition deﬁcits have
also been observed in obsessive-compulsive disorder (Menzies
et al., 2007), schizophrenia (Bellgrove et al., 2006), cocaine
dependence (Hester & Garavan, 2004), antisocial and borderline
personality disorders (Vollm et al., 2004) and major depression
(Langenecker et al., 2007). Importantly, these deﬁcits in executive
function have been linked to adverse clinical outcomes (Field &
O’Keefe, 2004). Yet progress towards a coherent neurobiological
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model remains limited due to the inherent difﬁculty of combining
data from heterogeneous study populations, varied drug doses and
differing response inhibition paradigms.
Classical neuropsychology asserts that response inhibition is
not a singular construct but instead has dissociable components
that can be tested through speciﬁc paradigms (Eagle, Bari, &
Robbins, 2008). One such paradigm is the go/no-go task (GNG),
which requires a motor response to be made to a dominant
stimulus or withheld to a less frequent one. The GNG assesses a
component of response inhibition known as ‘action restraint’, in
contrast to ‘action cancellation’, which is assessed by paradigms
such as the stop signal task (SST) (Eagle et al., 2008). It has been
suggested that the GNG and SST represent distinct forms of
response inhibition that have different evolutionary purposes,
and could therefore have different underlying neurobiology
(Aron, 2011). In support of this, a meta-analysis of functional
magnetic resonance imaging (fMRI) studies showed distinct,
though partially overlapping, neural circuits underpinning
response inhibition during the GNG and SST (Swick, Ashley, &
Turken, 2011). GNG inhibition was distinguishable from SST
inhibition by greater activation of the right middle frontal gyrus,
right inferior parietal lobule/precuneus and the right inferior
frontal gyrus (Swick et al., 2011). These cortical areas receive and
are modulated by ascending dopaminergic, noradrenergic and
serotonergic projections (Eagle et al., 2008). In addition to being
established treatments for ADHD, the ability of methylphenidate
and atomoxetine to modulate catecholamine levels has made
them prime candidates for pharmacoimaging studies of GNG and
SST inhibition.
The mixed noradrenaline and dopamine reuptake inhibitor,
methylphenidate, improves GNG performance in both ADHD
(Vaidya et al., 1998) and non-clinical individuals (Vaidya et al.,
1998) and remains the gold standard pharmacological treatment
for ADHD. Yet interpreting the available methylphenidate fMRI
data has been complex, with improved performance associated
with reduced caudate/putamen activity in non-clinical partici-
pants but increased caudate/putamen activity in ADHD patients
(Vaidya et al., 1998). Further, acute dosage studies have suggested
that methylphenidate modulates striatal activity during GNG
inhibition (Rosa-Neto et al., 2005; Rubia et al., 2011), as well as
down regulating activity in the inferior frontal gyrus during SST
inhibition (Pauls et al., 2012).
Atomoxetine is a non-stimulant noradrenaline reuptake inhi-
bitor that increases noradrenaline and dopamine levels in the
cortex without affecting subcortical dopamine (Chamberlain, Del
Campo et al., 2007). In contrast to methylphenidate, atomoxetine
has been associated with an up regulation of right inferior frontal
gyrus activity during SST inhibition in healthy adults (Chamberlain
et al., 2009; Graf et al., 2012). Up regulation of inferior frontal
gyrus activity has been reported during both improved and
impaired SST performance (Chamberlain et al., 2009; Graf et al.,
2012). These seemingly opposing results might be due to the
differing atomoxetine doses used in the two studies (40 mg versus
80 mg), suggesting an inverted U dose–response curve (Pauls et al.,
2012). There is less information available on the neural correlates
of GNG inhibition following acute dosage atomoxetine in healthy
adults. In a recent study of children with ADHD two parallel
groups took either methylphenidate or atomoxetine, but no
placebo, for 54 days and then completed a GNG task during fMRI
acquisition (Schulz et al., 2012). For both drugs comparable clinical
and task improvements was associated with bilateral decreases in
motor cortex activation (Schulz et al., 2012). There were, however,
differences between drug conditions in the right inferior frontal
gyrus, left anterior cingulate cortex/supplementary motor area and
bilateral posterior cingulate cortex (Schulz et al., 2012). Interest-
ingly, and in contrast to other studies of children with ADHD,
methylphenidate failed to modulate striatal activity suggesting
that acute and chronic dosing of the same compound may produce
different neurobiological activations.
In addition to the interest in ADHD pharmacotherapies, the
presence of inhibitory deﬁcits in major depression (Langenecker
et al., 2007), obsessive compulsive disorder (Menzies et al., 2007)
and personality disorder populations (Vollm et al., 2004) has
prompted analogous studies using serotonergic antidepressants.
Citalopram, a highly selective serotonin reuptake inhibitor, has
been shown to increase activation in the lateral orbitofrontal
cortex and attenuate activation in the medial orbitofrontal cortex
during GNG inhibition in healthy participants (Del-Ben et al.,
2005). Similar activations were found following chronic dosing
of escitalopram in patients with major depression during a GNG
task (Langenecker et al., 2007). There was, however, no beha-
vioural effect on GNG performance in either study (Del-Ben et al.,
2005; Langenecker et al., 2007), and citalopram does not appear to
affect SST performance (Chamberlain et al., 2006; Nandam et al.,
2011). Yet citalopram remains a treatment of interest for disorders
that exhibit impulsivity and aggression (Kamarck et al., 2009)
providing clinical impetus to keep exploring its neurobiology in
response inhibition.
Here we used fMRI to contrast the neural correlates of acute
doses of methylphenidate (30 mg), atomoxetine (60 mg) and
citalopram (30 mg) during GNG inhibition. A within-subject cross
over design was employed to control for individual differences in
neurochemistry and thus allow the direct comparison of drug
speciﬁc fMRI activation patterns. These direct comparisons are
difﬁcult to make in studies that use differing cohorts and testing
paradigms. Our study was restricted to healthy adult subjects to
maximise the applicability of ﬁndings towards foundational neu-
robiology. For each drug condition we expected that there would
be distinct but over lapping fMRI activation patterns associated
with successful inhibition, when contrasted to placebo. Methyl-
phenidate was predicted to modulate activity in the striatum, right
inferior frontal gyrus, and dorsal anterior cingulate; atomoxetine
was predicted to modulate the right inferior frontal gyrus, dorsal
anterior and posterior cingulate; and citalopram was predicted to
regulate activity in the lateral and medial orbitofrontal cortex.
To assess response inhibition we employed the Error Aware-
ness Task (EAT), a modiﬁed GNG task in which participants are
required to indicate their conscious awareness of performance
errors. In the EAT the no-go stimuli is either repeating or font-
colour congruent words, which increase its complexity when
compared to classical GNG paradigms that only use a single no-
go condition. We have previously published on error-related brain
activity elicited by this task as a function of drug condition (Hester
et al., 2012). Here we present the pharmacoimaging analysis
associated with successful GNG inhibition.
2. Methods and materials
2.1. Participants
Twenty-seven healthy (27), right-handed, 18–35 year old male participants
were recruited via advertisements at The University of Queensland and Grifﬁth
University, Queensland, Australia. A consultant psychiatrist (LSN) excluded any
participants with a history of psychiatric or neurological illness, acquired brain
injury, psychotropic medication use, or signiﬁcant illicit drug use. For further detail
please see Hester et al. (2012).
2.2. Drug administration
The study employed a randomised, double blind, placebo-controlled, within
subject, crossover design. Participants attended one testing session a week for four
(4) consecutive weeks. At each session, in a randomised order and in identical
capsules, they took either methylphenidate 30 mg, atomoxetine 60 mg, citalopram
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30 mg or placebo (dextrose). Doses were selected based upon clinical relevance to
ADHD (Michelson et al., 2003; Spencer, Biederman, Wilens, & Faraone, 1998), major
depression (Montgomery, 1995) and demonstrated cognitive effects from past
studies (Aron et al., 2003; Chamberlain, Del Campo et al., 2007; Nathan, Stough, &
Siteram, 2000). On testing days the participants were required to fast for at least
1 h before drug administration, after which they sat in a quiet waiting room for
90 min. From minutes þ90 to þ150, postdrug administration, they completed the
Error Awareness Task (EAT) during fMRI acquisition. Testing was done during this
time period because it included concomitant peak plasma levels for the three study
drugs (Henning & Netter, 2002; Muller et al., 2005; Sauer, Ring, & Witcher, 2005).
After completing the EAT participants exited the scanner and completed a SST, the
results of which have been published previously (Nandam et al., 2011).
2.3. Drug side effect screening
Participants completed Visual Analogue Scales (VAS) (Bond & Lader, 1974) to
assess subjective drug effects on alertness, contentedness and calmness. The scales
were completed at baseline; and at þ90 and þ180min post drug administration.
Blood pressure (BP) was also recorded at baseline, and again at time-points þ60 and
þ180 min, post drug administration, using an automated blood pressure monitor.
2.4. The error awareness task
In the EAT Go trials consist of consecutive single colour words, each of
800 milliseconds (ms) duration. The presentation of each word was separated by
a 700 ms interval. Participants were trained to respond to each Go-trial with a
single button press, and to withhold their response when either of two classes of
No-go trial occurred. The ﬁrst class was when the same coloured word appeared on
two sequential trials (Repeat no-go trial) and the second was when the word and
the font colour were congruent (Stroop no-go trial). Two classes of no-go trial were
included to make the EAT more difﬁcult. All go trials were colour incongruent (i.e.
the word ‘RED’ written in blue font). Key dependent variables included the
percentage of commission errors on No-go trials, and the mean correct Go response
time. The error awareness component of the EAT has been described in our
previous work (Hester et al., 2012) and required the participant to indicate their
awareness of a performance error via a secondary button response.
Each participant completed a total of 1350 trials, consisting of six blocks of 225
trials (200 go trials, 25 no-go trials), during fMRI data acquisition. 75 Repeat and 75
Stroop no-go trials were administered across the six blocks. Stimulus delivery and
response recording were controlled by E-Prime software (version 1.1; Psychology
Software Tools), which was synchronised with the MR scanner during data
acquisition. Participants made button presses with their right hand using an MR-
compatible response box (Fibre-Optic response pads; Current Designs).
2.5. fMRI screening parameters
A whole body 1.5 T Siemens Sonata scanner (Wesley Hospital, Brisbane,
Australia) was used to acquire echo planar images (EPI) using a gradient-echo
pulse sequence and sequential slice acquisition (TR, 2000 ms; TE, 30 ms; ﬂip angle,
901; 29 contiguous slices of 3 mm thickness; 10% gap; in-plane resolution of
3.6"3.6 pixels in a FOV of 384 mm). A total of 174 EPI volumes were collected for
each functional imaging run, and a total of six functional imaging runs were
performed for each participant during each of the four sessions. Activation data was
paired with high-resolution T1-weighted isotropic (1 mm3) structural MPRAGE
images to localise the pattern of neurophysiological changes associated with
the EAT.
2.6. Drug side effect screening
Full data can be found in Hester et al. (2012). Brieﬂy, the VAS did not reveal any
signiﬁcant drug" time interactions [alertness: F(6, 132)¼1.65, p40.05; contented-
ness: F(6, 132) ¼1.62, p40.05; calmness: F(6, 132)¼1.82, p40.05].
There was a signiﬁcant drug" time-point interaction for systolic blood pressure
(drug" time, F(6, 150)¼2.23, p¼0.05). Simple effects revealed an effect of time on
methylphenidate, (F¼4.25, p¼0.026). Post hoc tests showed that systolic blood
pressure was signiﬁcantly higher at þ180 min (mean¼142.62) relative to baseline
(mean¼136.12). No other simple effects were signiﬁcant (p¼0.05). There were
no signiﬁcant drug" time interactions for diastolic blood pressure (drug" time,
F(6, 132)¼1.18, p¼0.05).
2.7. Data analysis
Behavioural data from each participant were used to categorise the No-go trial
events for each drug session into successful responses (stops) and errors. All
analyses were conducted using AFNI software (http://afni.nimh.nih.gov/afni/) (Cox,
1996). Following image reconstruction, the time-series data were motion-corrected
using 3D volume registration (least-squares alignment of three translational and
three rotational parameters). Activation outside the brain was removed using edge
detection techniques.
Separate haemodynamic impulse response functions (IRFs) at 2-second tem-
poral resolution were calculated using deconvolution techniques for stop and error
events. Response functions for all regressor events were initiated at image
acquisition onsets because the presentation of all epochs-of-interest was timed
to coincide with the beginning of the 2-sec TR-cycle. A non-linear regression
programme determined the best-ﬁtting gamma-variate function for these IRFs as
previously described (Murphy & Garavan, 2005). The area under the curve of the
gamma-variate function was expressed as a percentage of the area under the
baseline. The baseline in this design is an implicit one and is indicative of task-
related go-trial processing that remains after the variance related to the other types
of events have been removed.
The percentage area (event-related activation) map voxels were re-sampled at
1 mm3 resolution, then spatially normalised to standard MNI space (MNI 152
template), and spatially blurred with a 3 mm isotropic root mean squared Gaussian
kernel. Group activation maps for drug-related effects were determined with repeated
measures t-tests of individual drug conditions versus placebo. The above procedures
were applied to each of the drug sessions independently, so that group maps were
produced for each of the three comparisons. Signiﬁcant voxels within group maps
passed a voxelwise statistical threshold (t¼2.77, pr0.01) and were required to be part
of a larger 414 ml cluster of contiguous signiﬁcant voxels. By using a combination of
probability thresholding and cluster thresholding, we aimed to maximise the power of
the statistical test whilst keeping false-positives to a minimum. To determine the
cluster threshold we used a programme called 3dClustSim. The programme was
provided with the number of voxels in the group map, the spatial correlation of voxels
(must be contiguous on three sides), and the voxelwise threshold. The programme
then ran a series of Monte Carlo simulations (10,000 iterations) to determine the
frequency of clusters of varying sizes produced by chance. From this frequency
distribution, we then selected the cluster size (414 μl given our parameters) that
occurred less than 5% of the time by chance, to give a threshold of p¼0.05 (corrected).
For comparing activity within a condition-speciﬁc cluster, mean activity estimates
for each drug condition were derived using the AFNI programme 3DRoistats.
The mean activity levels for each condition were compared using repeated measures
t-tests, corrected via Bonferroni procedure for multiple comparisons.
3. Results
3.1. Behavioural
No-go accuracy and go-trial reaction time as a function of drug
condition are presented in Table 1. The main effect of drug condition
on No-go accuracy tended towards signiﬁcance with inhibition
performance in the methylphenidate condition being higher than
the other conditions [F(3, 78)¼2.32, p¼0.08]. There was no sig-
niﬁcant interaction between drug condition and no-go trial type
Table 1
No-go accuracy and go-trial reaction time as a function of drug condition. The main effect of drug condition on No-go accuracy tended towards signiﬁcance with inhibition
performance in the methylphenidate condition being higher than the other conditions.
Category Placebo Methylphenidate Atomoxetine Citalopram
M SEM M SEM M SEM M SEM
NoGo accuracy (% correct) 50.2 4.2 54.2 4.6 47.9 4.7 47.4 4.2
GoRT (ms) 428.5 18.2 422.7 19.8 408.6 21.2 430.2 20.8
M, mean.
SEM, standard error of mean.
ms, milliseconds.
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(repeat, colour) (F(3, 78)¼1.76, p¼0.19) (Hester et al., 2012). There
was no effect of drug condition on go-RT [F(3, 78)¼0.59, p40.05].
There was a signiﬁcant main effect of no-go trial type type (repeat,
colour) (F(1, 26)¼66.6, po0.01) with higher accuracy for repeat
compared with colour no-go trials (Hester et al., 2012).
3.2. Imaging data
3.2.1. Methylphenidate versus placebo
The event-related functional analysis of stop-related BOLD
activity revealed 6 clusters of activity that differentiated the
methylphenidate from placebo condition (see Table 2). Five
clusters showed signiﬁcantly greater activity during the methyl-
phenidate condition, including the pregenual cingulate (dorsal
anterior cingulate), right inferior frontal (pars orbitalis), left mid-
dle frontal, left angular and right superior temporal gyri. One
cluster showed the opposite pattern of placebo having greater
activity than methylphenidate, in the right caudate nucleus.
3.2.2. Methylphenidate activations versus other conditions
Using these 6 clusters as functionally deﬁned regions of interest
(ROIs), we examined the speciﬁcity of methylphenidate stop-related
activity by comparing mean activity across the four drug conditions.
A bonferroni adjustment corresponding to 6 clusters by 4 drug
conditions (0.05/24) was applied. Using this statistical threshold,
methylphenidate differed from both atomoxetine, t(1, 26)¼4.35, 95%
CI¼0.039, 0.110), po0.001) and citalopram, t(1, 26)¼4.18, 95%
CI¼0.055, 0.163), po0.001) in the pregenual cingulate (dorsal
anterior cingulate) cluster (see Table 2 and Figs. 1–3). In addition,
methylphenidate showed signiﬁcantly less stop-related activation
compared to atomoxetine in the right caudate nucleus (Table 2 and
Figs. 2 and 4), t(1, 26)¼"4.16, 95% CI¼"0.103, "0.035), po0.001).
Stop-related activity within the right superior temporal, right inferior
frontal and left middle frontal clusters did not differ between
methylphenidate and atomoxetine but did differ between atomox-
etine and placebo. These data suggest largely comparable stop-
related activity associated with methylphenidate and atomoxetine
in these regions. Notably, there were no regions where citalopram
differed signiﬁcantly from placebo or the other drug conditions.
Table 2
Regions of stop-related BOLD activity showing a signiﬁcant difference between the methylphenidate and placebo conditions. The speciﬁcity of the methylphenidate
activations was tested using pair-wise comparisons between methylphenidate, atomoxetine, citalopram and placebo, bonferroni adjusted, with each of these functionally
deﬁned ROIs.
Brain region Volume (μl) MNI coordinates Signiﬁcant pair-wise
comparisons for ATM
Signiﬁcant pair-wise
comparisons for CIT
x y z
MPH4PLAC
L pregenual cingulate (dorsal anterior cingulate) 4432 "4 44 16 MPH4ATM MPH4CIT
L angular 549 "48 "70 29
R superior temporal 476 47 "26 11 ATM4PLAC
R inferior frontal 438 33 32 1 ATM4PLAC
L middle frontal 414 "30 28 43 ATM4PLAC
PLAC4MPH
R caudate nucleus 613 8 "1 7 ATM4MPH
MPH: methylphenidate; ATM: atomoxetine; CIT: citalopram; PLAC: placebo; ROI: Region of Interest.
Fig. 1. Stop-related activation differences as a function of drug condition within the
left pregenual cingulate (dorsal anterior cingulate) cluster deﬁned by the methyl-
phenidate-placebo contrast. Percent signal change within this cluster was extracted
for each drug condition and compared using ANOVA. Stop-related activity was
signiﬁcantly different in the methylphenidate compared to atomoxetine and
citalopram conditions.
Fig. 2. Stop-related activation differences as a function of drug condition within the
right caudate nucleus cluster deﬁned by the methylphenidate-placebo contrast.
Percent signal change within this cluster was extracted for each drug condition and
compared using ANOVA. Stop-related activity was signiﬁcantly reduced under
methylphenidate compared to atomoxetine. MPH: methylphenidate; ATM: ato-
moxetine; CIT: citalopram; PLAC: placebo.
Fig. 3. Stop-related BOLD activation within the left pregenual cingulate (dorsal
anterior cingulate) cluster deﬁned by the methylphenidate-placebo contrast.
L.S. Nandam et al. / Neuropsychologia 56 (2014) 263–270266
Author's personal copy
3.2.3. Atomoxetine versus placebo
The event-related functional analysis of stop-related BOLD
activity revealed 26 clusters of activity that differentiated atomox-
etine from placebo (see Table 3). All clusters showed signiﬁcantly
greater activity during the atomoxetine condition than placebo,
including the pregenual cingulate (dorsal anterior cingulate)
cortex, bilateral inferior frontal (pars orbitalis and triangularis),
left middle frontal, bilateral superior temporal, precentral, post-
central and inferior parietal gyrus.
3.2.4. Atomoxetine activations versus other conditions
As for methylphenidate, we again examined the speciﬁcity of
atomoxetine stop-related activity by comparing mean activity
across the four drug conditions across these 26 ROIs. A bonferroni
adjustment corresponding to 26 clusters by 4 drug conditions
(0.05/104) was applied. Using this statistical threshold there were
no differences between atomoxetine and either methylphenidate
or citalopram, or between each of methylphenidate and citalo-
pram and placebo that survived correction. These data suggest
that although atomoxetine compared to placebo was associated
with broad activation differences across the cortex, these stop-
related activation differences were either not speciﬁc to atomox-
etine or were not sufﬁciently robust to survive the bonferroni
correction.
3.2.5. Citalopram versus placebo
The event-related functional analysis of BOLD activity asso-
ciated with stops revealed 1 cluster of activity that differentiated
citalopram from placebo. This cluster in the left inferior occipital
lobe (X¼"37, Y¼72, Z¼"8) showed signiﬁcantly greater activity
during the citalopram condition relative to placebo.
3.2.6. Citalopram activation versus other conditions
The speciﬁcity of citalopram stop-related activity was exam-
ined by comparing mean activity across the four drug conditions
within the one citalopram-speciﬁc ROI. A bonferroni adjustment
corresponding to 1 cluster by 4 drug conditions (0.05/4) was
applied. Using this statistical threshold there were no differences
between citalopram and either methylphenidate or atomoxetine,
or between each of methylphenidate and atomoxetine and placebo
that survived correction.
4. Discussion
In this study we used fMRI to contrast the neural effects of
methylphenidate, atomoxetine, citalopram and placebo during
GNG inhibition in healthy adults. We found that during stops
(successful ‘no-go’ inhibitions), methylphenidate and atomoxetine
produced similar patterns of cortical activation that were not
shared by citalopram or placebo. In addition, methylphenidate
was dissociable from atomoxetine, citalopram and placebo,
in terms of its modulation of activity in the pregenual cingulate
(dorsal anterior cingulate).
Fig. 4. Stop-related BOLD activation within the right caudate cluster deﬁned by the
methylphenidate-placebo contrast (transverse and coronal views).
Table 3
Regions of stop-related BOLD activity showing a signiﬁcant difference between the
atomoxetine and placebo.
Brain region Volume
(μl)
MNI coordinates
x y z
L middle frontal 3299 "27 21 46
L superior temporal 3179 "53 "23 14
L cuneus 1910 "13 "72 11
L postcentral 1714 "32 "35 60
R precentral 1216 25 "27 56
R insula 1140 42 "19 11
R inferior frontal (p. Opercularis) 760 34 12 34
L inferior parietal 731 "47 "26 38
R postcentral 725 55 "12 20
L inferior occipital 693 "34 "74 "10
R superior temporal 681 37 "36 19
R superior frontal 677 20 "12 63
L middle occipital 637 "42 "78 18
R medial frontal 607 3 "32 63
R lingual 596 21 "80 "6
L inferior frontal (p. Opercularis) 520 "44 8 22
L precentral 512 "22 "21 65
R inferior frontal (p. Triangularis) 503 43 26 17
R pregenual cingulate (dorsal anterior cingulate) 494 "5 41 7
Right cuneus 491 20 "94 10
R superior parietal 483 24 "65 53
Left inferior frontal (p. Orbitalis) 471 "51 40 "4
Left SMA 471 "1 "12 57
Right inferior frontal (p. Orbitalis) 446 44 25 "16
Right amygdala 423 34 "2 "9
L pregenual cingulate (dorsal anterior cingulate) 420 "7 26 31
Although widespread activations across the brain were seen for atomoxetine
compared to placebo, pair-wise comparisons (bonferroni adjusted) between
methylphenidate, atomoxetine, citalopram and placebo within these functionally
deﬁned ROIs, did not reveal any regions in which atomoxetine differed signiﬁcantly
from either methylphenidate or citalopram.
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Our ﬁnding that methylphenidate modulated stop-related
activity in the caudate is consistent with earlier pharmacoimaging
GNG studies in ADHD and healthy children (Vaidya et al., 1998).
The caudate has a rich dopaminergic innervation and blockade of
dopamine transporters by methylphenidate likely underlies the
observed changes in fMRI signal (Volkow et al., 2007). Lesion,
microstimulation and imaging work have shown that the caudate
is important for the selection of goal-relevant motor behaviours
(Benke, Delazer, Bartha, & Auer, 2003; Lou et al., 2004; Vaidya
et al., 2005). Hence in the case of successful inhibition during the
GNG, methylphenidate may facilitate the accurate selection and
suppression of competing motor outputs through optimisation of
caudate activity (Dockree et al., 2004). Whether this ‘optimisation’
results in up or down regulation of caudate activity may depend
on individual differences in population baseline dopamine char-
acteristics. Indeed positron emission tomography (PET) has shown
that methylphenidate-induced changes in brain metabolism vary
as a function of striatal dopamine transporter (DAT) availability
(Volkow et al., 1997). The differences in DAT density between
ADHD and healthy populations likely underlie the opposing
patterns of striatal activation seen between these groups under
methylphenidate (Volkow et al., 1997). In healthy adults, such as in
our study, methylphenidate at the dose administered is able to
inhibit 60–70% of striatal DAT (Volkow et al., 2007) leading to a net
decrease in striatal activity, which could then translate into a
reduction of fMRI signal (Pauls et al., 2012). Non-drug fMRI studies
have conﬁrmed the importance of the striatum during response
inhibition with the anterior cingulate and right prefrontal cortex
regions also being implicated (Vink et al., 2005).
Theoretical models hold that the anterior cingulate is function-
ally interconnected with the basal ganglia and prefrontal cortex to
form a key node of the response inhibition network (Aron,
Robbins, & Poldrack, 2004). During response inhibition each of
these regions may contribute speciﬁc task elements to the ﬁnal
behavioural outcome (Aron et al., 2004). Hence whilst the pre-
frontal cortex maintains goals and the basal ganglia suppress
irrelevant motor responses, the anterior cingulate may detect
response conﬂict (Aron et al., 2004). In keeping with this, anterior
cingulate activity has been noted during tasks that require the
evaluation of incongruent stimuli to overcome a pre-potent
response, such as in the Stroop test (MacDonald, Cohen, Stenger,
& Carter, 2000). Therefore anterior cingulate activation during
response inhibition might reﬂect the conﬂict that occurs when
two incompatible responses, such as whether to go or stop, are
both compelling (MacDonald et al., 2000). Methylphenidate may
facilitate the pregenual cingulate (dorsal anterior cingulate) acti-
vations we observed via modulation of the prominent dopami-
nergic projections that project from the ventral tegmental to
medial frontal areas (Williams & Goldman-Rakic, 1998). The ability
of methylphenidate to block noradrenaline transporters might also
contribute to the activation, in keeping with the reciprocal con-
nectivity between the prefrontal cortex, anterior cingulate and
locus ceruleus (Morrison, Foote, O’Connor, & Bloom, 1982). Recep-
tor autoradiography studies show that the human, primate and
rodent pregenual cingulate (dorsal anterior cingulate) are densely
populated with GABAA and GABAB receptors suggesting that the
region is responsible for inhibitory modulation and has been
evolutionarily conserved (Vogt et al., 2013).
Successful inhibition under atomoxetine was associated with
broad activation of cortical regions including the right inferior
frontal gyrus, right superior temporal gyrus and right insula,
compared to placebo. Activation of the right fronto-temporal
junction is consistent with previous single dose studies of ato-
moxetine (Chamberlain et al., 2009) and likely demonstrates the
recruitment of the cortical portion of the response inhibition
network (Aron et al., 2004; Chambers et al., 2006). Activation
was also seen in other components of the response inhibition
network including the anterior cingulate and supplementary
motor area. Atomoxetine has been shown to increase noradrena-
line and dopamine levels in the cortex via blockade of promiscu-
ous noradrenaline transporters (Bymaster et al., 2002), and fMRI
activations likely represent modulation of these catecholamines
(Chamberlain et al., 2009). Atomoxetine's inability to modulate
caudate activity is consistent with the scarcity of noradrenaline
transporters in the striatum (Bymaster et al., 2002). Although we
did not observe any regions from the atomoxetine-deﬁned activa-
tion maps that speciﬁcally differed compared to methylphenidate
or citalopram, this could be a result of our correction for multiple
comparisons across the 26 observed clusters and the four drug
comparisons.
Activation of the right inferior frontal, left middle frontal and
right superior temporal gyri were seen across both the methyl-
phenidate and atomoxetine deﬁned GNGmaps, relative to placebo,
but not the citalopram map. This is consistent with the shared
ability of methylphenidate and atomoxetine to block noradrena-
line transporters in the prefrontal cortex, which leads to compar-
able increases between these drugs in prefrontal catecholamines
(Berridge et al., 2006; Bymaster et al., 2002; Lewis et al., 2001).
Increased levels of dopamine and noradrenaline are thought to
then modulate D1 and α2A receptors, respectively, which ﬁne-tune
neuronal activity producing changes in frontal signal (Gamo,
Wang, & Arnsten, 2010). These data suggest that acute doses of
methylphenidate and atomoxetine recruit similar cortical regions
in the service of response inhibition.
We did not observe any modulation by citalopram of the classic
neural circuitry for response inhibition. These data were consistent
with a recent GNG study in which acute dosing of citalopram was
compared to placebo in healthy participants (Macoveanu et al.,
2013). Earlier studies (Del-Ben et al., 2005; Langenecker et al.,
2007) had identiﬁed cortical regions associated with citalopram
and GNG, including occipital cortex activation as seen in our study,
but it remains unclear how this relates to theoretical frameworks
of serotonergic modulation of response inhibition (Eagle et al.,
2008). Behavioural studies have also failed to ﬁnd any beneﬁcial
effect of citalopram on response inhibition (Chamberlain et al.,
2006; Del-Ben et al., 2005; Langenecker et al., 2007; Macoveanu
et al., 2013; Nandam et al., 2011). Hence it appears that acute dose
citalopram might be a sub-optimal probe for exploring the role of
serotonin in human response inhibition.
There were some limitations to our study. The usage of two
different no-go trial types might have recruited different neuro-
biological mechanisms during inhibition though there was no
difference in inhibitory performance as a function of trial type
and drug condition. We also did not observe a signiﬁcant main
effect of drug on inhibition performance despite drug effects on
brain activation being in line with expectations. Speciﬁcally, stop-
related activations in the caudate and pregenual cingulate (dorsal
anterior cingulate) were speciﬁc to methylphenidate, suggesting
complimentary neural processes that may augment response
selection and inhibition during the GNG task. This speciﬁcity
may have contributed to the trend for behavioural performance
under methylphenidate to be superior to all other drug conditions,
although this will require further conﬁrmation. We also found that
methylphenidate and atomoxetine, but not citalopram, were both
associated with the activation of classical inhibition regions
including the inferior frontal gyrus.
A further limitation of this study was the use of single rather
than chronic dosing of atomoxetine and citalopram, both of which
reach maximum efﬁcacy in clinical populations only after weeks of
administration (Montoya et al., 2009). This may have weakened
our ability to detect drug-speciﬁc effects for atomoxetine and
citalopram. Nonetheless, the ability of methylphenidate, and to
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a lesser degree atomoxetine, to modulate the neural circuitry of
response inhibition after acute dosage (Chamberlain et al., 2006;
Nandam et al., 2013) remains relevant to speciﬁc clinical scenarios
such as drug holidays (Martins et al., 2004) or cognitive enhance-
ment in healthy adults (Finger, Silva, & Falavigna, 2013). Our study
demonstrates the common and dissociable neural correlates of
response inhibition between methylphenidate and atomoxetine,
and is suggestive of a mechanism underlying the difference in
effective size seen in ADHD treatment (Newcorn et al., 2008).
A signiﬁcant strength of this study was the within subject
design that allowed the direct comparison of the neural correlates
of GNG under methylphenidate, atomoxetine, citalopram and
placebo. Further within-subject imaging studies using agents that
are more selective and speciﬁc, particularly for D1, D2, and α2A
receptors, will allow a more precise delineation of the neuro-
chemical bases of response inhibition.
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How the brainmonitors ongoing behavior for performance errors is a central question of cognitive neuroscience. Diminished awareness
of performance errors limits the extent to which humans engage in corrective behavior and has been linked to loss of insight in a number
of psychiatric syndromes (e.g., attention deficit hyperactivity disorder, drug addiction). These conditions share alterations in mono-
amine signaling that may influence the neural mechanisms underlying error processing, but our understanding of the neurochemical
drivers of these processes is limited.We conducted a randomized, double-blind, placebo-controlled, cross-over design of the influence of
methylphenidate, atomoxetine, and citalopram on error awareness in 27 healthy participants. The error awareness task, a go/no-go
response inhibition paradigm, was administered to assess the influence of monoaminergic agents on performance errors during fMRI
data acquisition. A single dose of methylphenidate, but not atomoxetine or citalopram, significantly improved the ability of healthy
volunteers to consciously detect performance errors. Furthermore, this behavioral effect was associated with a strengthening of activa-
tion differences in the dorsal anterior cingulate cortex and inferior parietal lobe during the methylphenidate condition for errors made
with versuswithout awareness. Our results have implications for the understanding of the neurochemical underpinnings of performance
monitoringand for thepharmacological treatmentof a rangeofdisparate clinical conditions that aremarkedbypoor awarenessof errors.
Introduction
The neural basis of error-processing has become a key research
interest in cognitive neuroscience, not only because of its rele-
vance to human cognitive performance but also because dysfunc-
tion of self-monitoring is seen in a range of clinical conditions,
such as traumatic brain injury (TBI), schizophrenia, attention
deficit hyperactivity disorder (ADHD), and drug addiction
(Carter et al., 2001; Kaufman et al., 2003; Rubia et al., 2005;
O’Keeffe et al., 2007). In these conditions, diminished awareness
of errors has been linked to clinical symptoms, such as inatten-
tion, poor insight, and perseverative behavior, which in turn are
predictors of poor treatment outcome and functional recovery
(Mintz et al., 2004; O’Keeffe et al., 2004). Despite the clear im-
perative to understand and remediate such deficits, the issue of
awareness, and its instantiation in the brain, has been primarily
overlooked.
Recent electrophysiological work has demonstrated that the
early stages of error processing are preconscious and are unaf-
fected by an individual’s awareness of that error but later process-
ing stages are only initiated if the error is consciously perceived
(Nieuwenhuis et al., 2001;O’Connell et al., 2007; Steinhauser and
Yeung, 2010). This distinction has implications previous studies
that have shown abnormalities in error-related activity in a range
of clinical groups without controlling for potential differences in
error awareness. Studies that have contrasted errors that partici-
pants were or were not aware of have identified a bilateral net-
work of frontal and parietal regions (Nieuwenhuis et al., 2001;
Hester et al., 2005; Klein et al., 2007). Interestingly, this work has
failed to show a predictive relationship between dorsal anterior
cingulate cortex (dACC) activity and error awareness (Hester et
al., 2005; Klein et al., 2007), despite this region having a central
role in models of performance monitoring and its dysfunction in
a range of clinical disorders that involve awareness deficits.
Current models of performance monitoring argue that a pha-
sic decrease in midbrain dopamine (DA) provides a reward-
prediction error to the dACC, which coordinates post-error
adaptation of behavior (Holroyd and Coles, 2002). Othermodels
have suggested roles for norepinephrine (NE) (Nieuwenhuis et
al., 2005) and serotonin (5-HT) (Cools et al., 2008) in perfor-
mance monitoring (Jocham and Ullsperger, 2009). Pharmaco-
logical manipulations of error-related brain activity have shown
that enhancing catecholamines with amphetamine (de Bruijn et
al., 2004; de Bruijn et al., 2006) or the!2 adrenoceptor antagonist
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yohimbine (Riba et al., 2005) increased the amplitude of the
error-related negativity (ERN).Methylphenidate (MPH) has also
been shown to be effective in treating the cognitive deficits asso-
ciated with TBI (Willmott and Ponsford, 2009), in which there is
a fundamental problem of reduced awareness (O’Keeffe et al.,
2004). In contrast, the D2 receptor antagonist haloperidol (Zirn-
held et al., 2004) and the GABAA/benzodiazepine receptor mod-
ulators lorazepamand oxazepam (Johannes et al., 2001; de Bruijn
et al., 2004) have been shown to decrease error-related dACC
activity. Crucially, because the cognitive paradigms used in these
studies did not explicitly test for conscious awareness of errors,
one cannot disambiguate the effects of the pharmacological ma-
nipulation on preconscious versus conscious error processing.
Monoamine reuptake inhibitors, such as MPH, atomoxetine
(ATM), and citalopram (CIT), are routinely used to treat clinical
disordersmarked by poor error awareness.Herewe examined the
effect of a single acute dose of MPH, ATM, CIT, and placebo
(PLAC) using a randomized, placebo-controlled, crossover de-
sign on the proportion of behavioral errors that escaped con-
scious awareness.
Materials andMethods
Subjects. Twenty-seven male subjects (mean age, 22 years; range, 18–35
years)were recruited for this study via advertisements at theUniversity of
Queensland (Brisbane, QLD, Australia). All participants were right
handed and were excluded if they reported any history of psychiatric or
neurological illness, including head injury, previous usage of psychotro-
pic medication, or significant drug use [significant was defined as fol-
lows: (1) use of any illicit substances within the lastmonth; (2)more than
five lifetime intake of any illicit drug except cannabis; and (3) more than
monthly cannabis intake], smoking (more than five cigarettes per week),
or alcohol dependence (!24 units per week). Before commencing, all
participants were screened by a consultant psychiatrist who also admin-
istered the M.I.N.I. Screen (Sheehan et al., 1998) and the Kessler K10
(Kessler et al., 2003).
All participants were recruited according to the principles of the Dec-
laration of Helsinki and in accordance with the ethical guidelines of the
University of Queensland and the Wesley Hospital (Brisbane, QLD,
Australia).
Drug administration. Participants were tested on the same day and at
the same time for 4 consecutive weeks. On each occasion, the participant
ingested with water (in a randomized order) a single blue gelatin capsule
containing 30 mg of MPH, 60 mg of ATM, 30 mg of CIT, or PLAC
(dextrose). Dosage selection was based on clinically relevant doses for
ADHD (Spencer et al., 1998; Michelson et al., 2003) and depression, as
well as on data from previous acute challenge studies that have demon-
strated neurocognitive effects of these drugs (Nathan et al., 2000; Aron et
al., 2003; Chamberlain et al., 2006)
All participants were required to fast for at least 1 h before drug ad-
ministration. Caffeine was not to be consumed on test days. After drug
administration, subjects rested in a quiet waiting room for 90min before
commencing. From minutes "90 to "150 (after administration), sub-
jects undertook the fMRI experiment testing error awareness. Task tim-
ing was based on the region of concomitant peak plasma levels for the
three study drugs (#90–180 min after oral ingestion in adults) (Kragh-
Sorensen et al., 1981; Henning and Netter, 2002; Sauer et al., 2005) and
on findings from previous neurocognitive studies (Aron et al., 2003;
Chamberlain et al., 2006). Data on the influence of these agents on sub-
jective (visual analog scales) and physiological measures (e.g., blood
pressure) are presented.
Behavioral task. To examine conscious recognition of errors, we ad-
ministered the error awareness task (EAT) (Fig. 1) (Hester et al., 2005), a
motor go/no-go response inhibition task in which subjects make errors
of commission of which they are aware (aware errors) or unaware (un-
aware errors). Using this task, we have previously examined the neural
mechanisms associated with error awareness (Hester et al., 2005;
O’Connell et al., 2007), as well as the diminished awareness of perfor-
mance errors in ADHD (O’Connell et al., 2009) and drug addiction
(Hester et al., 2007). The EAT presents a serial stream of single color
words, with the word presented for 800 ms followed by a 700 ms inter-
stimulus interval. Participants were trained to respond to each of the
words with a single “go trial” button press and withhold this response
when either of two different circumstances arose. The first circumstance
arose if the same word was presented on two consecutive trials (“repeat
no-go”) and the second if the word and its font color matched (“color
no-go”) rather than the typical word and color incongruency (for exam-
ples, see Fig. 1). By having two competing types of response inhibition,
we aimed to vary the strength of stimulus–response relationships,
whereby representations of rules competitively suppress one another
such that themore prepotent rule would suppress the weaker rule and so
produce a significant number of errors, a small proportion of whichmay
go unnoticed as a result of focusing primarily on the prepotent rule. To
indicate “error awareness,” participants were trained to forego the regu-
lar go-trial button response (left) and instead to make a non-speeded
responsewith the alternative (right) button on the trial immediately after
a commission error. Although the online assessment of error awareness
Figure 1. The EAT. The EAT presents a serial stream of single color words in incongruent fonts, with theword presented for 800ms followed by a 700ms interstimulus interval. Participants were
trained to respond to each of the words with a single go trial (left) button press and to withhold this response when either of two different circumstances arose. The first was if the same word was
presented on two consecutive trials (repeat no-go), and the secondwas if theword and font of thewordmatched (color no-go). To indicate error awareness, participants were trained to forego the
regular go-trial button response (left; L) and instead to respond with the alternative (right; R) button after any commission error. Past studies have demonstrated that error-related BOLD signal is
uninfluenced by the awareness response itself (Hester et al., 2005). Although levels of awareness undoubtedly vary on a continuum,wemade a qualitative distinction between aware and unaware
errors to facilitate our event-related fMRI analysis.
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required that the participant make an additional overt response, control
experiments with the EAT have ruled out the possibility that error-
related brain activity might be contaminated by this additional response
demand (Hester et al., 2005; O’Connell et al., 2007).
Before entering the MRI scanner, participants practiced two novel
blocks of the task to ensure they understood the task instructions. Six
blocks of 225 trials (200 go trials, 25 no-go trials) for a total of 1350 trials
were administered duringMRI data collection. An equivalent number of
color and repeat no-go trials were administered across the six blocks for
a total of 75 repeat and 75 color no-go trials. All aspects of stimulus
delivery and response recording were controlled by E-Prime software
(version 1.1; Psychology Software Tools) running on a laptop computer,
which was interfaced with the MR scanner during acquisition of fMRI
data. Participants responded to each stimulus using their right hand,
entering their response on anMR-compatible response box (Fiber-Optic
response pads; Current Designs).
Scanning parameters. FunctionalMR imageswere acquired at theWes-
ley Hospital (Auchenflower, Brisbane, QLD, Australia) using a whole-
body 1.5 tesla Siemens Sonata scanner with a gradient-echo echo-planar
imaging (EPI) sequence. The quadrature transmit-receive radiofre-
quency head coil was for signal acquisition. Echo planar images were
acquired using a gradient-echo pulse sequence and sequential slice ac-
quisition (TR, 2000ms; TE, 30 ms; flip angle, 90°; 29 contiguous slices of
3 mm thickness; 10% gap; in-plane resolution of 3.6 ! 3.6 pixels in a
FOV of 384 mm). A total of 174 EPI volumes were collected for each
functional run, and a total of six functional runs were performed for each
participant, during each of the four sessions. Activation data were regis-
tered to high-resolution T1-weighted isotropic (1 mm3) structural
MPRAGE images, collected during each of the four sessions, to localize
the pattern of physiological changes associated with the task.
Data analysis. Behavioral data from each participant were used to
categorize the no-go trial events for each drug session into successful
responses (stops), aware errors, and unaware errors. All analyses were
conducted using AFNI software (http://afni.nimh.nih.gov/afni/)(Cox,
1996). After image reconstruction, the time-series data weremotion cor-
rected using 3D volume registration (least-squares alignment of three
translational and three rotational parameters). Activation outside the
brain was removed using edge detection techniques.
Separate hemodynamic impulse response functions (IRFs) at 2 s tem-
poral resolution were calculated using deconvolution techniques for
aware errors, unaware errors, and stop events. Response functions for all
regressor events were initiated at image acquisition onsets because the
presentation of all epochs-of-interest was timed to coincide with the
beginning of the 2 s TR cycle. A nonlinear regression program deter-
mined the best-fitting gamma-variate function for these IRFs as de-
scribed previously (Murphy and Garavan, 2005). The area under the
curve of the gamma-variate functionwas expressed as a percentage of the
area under the baseline. The baseline in this design is an implicit one and
is indicative of task-related go-trial processing that remains after the
variance related to the other types of events have been removed.
The percentage area (event-related activation) map voxels were resa-
mpled at 1 mm3 resolution, then spatially normalized to standard MNI
space (MNI 152 template), and spatially blurred with a 3 mm isotropic
root mean squared Gaussian kernel. Group activation maps for event
type (errors, stops) were determined with one-sample t tests against the
null hypothesis of zero event-related activation changes (i.e., no change
relative to baseline). The above procedures were applied to each of
the four drug sessions independently, so that group maps of errors were
available for each of the four conditions. Significant voxels within group
maps passed a voxelwise statistical threshold (t" 4.69, p! 0.00001) and
were required to be part of a larger 72"l cluster of contiguous significant
voxels. By using a combination of probability thresholding and cluster
thresholding, the aim is tomaximize the power of the statistical test while
holding the likelihood of false positives to aminimum. To determine the
cluster threshold, we use a program called 3dClustSim. The program is
provided with the number of voxels in the group map, the spatial corre-
lation of voxels (must be contiguous on three sides), and the voxelwise
threshold. The program then runs a series of Monte Carlo simulations
(10,000 iterations for our study) to determine the frequency of clusters of
varying sizes produced by chance. From this frequency distribution, we
then select the cluster size (72"l given our parameters) that occurs#1%
of the time by chance, to give a threshold of p" 0.01 (corrected).
The comparison of interest was between aware and unaware errors.
Because of the significant behavioral effect of MPH on error awareness,
the activation clusters from whole-brain analyses of errors in both the
PLAC and MPH conditions were used to create an OR map for the
purposes of a region-of-interest (ROI) analysis. An OR map includes
the voxels of activation indicated as significant from either of the constit-
uent maps. The mean activation for clusters in the combined error map
was then calculated for the purposes of an ROI analysis, deriving mean
activation levels for aware and unaware errors in each of the conditions,
which were compared using repeated-measures t tests, corrected via a
modified Bonferroni’s procedure for multiple comparisons (Keppel,
1991). To examine the specificity of this effect, we also performed the
same analysis on the OR map of ATM and PLAC conditions.
Results
Behavioral results
Performance indices from the EAT for all four drug conditions
are presented in Figure 2 and Table 1. Tests of normality revealed
that behavioral measures of inhibition accuracy and error aware-
ness from the EAT task were not normally distributed, and these
were transformed using an arcsine function before analysis with
parametric analyses. The proportion of EAT no-go inhibition
errors of which participants (n" 27) indicated awareness during
each of the four drug conditions (MPH, ATM, CIT, and PLAC)
was examined using repeated-measures ANOVA. A significant
main effect of drug condition was present (F(3,78) " 10.28, p #
0.001), with participants aware of a significantly higher pro-
portion of errors in the MPH condition when compared with
PLAC (p# 0.008, Bonferroni’s adjusted probability threshold
corrected for multiple post hoc comparisons; Cohen’s d$ "
2.34), ATM, or CIT conditions. ATM was also associated with
an improvement in error awareness compared with PLAC
(p " 0.046), although this effect did not survive Bonferroni’s
adjustment.
There was a trend for response inhibition accuracy on no-go
trials to differ as a function of drug condition (F(3,78)" 2.32, p"
Figure 2. Behavioral performance on the EAT. A, The proportion of errors for which partici-
pants (n" 27) indicated awareness of errors as a function of the four drug conditions: MPH,
ATM, CIT, and PLAC. A significant main effect of drug condition was present (F(3,78)" 10.28,
p# 0.001). Participants were aware of a significantly higher proportion of errors in the MPH
condition than in thePLAC, ATM, or CIT conditions (*p#0.008 for all comparisons, Bonferroni’s
adjusted). B, The percentage of successful response inhibitions on EAT no-go trials during each
of the four drug conditions. There was a trend toward a main effect of drug condition on the
percentage of response inhibition errors (F(3,78)" 2.32, p" 0.08).
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0.08). Exploratory post hoc analysis demonstrated significant im-
provement in response inhibition in the MPH condition when
compared with PLAC (p! 0.009, Cohen’s d" ! 0.40). Consistent
with previous use of this task (Hester et al., 2005; O’Connell et al.,
2007), individual differences in response inhibition performance
were not associated with awareness of errors (PLAC, r!#0.04,
p! 0.84; MPH, r! 0.02, p! 0.91).
The influence of no-go type (repeat, color) on error awareness
and response inhibition accuracy was also examined in separate 2
(no-go type) $ 4 (drug) repeated-measures ANOVAs. Error
awareness rates showed a significant main effect of no-go type
(F(1,26)! 19.9, p! 0.01), with poorer awareness of repeat errors
comparedwith color, an effect previously demonstratedwith this
task (Hester et al., 2009). There was, however, no significant in-
teraction between no-go type and drug condition for error
awareness rates (F(3,78)! 0.52, p! 0.67). The comparable anal-
ysis for successful response inhibition demonstrated a significant
main effect of no-go type (F(1,26)! 66.6, p! 0.01), with accuracy
significantly higher for repeat no-go trials compared with color
[also replicating a previous finding (Hester et al., 2009)] but again
no interaction between no-go type and drug condition (F(3,78)!
1.76, p! 0.19).
There was neither a significant main effect of drug condition
on go trial response time (RT) (F(3,78)! 0.59, p! 0.62) nor no-go
error RT (F(3,78) ! 1.41, p ! 0.24). Although no-go error RT
significantly differed between aware and unaware errors (F(3,66) !
11.5, p! 0.003), there was no interaction with drug condition
(F(3,66) ! 2.24, p ! 0.14).
Post-error RTs showed two distinct patterns consistent with
previous use of this task (Hester et al., 2005, 2007), with faster RT,
or speeding up, after an aware error (post-aware error go trial
RT# pre-aware error go trial RT!#150.6 ms) and slower RT
after an unaware error (post-unaware error go trial RT # pre-
unaware error go trial RT ! 52.9 ms). Post-aware error RT was
significantly faster than post-unaware error RT (F(1,21) ! 156.8,
p! 0.01), but drug condition did not have a significant effect on
either post-aware error RT (F(3,78) ! 1.8, p ! 0.15) or post-
unaware error RT (F(3,63) ! 1.5, p ! 0.21). The interaction be-
tween drug condition and post-error RT changes was also
nonsignificant (F(3,63) ! 0.72, p ! 0.54). It is important to note
that the speeding of post-aware error responses is confounded by
subjects providing the alternate “awareness” button press (in
which the go stimulus is ignored), but a similar pattern of signif-
icantly faster RT was observed for the second go trial after an
aware error.
Effects of drug on subjective ratings and blood pressure
Participants completed visual analog scales (Norris, 1971; Bond
and Lader, 1974) to assess possible drug effects on subjective
alertness, contentedness, and calmness. Sixteen opposing subjec-
tive states were rated at baseline and %90 and %180 min after
capsule administration. A log transformation was applied to the
items. Factors of “alertness,” “contentedness,” and “calmness”
were calculated by taking the mean transformed score across
loading items for each time point. Each factor was then subject to
a 4 (drug) $ 3 (time) repeated-measures ANOVA. Crucially,
there were no significant drug $ time interactions (alertness,
F(6,156)! 1.14, p& 0.05; contentedness, F(6,156)! 0.50, p& 0.05;
calmness, F(6,156)! 1.41, p& 0.05).
Blood pressure was also recorded at baseline and then again at
time points%60 and%180 min. There was a significant drug$
time-point interaction for systolic blood pressure (drug$ time,
F(6,150)! 2.23, p' 0.05). Simple effects revealed an effect of time
onMPH, (F! 4.25, p! 0.026).Post hoc tests showed that systolic
blood pressure was significantly higher at %180 min (mean !
142.62) relative to baseline (mean ! 136.12). No other simple
effects were significant (p & 0.05). There were no significant
drug $ time interactions for diastolic blood pressure (drug $
time, F(6,132)! 1.18, p& 0.05).
Imaging data: errors
The event-related functional analysis of BOLD activity associated
with errors revealed 12 clusters of activity that differentiated
aware from unaware errors (see Table 2). In contrast with null
results from previous studies (Nieuwenhuis et al., 2001; Hester et
al., 2005; Klein et al., 2007; O’Connell et al., 2007), we identified
an activity cluster in the dACC region (x!#1, y! 9, z! 41) that
also showed significantly greater activity during aware versus un-
aware errors (Fig. 3). This effect appeared consistently and ro-
bustly across drug conditions, with the difference between aware
and unaware error activity within this dACC ROI significant for
each of the drug conditions (Fig. 3).
To examine the association between changes in BOLD activity
and the behavioral improvement in awareness during the MPH
condition, we tested for interaction effects, focusing on the com-
parison between MPH and PLAC in which behavioral effects
were maximal. Error-related ROIs from the group maps of the
PLAC and MPH conditions were combined, including all signif-
icant voxels from the two constituent maps (Hester et al., 2005),
to examine mean BOLD activity during each of the four event
Table 1. Mean accuracy, RT, and SE of measurement scores for participants
(n! 27) during the four drug conditions of the EAT
Placebo Methylphenidate Atomoxetine Citalopram
Category M SEM M SEM M SEM M SEM
No-go accuracy (% correct) 50.2 4.2 54.2 4.6 47.9 4.7 47.4 4.2
Error awareness (% of aware
errors)
80.5 2.4 91.1 1.9 85.1 2.1 81.8 1.9
Go RT (ms) 428.5 18.2 422.7 19.8 408.6 21.2 430.2 20.8
No-go error RT (ms) 467.2 23.9 443.8 20.1 428.4 21.2 457.5 25.6
Aware error RT (ms) 458.1 22.2 433.4 20.6 417.2 23.8 437.6 25.1
Unaware error RT (ms) 508.9 37.1 511.6 36.6 448.2 28.6 461.2 30.4
Post-aware# pre-aware error RT
(ms)
#0.142.6 16.9 #164.4 17.2 #135.4 18.2 #146.6 17.2
Post-unaware# pre-unaware
error RT (ms)
36.5 12.2 23.1 16.5 95.1 42.3 57.1 17.1
Post-aware (n% 2)# pre-aware
error RT (ms)
#88.3 10.2 #84.8 9.6 #86.4 10.7 #88.0 9.3
M, Mean.
Table 2. Regions of error-related BOLD activity in the PLAC conditionmapwhose
level of activity differentiated aware from unaware errors
MNI coordinates
Brain region Volume (!l) x y z
Aware errors& unaware errors
L Inferior parietal 3984 #46 #36 47
L Anterior cingulate 2082 #1 9 41
L Supplementary motor area 1952 #2 #11 55
R Inferior parietal 1855 48 #52 36
L Precuneus 1718 #1 #75 33
L Insula 332 #53 10 8
R Supramarginal 278 50 #30 38
R Insula 258 44 11 1
R Inferior parietal 191 38 #42 42
R Cerebellum 141 16 #53 #23
L Precentral 91 #27 #28 70
R Inferior frontal 80 52 3 36
L, Left; R, right.
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types. Because of the improvement in error awareness withMPH,
five participants had insufficient unaware error events for inclu-
sion in this analysis. The resulting interaction analysis was there-
fore based on the remaining 22 participants. We note that the
benefit to error awareness conferred by MPH, relative to PLAC,
remained significant in this subsample (F(1,21)! 31.9, p" 0.001)
We used a two-drug condition (PLAC, MPH) # 2 error type
(aware, unaware) repeated-measures ANOVA to compare aware
and unaware error-related activity during the PLAC and MPH
conditions. Significantmain effects for drug conditionwere iden-
tified in the right middle frontal, left insula, and right inferior
frontal regions, with all clusters showing significantly greater ac-
tivity during theMPHconditionwhen comparedwith PLAC (see
Table 3). Consistent with the results from the PLACmap, signif-
icant main effects of awareness were detected in bilateral inferior
parietal, left insula, bilateral precuneus, bilateral middle frontal,
right temporal, right cerebellar, and right angular gyrus regions.
All regions showed significantly greater activity during aware er-
rors when compared with unaware errors. The three regions
showing main effects for the effect of MPH did not differentiate
aware from unaware errors.
Only two clusters demonstrated significant interaction effects:
the left inferior parietal lobe (IPL) and the dACC (Fig. 4). Both
regions demonstrated the same pattern of activity, wherebyMPH
produced an increase in aware error activity (relative to PLAC)
and a decrease in unaware error activity (relative to PLAC).
To clarify the neuroanatomical specificity of the effect ofMPH
on activity differences in the left IPL and dACC, we performed
two additional analyses, this time comparing changes in BOLD
activity and behavioral improvement in awareness during the
ATM condition. First, we repeated the steps from above and sub-
stituted the ATMcondition for theMPH. Significantmain effects
for drug conditionwere identified in six regions, the right inferior
parietal, left insula, left caudate, posterior cingulate, left supra-
marginal, and right middle frontal, with all clusters showing sig-
nificantly greater activity during the ATM condition when
compared with PLAC (Table 4). Consistent with the results from
the PLAC map, significant main effects of awareness were de-
tected in bilateral inferior parietal, left insula, bilateral precuneus,
bilateral middle frontal, right temporal, right cerebellar, and tha-
lamic regions. All regions showed significantly greater activity
during aware errors when compared with unaware errors.
Two regions (Fig. 4C,D), the left inferior frontal gyrus (IFG)
(MNI: x!$54, y! 3, z! 13) and right inferior temporal gyrus
(ITG) (x ! 56, y ! $54, z ! $6), demonstrated significant
interaction effects. Both regions showed the same pattern of ac-
tivity, whereby ATMwas associated with a large increase in aware
error activity (relative to PLAC) and a small decrease in unaware
error activity (relative to PLAC).
Second, we used the ROIs from the PLAC condition group
map to compare activity in a 2 # 3 repeated-measures ANOVA
for awareness-related changes in BOLD activity as a function of
the three drug conditions (PLAC, ATM, MPH). Three regions
showed a significant interaction effect (Fig. 5), two in closely
aligned regions to those identified in the PLAC and MPH com-
parison, namely the left IPL (MNI: x ! $45, y ! $36, z ! 47)
and dACC (MNI: x!$1, y! 9, z! 41), as well as the right IPL
(MNI: x! 48, y!$52, z! 36). The difference in BOLD activity
between aware and unaware errors was significantly greater in the
MPHcondition thanPLAC (p! 0.047, corrected), whereas ATM
was not significantly different from PLAC (p! 0.86).
Our results therefore suggest a neuroanatomical dissociation
in terms of the effect of MPH and ATM on awareness-related
brain activity. Whereas robust enhancement of error awareness
by MPH was mediated by activity differences within the dACC
and left IPL, the relatively more subtle effects of ATM were me-
diated by activity differences within the left IFG and right ITG.
Discussion
The results of this study demonstrate the pharmacological en-
hancement of conscious error awareness. A single, clinically rel-
evant dose ofMPHwas able to considerably (10%) improve error
Figure 3. Activity within the dACC differentiates errors made with and without awareness.
Bar graphs represent the mean BOLD percentage signal change for aware and unaware errors
during the PLAC condition. A significant main effect of awareness on error-related ACC activity
was observed during the PLAC condition, along with the three other drug conditions. The MNI
coordinates for the dACC cluster region are listed in the title, and the sagittal 3D-rendered view
of the activity cluster is taken from the MNI center-of-mass x-coordinate (x!$1).
Table 3. Regions of error-related BOLD activity in the combined PLAC andMPH OR
map demonstrating significant main effects of drug condition or error awareness
MNI coordinates
Brain region Volume (!l) x y z
Aware errors% unaware errors
L Inferior parietal 6569 $43 $39 51
R Inferior parietal 2674 48 $51 39
L Anterior cingulate 1632 $1 15 39
L Supplementary motor area 901 $2 $12 56
R Middle temporal 535 56 $51 3
R Precuneus 437 5 $74 33
R Temporal 304 50 11 2
L Supramarginal 221 $56 $26 25
L Precuneus 203 $8 $77 32
L Inferior frontal 152 $56 11 8
L Inferior frontal 145 $57 1 11
R Cerebellar 144 19 $54 $24
R Angular 132 52 $55 21
MPH% placebo
R Middle frontal 438 27 42 34
L Insula 172 $35 16 $4
R Inferior frontal 142 52 8 16
L, Left; R, right.
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awareness in nonclinical adults compared with ATM, CIT, and
PLAC. The beneficial effect of MPH was specific to error aware-
ness, without concomitant changes in response speed. Crucially,
this behavioral improvement in error awareness was under-
pinned by physiological changes within the dACC and IPL, with
activity differences between aware and unaware trials being sig-
nificantly larger under MPH than under PLAC.
Holroyd and Coles (2002) have argued that performance
monitoring is dependent on ascending mesencephalic DA pro-
jections that transmit predictive error signals via the basal ganglia
to the ACC. The results of the current study are broadly consis-
tent with this hypothesis, because the indirect DA agonist MPH,
which has been shown to increase DA levels within subcortical
regions, including the striatum and basal ganglia (Volkow et al.,
2005), was able to modulate activity within the dACC and pro-
mote conscious error awareness.
Although MPH is often viewed as an exclusive DA reuptake
inhibitor, in common with ATM it has profound effects on NE
signaling in prefrontal cortex (PFC) via reuptake inhibition of the
NE transporter (Berridge et al., 2006). A potential role for NE in
error processing is indicated by the strong reciprocal connections
between the PFC, ACC, and the locus ceruleus (LC) arousal sys-
tem. The LC also provides a strong phasic response to transient
decreases in performance and serves to boost task-specific repre-
sentations in top-down control regions (Aston-Jones andCohen,
2005; Nieuwenhuis et al., 2005). Intracranial recordings in mon-
keys have demonstrated that the magnitude of phasic NE cell
firing is determined by tonic activity levels in the LC (Aston-Jones
and Cohen, 2005), and important relationships between error
awareness and arousal have been reported previously. For exam-
ple, awareness of errors on the EAT is reduced by task manipula-
tions that engender attentional drift (Shalgi et al., 2007) and is
inversely correlated with tonic EEG measures of cortical arousal
(O’Connell et al., 2007). These models further propose that the
balance between tonic and phasic modes of LC/NE activity is
driven by a representation of current task utility that may be DA
dependent (Aston-Jones and Cohen, 2005). Thus, the beneficial
effect of MPH, and intermediate effect of ATM, on error aware-
ness is consistent with the view that DA and NE are likely to play
overlapping, complimentary roles in the processing of errors (Jo-
cham and Ullsperger, 2009).
Figure 4. BOLD activity clusters for aware versus unaware errors demonstrating anatomically dissociable effects of MPH and ATM. The dACC activity cluster (A) (MNI coordinates: x!"1, y!
15, z! 39) and left IPL cluster (B) (MNI coordinates: x!"44, y!"39, z! 51) demonstrating a significant interaction effect between error awareness (aware, unaware) and drug condition
(MPH, PLAC). The left IFG (C) (MNI coordinates: x!"54, y! 3, z! 13) and right ITG (D) (MNI coordinates: x! 56, y!"54, z!"6) represent the regions showing a significant interaction
between ATM and error awareness. Bar graphs represent themean BOLD percentage signal change (relative to baseline) for aware and unaware errors, for theMPH, ATM, or PLAC conditions. Error
bars represent the SEM. L, Left; R, right.
Table 4. Regions of error-related BOLD activity in the combined PLAC and ATM OR
map demonstrating significant main effects of drug condition or error awareness
MNI coordinates
Brain region Volume (!l) x y z
Aware errors# unaware errors
L Postcentral 11716 "41 "33 50
R Inferior parietal 4615 46 "50 39
L Middle cingulate 4266 "2 "2 45
L Precuneus 1846 1 "72 39
R Inferior frontal 1667 43 8 8
R Cerebellum 1492 26 "53 "22
R Thalamus 1359 8 "15 14
L Inferior frontal 909 "54 3 12
L Thalamus 880 "12 "21 9
R Inferior temporal 849 55 "52 "2
L Insula 759 "38 13 5
R Superior frontal 663 21 "13 60
L Cerebellum 371 "35 "46 "24
L Caudate 316 "13 "5 16
R Posterior cingulate 279 2 "32 26
L Supramarginal 251 "56 "50 27
R Middle frontal 136 33 27 37
R Middle frontal 116 41 28 31
R Supplementary motor area 108 10 "10 68
ATM# placebo
R Inferior parietal 4615 46 "50 39
L Insula 759 "38 13 5
L Caudate 316 "13 "5 16
R Posterior cingulate 279 2 "32 26
L Supramarginal 251 "56 "50 27
R Supplementary motor area 108 10 "10 68
L, Left; R, right.
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A possible noradrenergic influence on error processing is also
supported by the nominally significant effect of ATM compared
with PLAC. ATM also strengthened awareness-related brain ac-
tivity but within a distinct set of awareness-related regions to
those targeted by MPH. The enhancement of IFG activity by
ATM is consistent with known NE inputs and expression of the
NE transporter within PFC (Arnsten, 2011). Our result is also
consistent with a previous study that examined the impact of an
acute dose of ATM (80 mg) versus PLAC on error monitoring
and reported drug-related activity changes in the IFG (Graf et al.,
2011). Together, our study suggests dissociable neural pathways
by whichMPH and ATMmay improve conscious error awareness.
Notwithstanding evidence thatMPHmodulates catecholamine sig-
naling in PFC, the functional dissociations underpinning error
awareness reported here recapitulate the known expression patterns
of themolecular targets ofMPH andATM. Thus,MPH inhibits the
action of DA transporter within the mesencephalic DA system pro-
jecting to the ACC, whereas ATM inhibits the action of NE trans-
porterwithin prefrontal but not subcortical regions (Bymaster et al.,
2002). Future studies should assess the po-
tential clinical utility of these findings.
The results of the current study show
that enhancing catecholamine neu-
rotransmission with MPH produces a
more robust error signal within the ACC
and inferior parietal cortex and that this
same enhancement significantly increases
the likelihood that errors will be con-
sciously perceived. The specificity and size
of the MPH effect on error awareness in
healthy adults is directly relevant to the
treatment of performance monitoring
and insight deficits identified in clinical
conditions. For example, MPH is rou-
tinely used to treat ADHD and has been
more recently trialed as a treatment for
cocaine dependence (Castells et al., 2007).
These groups are known to demonstrate
impaired error awareness (Hester et al.,
2007; O’Connell et al., 2009) and dimin-
ished error-related neural activity in re-
gions including the dACC (Kaufman et
al., 2003; Rubia et al., 2005), with the level
of impairment associated with increased
symptom severity (Moeller et al., 2010).
Recent evidence suggests that MPH sig-
nificantly increases ACC activity in
ADHD and cocaine dependence (Jonk-
man et al., 2007; Goldstein et al., 2010; Li
et al., 2010). It is not known, however,
whether chronic use of MPH during typ-
ical treatment regimens has beneficial
effects for error awareness or clinical
symptomatology. Given the relationship
between the severity of awareness deficits
and clinical symptoms in psychiatric con-
ditions, the current data highlight the po-
tential for such medications to enhance
error awareness and in turn improve clin-
ical outcomes.
The absence of any significant influ-
ence of CIT on behavioral or imaging
measures of error processing is consistent
with previous pharmacologic studies examining the acute effect
of other drugs thought to influence the serotonergic system (de
Bruijn et al., 2004, 2006). Previous studies using acute tryptophan
depletion to perturb the serotonergic system had found a nega-
tive impact on dorsomedial PFC during cognitive control tasks,
in both humans (Evers et al., 2006) and rats (Narayanan and
Laubach, 2008), potentially implicating this system in perfor-
mancemonitoring. However, the consistent absence of influence
from serotonergic manipulation on error processing in previous
studies, including those examining feedback processing in the
absence of punishment (Barnes et al., 2011; Cools et al., 2011),
appears to discount a specific role for 5-HT in error processing.
With respect to the role of dACC in awareness of errors, we
note that the finding of significantly greater dACC activity for
aware errors compared with unaware errors is inconsistent with
previous fMRI studies of error awareness (Hester et al., 2005,
2009; Klein et al., 2007). This finding is significant because theo-
retical models have consistently implicated ACC activity in per-
formance monitoring, yet previous fMRI studies have failed to
Figure 5. BOLD activity clusters from the PLAC condition map showing significant error awareness! drug condition interac-
tion effects. The dACC activity cluster (A) (MNI coordinates: x"#1, y" 9, z" 41) and left IPL cluster (B) (MNI coordinates: x"
#45, y"#36, z" 47) and right IPL (C) (MNI coordinates: x" 48, y"#52, z" 36) demonstrating a significant interaction
effect between error awareness (aware, unaware) and drug condition (MPH, ATM, PLAC). Bar graphs represent the mean BOLD
percentage signal change (relative to baseline) for aware and unaware errors, for the MPH, ATM, or PLAC conditions. Error bars
represent the SEM. L, Left; R, right.
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demonstrate a critical role for this region in conscious error de-
tection. ERP studies of error awareness have provided mixed re-
sults with regard to the relationship between the ERN and error
awareness (Scheffers and Coles, 2000; Nieuwenhuis et al., 2001;
Endrass et al., 2007; O’Connell et al., 2007; Steinhauser and
Yeung, 2010), with a recent review fromWessel (2012) highlight-
ing several factors that may explain these contrary findings. One
of those factors, statistical power, may in part account for our
contrary finding, with the current study being the largest yet to
test the association of error awareness and dACC activity. Previ-
ous fMRI studies demonstrated a nonsignificant trend toward
greater dACC activity during aware errors when compared with
unaware (Hester et al., 2005; Klein et al., 2007) and had effect
sizes (Hester et al., 2005, Cohen’s d! " 0.32) that would have
more probably been significant with the sample size of the cur-
rent study.
One hypothesis to account for the difference in dACC activity
between aware and unaware errors is the potential for greater
response conflict during aware error trials, for example, between
the delayed, but unsuccessful, inhibitory control response and
the subsequent error detection (or awareness) response (Nieu-
wenhuis et al., 2003). We have previously attempted to examine
the effect of the awareness response on BOLD activity by repli-
cating the stimuli and timing from the EAT task and requiring
participants tomake the awareness response after a high response
conflict trial. BOLD activity during these trials indicated signifi-
cant activity in only one functionally defined error-related ROI,
the left middle temporal gyrus, suggesting that this response re-
quirement does not account for the dACC difference (Hester et
al., 2005).However, although this control condition attempted to
capitalize on the overlearned response to the word “STOP,” it did
not require the participant to withhold their response. Future
research could test whether this response requirement accounted
for the increased dACC activity for aware errors identified by
go/no-go paradigms, by temporally dissociating the awareness
response from the no-go error event.
Human performance is inherently error prone, and, in some
cases, action errors occur without conscious awareness. This
study provides foundational evidence that the explicit awareness
of errors is dependent on activity within an error-monitoring
network, including the dACC, IPL, as well as frontal and cerebel-
lar regions. Critically, we show that the catecholamine reuptake
inhibitor MPH promotes the conscious awareness of perfor-
mance errors by strengthening activation differences within the
dACC and IPL for errors made with versus without awareness
compared with PLAC. Modulation of error awareness by the NE
reuptake inhibitor ATM was smaller in effect size and mediated
via anatomically distinct regions, including the left IFG. Con-
versely, the selective 5-HT reuptake inhibitor CIT had no signif-
icant behavioral effects, suggesting that error awareness is
particularly dependent on catecholaminergic neurotransmis-
sion. Our results have implications for our understanding of the
neurochemical underpinnings of performance monitoring and
for the pharmacological treatment of a range of disparate clinical
conditions that are marked by poor awareness of errors.
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Dopamine D2 Receptor Modulation of Human Response
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Abstract
■ Response inhibition, comprising action cancellation and action
restraint, and error awareness are executive functions of consider-
able clinical relevance to neuropsychiatric disorders. Nevertheless,
our understanding of their underlying catecholamine mecha-
nisms, particularly regarding dopamine, is limited. Here, we used
the dopamine D2 agonist cabergoline to study its ability to im-
prove inhibitory control and modulate awareness of performance
errors. A randomized, double-blind, placebo-controlled, crossover
design with a single dose of cabergoline (1.25 mg) and placebo
(dextrose) was employed in 25 healthy participants. They each
performed the stop-signal task, a well-validated measure of action
cancellation, and the Error Awareness Task, a go/no-go measure
of action restraint and error awareness, under each drug condi-
tion. Cabergoline was able to selectively reduce stop-signal RT,
compared with placebo, indicative of enhanced action cancella-
tion ( p < .05). This enhancement occurred without concomitant
changes in overall response speed or RT variability and was not
seen for errors of commission on the Error Awareness Task. Aware-
ness of performance errors on the go/no-go task was, however, sig-
nificantly improved by cabergoline compared with placebo ( p <
.05). Our results contribute to growing evidence for the dopa-
minergic control of distinct aspects of human executive ability,
namely, action cancellation and error awareness. The findings
may aid the development of new, or the repurposing of existing,
pharmacotherapy that targets the cognitive dysfunction of psy-
chiatric and neurological disorders. They also provide further
evidence that specific cognitive paradigms have correspondingly
specific neurochemical bases. ■
INTRODUCTION
Inhibiting inappropriate actions and recognizing errors
in performance are critical aspects of human cognition.
Unfortunately, these abilities are impaired in a range of
neuropsychiatric disorders. Response inhibition deficits
are seen in schizophrenia (Bellgrove et al., 2006), co-
caine dependence (Garavan & Hester, 2007), attention-
deficit hyperactivity disorder (ADHD; Crosbie & Schachar,
2001), Parkinson disease (Aron & Poldrack, 2006), and
obsessive–compulsive disorder (Volkow, Wang, Fowler,
& Ding, 2005). Similarly, diminished error awareness has
been demonstrated in schizophrenia (Carter, MacDonald,
Ross, & Stenger, 2001), cocaine dependence (Kaufman,
Ross, Stein, & Garavan, 2003), Huntington disease (Hoth
et al., 2007), Parkinson disease ( Jocham & Ullsperger,
2009), and ADHD (Rubia, Smith, Brammer, Toone, &
Taylor, 2005). An increasing recognition that deficits
in these cognitive processes can influence clinical out-
come (Field & OʼKeefe, 2004; Mintz, Addington, &
Addington, 2004) has driven efforts to better understand
their neurochemistry.
Response inhibition has been examined in both animals
and humans using behavioral paradigms such as the go/
no-go (GNG) task and stop-signal task (SST). These tasks
represent distinct behavioral forms of response inhibition,
with the GNG requiring “action restraint” and the SST re-
quiring “action cancellation” (Eagle, Bari, & Robbins, 2008).
The validity of action restraint and action cancellation,
being dissociable constructs, has received support from
experimental studies suggesting that they have distinct
neurochemical bases (Eagle, Bari, et al., 2008). Although
specific roles for noradrenaline (Chamberlain et al., 2006)
and serotonin (Harrison, Everitt, & Robbins, 1999) have
been recognized, studies on dopamine have been proved
as more controversial.
Initially, a role for dopamine in action cancellation was
rejected. This followed rodent studies in which the sys-
temic administration of the dopamine reuptake inhibitor
GBR-12909 and the nonspecific dopamine receptor antag-
onist flupenthixol both failed to influence the primary
index of SST inhibitory efficiency, the stop-signal RT (SSRT;
Eagle, Tufft, Goodchild, & Robbins, 2007). Later work
showed, however, that the infusion of a selective D1 an-
tagonist, SCH 23390, into the rat striatum improved SSRT,
whereas infusion of a selective D2 antagonist, sulpiride,
impaired SSRT (Eagle, Wong, et al., 2008). Furthermore, in
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healthy volunteers, administration of amphetamine, a
dopamine and noradrenaline reuptake inhibitor, increased
D2 gene expression and also improved SSRT (Hamidovic,
Dlugos, Skol, Palmer, & de Wit, 2009).
With respect to action restraint, neither L-dopa adminis-
tration nor phenylalanine/tyrosine depletion influenced
GNG performance in healthy volunteers (Vrshek-Schallhorn,
Wahlstrom, Benolkin, White, & Luciana, 2006; Hershey
et al., 2004). Frank and OʼReilly administered cabergoline
(a selective D2 agonist) or haloperidol (a selective D2
antagonist) to healthy volunteers and proposed that in-
hibition, during a reward-learning GNG paradigm, was
controlled via phasic and tonic modulation of D1 and D2
receptors within the direct and indirect pathways of the
striatum (Frank & OʼReilly, 2006). However, Eagle, Bari,
and Robbins challenged this, noting that what had been
defined as improved action restraint was likely only a nega-
tive modulation of the go pathway rather than a positive
modulation of the no-go pathway (Eagle, Bari, et al.,
2008). The argument against a role for dopamine in ac-
tion restraint received further support when D1 and D2
manipulations were unable to influence GNG in either
rats or monkeys (Eagle et al., 2007; Inase, Li, & Tanji,
1997). Hence, in contrast to the SST, evidence for the
dopaminergic modulation of GNG performance remains
equivocal.
Error processing may also be sensitive to D1 and D2
modulation. Pharmacological studies of error processing
have extended findings from electrophysiology, which
showed that the early stages of error processing are pre-
conscious and independent of any awareness of errors
(OʼConnell et al., 2007). This stage has a characteristic
ERP, the error-related negativity (ERN), which may arise
from the ACC via signaling from the mesencephalic dopa-
mine system (Holroyd & Coles, 2002). A separate ERP
known as the error positivity (Pe) is seen around 200 msec
later and has been associated with the conscious aware-
ness of errors (OʼConnell et al., 2007). The role of dopa-
mine during error processing has been investigated in
Parkinson disease (Gauggel, Rieger, & Feghoff, 2004)
and by using amphetamine (de Bruijn, Hulstijn, Verkes,
Ruigt, & Sabbe, 2004) and haloperidol (de Bruijn, Sabbe,
Hulstijn, Ruigt, & Verkes, 2006; Zirnheld et al., 2004). From
these studies, Joacham et al. concluded that alterations
in the balance between presynaptic and postsynaptic D2
and D1 modulated the amplitude of the ERN ( Jocham &
Ullsperger, 2009). Caffeine, which indirectly modulates do-
pamine via adenosine, influences the Pe (Tieges, Richard
Ridderinkhof, Snel, & Kok, 2004); however, the Pe is un-
affected by two indirect dopamine modulators, lorazepam
and ethanol (Overbeek, 2005). Hester et al. demonstrated
that methylphenidate (a dopamine and noradrenaline
reuptake inhibitor) and atomoxetine (a noradrenaline
reuptake inhibitor) improved error awareness behavior
in healthy volunteers (Hester et al., 2012). Significantly,
the pharmacological modulation of error awareness had
distinct neuroanatomical correlates for methylphenidate
(dorsal ACC, parietal cortex) versus atomoxetine (inferior
frontal gyrus; Hester et al., 2012). These data suggest that
there may be separate dopaminergic and noradrenergic
mechanisms for error awareness (Hester et al., 2012).
Here, we used cabergoline, which has high affinity for
postsynaptic D2 receptors (0.4 nM) and almost no affinity
for D1 receptors (32,000 nM; Sharif et al., 2009), to exam-
ine the effects of D2 receptor modulation on action can-
cellation, action restraint, and error awareness tasks in
healthy adults. Participants performed an SST and the Error
Awareness Task (EAT; Hester, Foxe, Molholm, Shpaner, &
Garavan, 2005), a modified GNG task that allows partici-
pants to explicitly indicate their awareness of performance
errors. Previous electrophysiological analysis has shown
that error awareness on the EAT is positively correlated
with the amplitude of the Pe (OʼConnell et al., 2007). We
hypothesized that cabergoline would improve action can-
cellation in the SST but not action restraint in the GNG
task. Furthermore, given our previous finding that methyl-
phenidate enhanced error awareness and other data show-
ing D2 modulation of error processing more broadly, we
predicted that cabergoline would enhance error awareness
relative to placebo.
METHODS
Participants
Twenty-five healthy male volunteers were recruited for this
study via advertisement at the University of Queensland,
Australia. All participants were right-handed and aged from
18 to 26 years (M = 21.6 years, SD = 2.06 years). Par-
ticipants were excluded if they reported any history of
psychiatric or neurological illness including head injury,
previous usage of psychotropic medication, or significant
illicit drug use (significant was defined as [a] use of any
illicit substances within the last month; [b] >5 lifetime
intake of any illicit drug except cannabis; [c] more than
monthly cannabis intake, smoking [>5 cigarettes/week],
or alcohol dependence [>24 units/week]). Participants
were also excluded if there were any contraindications to
cabergoline. Before commencing, all participants were
screened by a consultant psychiatrist who also adminis-
tered the M.I.N.I. Screen and the Kessler K10. Blood pres-
sure (BP), heart rate, weight, and height were all recorded.
Participants also completed the Connersʼ Adult ADHD
Rating Scale (Patton, Stanford, & Barratt, 1995) and the
Barratt Impulsivity Scale (Patton et al., 1995).
All participants were recruited according to the princi-
ples of the Declaration of Helsinki and in accordance with
the ethical guidelines of the University of Queensland.
Drug Administration
The study employed a randomized, double-blind, placebo-
controlled, within-subject, crossover design. Participants
were tested twice, on the same day and time, during
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two consecutive weeks. At each testing session, the par-
ticipant ingested with water a single identical blue gela-
tine capsule, receiving either 1.25-mg cabergoline or
placebo (dextrose) in a randomized order. Cabergoline
dosage was based on data from previous acute challenge
studies that have demonstrated cognitive effects at the
chosen dose (Frank & OʼReilly, 2006).
All participants were required to fast for at least 1 hr
before drug administration. Caffeine was not to be con-
sumed on test days. After drug administration, participants
rested in a quiet waiting room for 90 min to await peak
plasma levels (Persiani et al., 1996) before commencing
the cognitive tasks that took a further 90 min. Participants
then completed a battery of four cognitive tasks, with
order of presentation counterbalanced using a balanced
Latin square. Data from the SSRT task and the EAT are
presented here. No participants withdrew because of
drug-related side effects.
SST
Participants performed 512 trials of the stop-signal para-
digm, in which the go stimuli were the letters O and X
mapped to the left and right button press responses, re-
spectively. The stop signal was a red box that surrounded
the go stimulus on 25% of trials. The delay between the
onset of the go stimulus and the onset of the stop signal
(stop-signal delay [SSD]) was initially set to 250 msec
and thereafter was adjusted dynamically in increments of
50 msec contingent on the performance of the participant.
Successful inhibitions resulted in an increase of the SSD,
whereas failed inhibitions resulted in a reduction of the
SSD, thereby facilitating inhibitory success. This procedure
ensured that, on average, each participant in each session
had a probability of successful inhibition approaching
50%. Under these circumstances, SSRT—a measure of
the latency of the inhibitory process—is derived as the
mean RT to go stimuli minus the SSD for the 50% inhibi-
tion threshold (SSRT = MRT − SSD; Logan, Schachar, &
Tannock, 1997).
EAT
The EAT was used to assess conscious detection of errors.
It is a motor GNG response inhibition task that is used
to assess whether participants are aware (aware errors)
or unaware (unaware errors) of their errors of commis-
sion. The go trials consisted of a consecutive stream of
single color words in incongruent font (e.g., the word
“RED” written in blue font) presented to the participant
for 800 msec followed by a 700-msec intertrial interval. Par-
ticipants were trained to respond to each presentation of
the go stimuli with a single button press and to withhold
their response when either of two classes of no-go trial
occurred (see Figure 1). The first type of no-go trial arose
if the same colored word appeared on two sequential trials
(repeat no-go trial), and the second arose if the word and
the font were congruent (Stroop no-go trial; see Figure 1).
Critically, in cases where the participants were aware of
their commission error, they were trained to forego the
regular go-trial response on the trial immediately subse-
quent to the error and to make an alternative nonspeeded
“error awareness response.” The dual requirement to moni-
tor for two classes of no-go event was designed to lead to
increased errors of commission, a percentage of which
should escape conscious awareness (Hester et al., 2005).
Previous electrophysiological studies have shown that
error awareness on the EAT is associated with the dis-
tinct ERP waveform known as the Pe (OʼConnell et al.,
2007). Specifically, OʼConnell et al. showed that the Pe
was maximal when participants indicated an explicit
awareness of their error and was virtually absent when
errors went unnoticed. The same modulation by error
awareness was not seen for other error-related com-
ponents such as the ERN and Pe, suggesting that the
Pe may indeed index the awareness response (see also
Steinhauser & Yeung, 2010). In support of this, Murphy,
Figure 1. The EAT. The
EAT presents a serial stream
of single color words in
incongruent fonts, with the
word presented for 800 msec
followed by a 700-msec ISI.
Participants were trained to
respond to each of the words
with a single “go trial” (left)
button press and to withhold
this response when either of
two different circumstances
arose. The first was if the
same word was presented
on two consecutive trials
(repeat no-go), and the
second was if the word and
font of the word matched (color no-go). To indicate “error awareness,” participants were trained to forego the regular go-trial button response (left)
and, instead, to respond with the alternative (right) button following any commission error.
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Robertson, Allen, Hester, and OʼConnell (2012) have re-
cently shown that the latency and amplitude of the Pe
during the EAT were significantly correlated with error
awareness rates between individuals but not with the
overall number of commission errors to the no-go trials.
In this study, participants performed 900 trials of the
EAT across four blocks including 100 pseudorandomly
placed no-go trials. Key dependent variables included
the percentage of commission errors on no-go trials,
the mean and standard deviation of correct go responses,
and the percentage of errors for which awareness was
indicated.
Other Assessments: Subjective and
Physical Measurements
Subjective and physical ratings of participantsʼ side effects
to cabergoline and the placebo were taken. Subjective side
effects were measured using the Visual Analogue Scale
(VAS), a 16-item rating battery (Bond, James, & Lader,
1974). The VAS items are divided into three categories:
alertness, contentedness, and calmness. Participants were
required to mark an ungraduated 10-cm line to express
the state of their feelings for each dimension, with the
ends of each line indicating the extremes for that dimen-
sion. The ratings for each category were compared be-
tween testing time and drug condition to determine if
participants were subjectively aware of any changes in their
feelings because of drug condition.
Physical side effect ratings included measures of heart
rate, systolic BP, and diastolic BP. These three objective
measures were similarly compared between time point
and drug condition to see if the drug condition, the testing
time, or the interaction of the two was having significant
effects on the participantsʼ physical status. Subjective and
physical ratings were recorded at baseline and at +90 and
+180 min after drug administration.
RESULTS
Stop-signal Paradigm
Data from two participants for the stop-signal paradigm
was incomplete because of computer malfunction. A
further two participants had SSRTs that were 2 SD outside
the mean and were excluded from analysis. The final anal-
ysis was therefore based on 21 participants. The mean
percentage inhibition rate in both the cabergoline and
placebo conditions was 49.5%, indicating that the tracking
algorithm had successfully converge on the critical 50%
inhibition threshold. Dependent variables from the stop-
signal paradigm were submitted to a paired-samples t test
comparing the effect of cabergoline versus placebo. There
was a significant main effect of Drug Condition on SSRT
[t(20) = 2.41, p< .05] such that cabergoline speeded SSRT
(M = 217 msec, SD = 31.7 msec) compared with placebo
(M = 232 msec, SD = 37.9 msec). The enhancement of
action cancellation by cabergoline, compared with placebo,
was associated with a medium Cohenʼs d effect size of
0.43. The enhancement of action cancellation by cabergo-
line occurred in the absence of any effect of the drug on
mean go RT [t(20) = 0.33, p > .05] or go-trial RT vari-
ability [t(20) = 0.505, p > .05]. Full results can be found
in Table 1.
EAT
The critical behavioral measure of error awareness was
transformed to improve normality using an arcsine func-
tion before parametric analyses (see Hester et al., 2012).
A paired-samples t test revealed that cabergoline was able
to significantly increase awareness of the percentage of
commission errors (M = 73%, SD = 16.5), compared with
placebo [M = 65%, SD = 17.9; t(24) = 2.2, p < .05]. This
enhancement of error awareness by cabergoline com-
pared with placebo was associated with a medium Cohenʼs
d effect size of 0.43. In contrast to enhancement of action
cancellation in the SST by cabergoline, the drug had no
effect on improving the number of commission errors for
the GNG element of the EAT [t(24) = 0.45, p > .05]. In
line with the results for the SST, no effect of Drug was
found for go-trial RT [t(24) = 0.24, p > .05] or go-trial
variability in RT [t(20) = 0.18, p > .05]. Full results can
be found in Table 2.
Other Assessments: Subjective and
Physical Measurements
There were no significant effects of cabergoline on sub-
jective side effects as measured by the VAS. Critically,
there were no significant Drug × Time interactions for
any of the three VAS factors [calmness: F(2, 48) = 1.05,
p > .05; alertness: F(2, 48) = .14, p > .05; contentedness:
F(2, 48) = 2.53, p > .05]. Equally, the results for heart
rate revealed no significant Drug × Time interaction,
F(2, 48) = 2.71, p > .05. Neither where there Drug ×
Table 1. SSRT Task Performance Measures as a Function
of Drug Condition (Cabergoline vs. Placebo)
Cabergoline
(1.25 mg) Placebo
M SD M SD
SSRT (msec)* 217 31.7 232 37.9
go RT (msec) 447 72.8 442 82.7
% Stop 49.5 1.1 49.5 0.75
SD of go RT 98.7 16.9 95.9 26.8
go RT = mean correct RT to go trials; % stop = mean percentage of
successful inhibition on stop trials; SD of go RT = SD of correct RT to go
trials.
*p < .05.
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Time interactions for systolic BP, F(2, 48) = .74, p > .05,
nor diastolic BP, F(2, 48) = 1.59, p > .05.
DISCUSSION
The results of the current study show that a D2 agonist,
cabergoline, was able to improve behavioral measures of
action cancellation and error awareness, compared with
placebo. Notably, the enhancement of these clinically
relevant components of cognitive control occurred with-
out concomitant changes in RT or RT variability.
During the SST, stop and go processes are in direct
competition to produce the final behavioral outcome of
either successful or unsuccessful action cancellation. Yet,
the stop process begins at a competitive disadvantage,
having to start after the onset of the prepotent go stimu-
lus. Hence, for successful action cancellation, the stop
process must “overtake” the prepotent go response. In
existing models of the striatal control of action, post-
synaptic D2 activation promotes the rapid completion of
action via suppression of inhibitory medium projection
neurons within the indirect pathway of the BG (Surmeier,
Ding, Day, Wang, & Shen, 2007). Accordingly, postsynap-
tic D2 stimulation also promotes the rapid completion of
action. Hence, during successful action cancellation in the
SST, which, crucially, must be understood as an “active”
process, striatal dopamine at postsynaptic D2 receptors
(within the indirect pathway of the BG) facilitates the sa-
lient “stop” process to rapidly complete before the prepo-
tent go response (Eagle, Wong, et al., 2008). Cabergolineʼs
potent postsynaptic D2 agonist activity (0.4 nM) and lack
of D1 effects (32,000 nM; Sharif et al., 2009) would favor
such a disinhibition of the indirect pathway and the rapid
completion of the stop process to improve SSRT, as we
observed. Our data compliment that from rodent striatal
infusion studies in which D2 antagonism worsened SSRT
(Eagle, Wong, et al., 2008). The latter finding was inter-
preted as post D2 antagonism retarding the completion
of action cancellation. This is because postsynaptic D2
blockade would prevent endogenous dopamine from
suppressing indirect pathway inhibitory activity, thus pre-
venting a salient stop process from efficiently completing
before the prepotent response. Considering the transfer-
ability of the SST between species, these rodent findings
make it plausible that the enhancement of human action
cancellation with cabergoline was likely because of post-
synaptic D2 agonism in the striatum. Importantly, cabergo-
line did not reduce mean go RT compared with placebo,
supporting the interpretation that cabergoline was differ-
entially enhancing the salience of the stop process rather
than simply speeding overall responding as had been seen
with non-receptor-specific dopamine agonists (Overtoom
et al., 2003).
One cannot however discount the possibility that the
positive effect of cabergoline on action cancellation might
be because of its moderate α2A receptor binding (132 nM;
Sharif et al., 2009). Antagonism of α2A autoreceptors in
the locus coeruleus is thought to increase noradrenaline
levels throughout the forebrain, allowing increased re-
sponsiveness to salient stimuli such as the stop signal
( Jocham & Ullsperger, 2009). However, considering that
guanfacine, a significantly more potent α2A receptor ago-
nist (20 nM; Uhlen, Muceniece, Rangel, Tiger, & Wikberg,
1995), was unable to influence SST performance in hu-
mans (Muller et al., 2005), it seems unlikely that our SST
results were because of an alpha adrenoceptor mediated
effect. In addition, cabergoline was not able to influ-
ence go RT variability, arguably an objective measure of
arousal/attention or subjective measures of attention on
the VAS. Such attention processes are thought to be regu-
lated by noradrenergic mechanisms (Smith & Nutt, 1996),
and cabergolineʼs lack of effect on these markers also
supports the contention that our SST results are unlikely
to be noradrenergic in origin.
Cabergolineʼs inability to improve inhibition during the
EAT, which is a modified GNG task, supports the accumu-
lating experimental evidence that modulating D1/D2 does
not affect action restraint (Eagle, Wong, et al., 2008; Inase
et al., 1997). Considering that DNA variation in the D4
receptor gene predicts poor action restraint in humans
(Altink et al., 2011), cabergolineʼs lack of effect is con-
sistent with its only moderate activity at D4 (56 nM; Sharif
et al., 2009). On the first inspection, our negative GNG
findings may appear to contradict those of Frank and
OʼReilly (2006), who reported modulation of performance
on a GNG task by cabergoline in healthy volunteers. There
are, however, significant differences between the GNG
tasks in the two studies. During the EAT, GNG is denoted
as a simple choice of go versus no-go depending on a set of
fixed criteria, whereas in Frank and OʼReillyʼs study, go ver-
sus no-go was linked to reward modulated by probabilistic
learning. Correspondingly, Frank and OʼReilly attributed
a significant portion of their results to cabergoline being
able to influence the learning of changing go versus no-go
criteria to maximize reward. Indeed, the only other study
Table 2. Error Awareness Task Performance Measures as a
Function of Drug Condition (Cabergoline vs. Placebo)
Cabergoline
(1.25 mg) Placebo
M SD M SD
no-go accuracy (% correct) 45 18.1 44 20.6
Error awareness*
(% aware errors)
73 16.5 65 17.9
go RT (msec) 460 71.9 464 65.9
SD of go RT 143 37.8 144 37.2
no-go accuracy = % of successful inhibitions on no-go trials; error aware-
ness = % of commission errors for which the participant indicated
awareness of their error (statistics performed on arcsine transformed
data); go RT = mean correct RT to go trials; SD of go RT = SD of correct
RT to go trials.
*p < .05.
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to find effects of nonstimulant dopamine agents on action
restraint also required learning reinforcement during a
GNG task (Leyton et al., 2007). Hence, our failure to mod-
ulate GNG inhibition on the EAT with cabergoline is consis-
tent with the assertion that dopaminergic modulation has
only a minimal influence on pure action restraint (Eagle,
Bari, et al., 2008).
The result of cabergoline improving error awareness
during the EAT might be understood by reference to
earlier pharmacological studies that attempted to modu-
late physiological indices of both preconscious and con-
scious error processing, such as ERN and Pe, respectively.
Although there is evidence that D2 modulation can affect
the amplitude of the ERN (Zirnheld et al., 2004), there
is only indirect evidence that dopamine can modulate
ERP markers of error awareness such as the Pe in healthy
populations. Caffeine, an indirect dopamine agonist via
adenosine, was shown to modulate the Pe, but ethanol
and lorazepam, indirect dopamine antagonists via GABA,
do not (Overbeek, 2005). Hence, it remains unknown
whether specific dopamine receptor modulation can in-
fluence the Pe. Hester and colleagues showed that, during
the EAT, the indirect dopamine agonist methylphenidate
improved error awareness behavior and that this effect
was underpinned by BOLD changes within the dorsal
ACC and inferior parietal lobule (IPL) for errors made with,
versus without, awareness (Hester et al., 2012). The rela-
tionship between error awareness and activity within the
IPL accords well with electrophysiological evidence that
P300-like components such as the Pe have neural gen-
erators in the IPL (Linden, 2005). Accordingly, one may
hypothesize that error awareness is mediated, at least in
part, by nigro-cortical dopamine (i.e., D2) inputs to pa-
rietal cortex. Indeed, strong dopamine projections to pa-
rietal cortex exist in addition to the well-documented
dopamine inputs to striatum and frontal cortex (Haber &
Knutson, 2010).
As is the case with action cancellation, we cannot rule
out a contribution of the noradrenergic system in the
error awareness result. For instance, the moderate α2A
receptor effects of cabergoline may alter the optimal bal-
ance between tonic and phasic modes of locus coeruleus
activity, which may then influence the selection of appro-
priate behavioral responses (Aston-Jones & Cohen, 2005;
Nieuwenhuis, Aston-Jones, & Cohen, 2005). As has been
more broadly suggested for error processing ( Jocham &
Ullsperger, 2009), dopamine and noradrenaline may
share overlapping and complimentary roles during error
awareness (Hester et al., 2012). However, cabergoline
has much less affinity for α2A receptors than D2 receptors
(K1 of 132 nM vs. 0.4 nM, respectively; Sharif et al., 2009),
again favoring dopaminergic mechanisms in our results.
In summary, this study has shown that cabergoline is
able to selectively enhance components of response in-
hibition and error processing in humans. Specifically,
cabergoline improved SST performance without changing
overall response times and had no effect on commission
errors during a GNG task. These findings suggest a disso-
ciable contribution of dopamine D2 receptor mechanisms
to action cancellation versus action restraint. The cur-
rent study also provides critical evidence for the enhance-
ment of human error awareness by dopamine D2 receptor
mechanisms. These data add to a growing body of evi-
dence for a pivotal role of D2 in error processing and help
demonstrate the subtle yet specific neurobiology of execu-
tive processes. Considering the prevalence and burden of
these cognitive impairments in neuropsychiatric popula-
tions, defining their precise neurochemical architecture
must remain a priority for the future development of more
specific and targeted pharmacotherapy.
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Discussion  
Summary of results 
The studies reported in this thesis found that acute doses of methylphenidate and 
cabergoline were able to augment adult human action cancellation and error awareness 
behaviour, without effects on action restraint. In contrast, atomoxetine and citalopram did 
not influence behavioural measures on either the SST or EAT, compared to placebo. With 
respect to functional imaging, methylphenidate was associated with increased drug-
specific BOLD activations in the dACC and left inferior parietal lobule (IPL), versus 
placebo, during error awareness behaviour. The same analysis for the EAT for 
atomoxetine showed more subtle activations of the left inferior frontal (IFG) and right 
inferior temporal gyri (ITG). No significant effects of citalopram were observed on brain 
activity associated with error awareness. A comparison of BOLD activity by drug condition 
for the no-go condition of the EAT revealed that only methylphenidate had drug-specific 
effects, with increased activation of the pregenual area of the ACC and decreased 
activation of the caudate associated with successful inhibition (that is, these regions still 
showed a difference in BOLD activity during inhibition after subtracting baseline BOLD 
activation as defined by the dominant go condition). In Chapter 4, cabergoline was found 
to improve both action cancellation and error awareness behaviour without concomitant 
effects on action restraint. In broad terms our results support the hypothesis that 
dopaminergic, noradrenergic and potentially D2 receptor specific fronto-subcortical 
mechanisms facilitate error awareness and dissociable components of response inhibition. 
Here we discuss how these results might be situated within, and contrasted against, 
existing theoretical models of executive control.  
Error awareness 
The work of Ullsperger et al. and Wessel et al. suggests that error awareness is the result 
of an accumulation of evidence (AE), garnered from a host of ‘neural modules’, which, 
eventually, meet criteria for entering access consciousness (8, 149). It is hypothesised that 
these modules act in a feed-forward manner, progressively contributing information during 
the assessment of an action, and if sufficient evidence is present the conscious detection 
of an error occurs (8). Conversely, if an error has been made but there was insufficient 
evidence to fulfil detection criteria, the subject remains unaware of the error (8). Sub 
threshold levels of evidence likely correlate with the more subtle forms of error awareness, 
such as ‘gut feelings’, that precede access consciousness (8). It is thought that the ERN 
and Pe might be electrophysiological markers of the AE process (7). Indeed, the late Pe, 
including in the EAT, has been associated with access consciousness awareness, 
whereas early Pe/ERN amplitude has been correlated with the number of cues indicating 
that an error has occurred (144, 146). Changes in attention, response conflict, 
proprioception, sensory input and autonomic activity are some of the ‘cues’ that contribute 
to the emergence of error awareness (7). The AE model provides a means of linking 
neurobiological accounts of performance monitoring and contemporary experimental 
observations such as those reported in this thesis (7).  
 
In Chapter 3 methylphenidate was associated with increased BOLD activations for aware 
versus unaware errors in the dACC and IPL. The dACC activation is consistent with an 
influential theoretical model that suggests that ascending dopaminergic neurons in the 
ventral midbrain transmit predictive error signals, via the basal ganglia, to the ACC during 
performance monitoring (186). Methylphenidate, as detailed later, could facilitate this 
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process by increasing dopamine concentrations within specific regions of the basal ganglia 
(187). The dACC activation is also in keeping with the finding that methylphenidate 
increases ERN amplitudes following error awareness in the EAT, as the dACC is thought 
to be the neural generator of the ERN (8, 134). The concomitant activity in the IPL is 
consistent with a proposal that the parietal cortex, along with the IFG and pre 
supplementary motor area, form an ‘executive control network’ that responds to events 
deemed salient by the ACC and insula (188). The IPL is thought to contribute sustained 
visual attention to task goals, including, presumably, the errors seen during the EAT (189). 
Methylphenidate’s subcortical noradrenergic activity could enhance this process by 
increasing phasic activity in the locus ceruleus, which then boosts gain in cortical target 
neurons, including the parietal cortex, in response to ACC input (176). As detailed below, 
methylphenidate has pharmacological mechanisms that can facilitate synergistic 
dopaminergic and noradrenergic neural processes during error awareness (166).  
 
IFG activation during error awareness under atomoxetine has been seen in at least one 
other performance monitoring study (190). It is noteworthy, however, that atomoxetine has 
also been shown to modulate IFG activity during response inhibition paradigms (70). 
Hence the atomoxetine-IFG activation seen in our results might reflect the hybrid nature of 
the EAT, which is both a GNG and performance monitoring task and likely requires a 
combination of executive processes (8). During the EAT repeatedly executing the go 
response requires only minimal executive control, however, the sudden detection of an 
error requires top-down biasing to overrule the pre-potent go response and instead report 
error awareness. This ‘attentional switching’, where the focus of attention is moved from 
one response to another, is associated with IFG activation in a range of behavioural 
paradigms requiring attention and inhibition (191). Atomoxetine’s ability to enhance frontal 
noradrenaline levels, without concomitant subcortical effects, may explain the selective 
activation of the IFG in our study (71, 192). In rodents not expressing trait impulsivity, 
however, atomoxetine has been shown to modulate impulsivity following direct infusion 
into the nucleus accumbens (193) although such subcortical effects were not evident in 
our imaging results. Atomoxetine’s blockade of frontal noradrenaline transporters also 
increases frontal dopamine levels in rodents (71). Attempts to control for this by giving 
atomoxetine in combination with dopamine antagonists do suggest, however, that the 
predominant effect is noradrenergic but this remains to be proven in humans (72).  
 
An acute dose of citalopram 30mg was unable to induce behavioural or imaging changes 
during error awareness. Our null finding was consistent with other performance monitoring 
studies that used acute doses of citalopram in humans (70, 134, 159). The finding that 
acute low doses of SSRIs actually lower central serotonin levels due to activation of 5-
HT1A autoreceptors may explain these null results (194). In contrast, the much higher SSRI 
doses used in animals lead to elevated central serotonin (195). Accordingly, human and 
rodent performance monitoring studies using the same SSRIs, but at significantly different 
mg/kg dosing, have shown opposing effects (7). Animal studies employing a range of 
specific serotonin receptor manipulations have, however, demonstrated that the serotonin 
system plays a significant role in performance monitoring and it seems that acute doses of 
SSRIs are ineffective tools for examining its function in humans (7).  
 
Interestingly, in Chapter 3 the placebo condition showed activations in the insula during 
error awareness. An association between error awareness and the insula has been 
demonstrated during a non-pharmacological eye movement error awareness paradigm 
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(154). Although stimulus locked autonomic activity was not recorded in our study, previous 
work with the EAT showed that changes in cortical arousal and skin conduction, which are 
thought to index autonomic activity, are more pronounced after error awareness (144). 
Changes in heart rate and pupil diameter have also been noted following error awareness 
(147). The insula is thought to be crucial for monitoring and responding to these autonomic 
changes (155). It seems plausible that similar autonomic changes were occurring during 
error awareness in our study and caused the insula activations. Nonetheless, the temporal 
and causal relationship between autonomic changes and error awareness remains 
indeterminate as it is unknown whether awareness of an error leads to autonomic 
changes, or if making an error causes autonomic changes that provides a cue for its 
conscious detection (7).  
 
The findings in Chapter 3 suggested that catecholaminergic processes modulate error 
awareness, which led to the decision to examine the impact of a D2 agonist on error 
awareness. Cabergoline is a potent D2 receptor agonist (0.4nM) that has almost no affinity 
for D1 (32 000nM) and moderate affinity for α2A (132nM) (196). Hence the finding that 
cabergoline was able to improve error awareness behaviour had to be contrasted against 
potential dopaminergic and noradrenergic mechanisms. In chapter 3, dACC and parietal 
lobe activations were seen with methylphenidate during error awareness, which might 
represent the cortical targets of amplified D2 transmission from the basal ganglia and 
midbrain (197). Considering that cabergoline was also able to improve error awareness 
performance in the EAT, and has potent D2 activity, it seemed plausible that it may have a 
similar functional neurobiology to methylphenidate. Nonetheless, yohimbine, an α2A 
antagonist, is known to reduce ERN amplitude suggesting that adrenergic effects cannot 
be discounted in our results (175). Arguing against a predominant α2A effect, however, is 
the concomitant finding in the same cohort that cabergoline also enhanced SST 
performance. The SST result supports that dopaminergic activity was predominant 
because in an earlier study guanfacine, a more potent α2A agonist (20nM), was unable to 
affect SST performance (76). Hence it seems reasonable to posit that dopaminergic 
processes, and potentially D2 specific mechanisms, play an important role in error 
awareness. 
Action cancellation 
In Chapter 1 an acute dose of methylphenidate, but not citalopram or atomoxetine, 
decreased SSRT and reaction time variability without concomitant changes in mean go 
reaction time. This suggests that methylphenidate was augmenting inhibition-specific 
processes rather than indiscriminately increasing overall motor speed. This was the first 
study to use these three agents in a within-subjects placebo controlled design with the 
SST, thus facilitating a direct comparison of the neurochemical drivers of human action 
cancellation.  
  
As described later, methylphenidate increases extracellular dopamine and noradrenaline 
levels throughout the brain (55). Atomoxetine also increases noradrenaline, and to a lesser 
extent, dopamine levels but is restricted to activity within the cortex (71). Yet in contrast to 
methylphenidate we only saw a trending beneficial effect from atomoxetine during the SST 
that did not survive correction for multiple comparisons. Although the pharmacology of 
these agents is contrasted later, the modulation of response inhibition by catecholamines 
is reviewed first below.  
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In the striatum postsynaptic D1 and D2 mediated pathways compete and whichever 
completes first, results in either the expression or inhibition of cortically determined action, 
respectively (43). This model has been empirically probed using specific D1 and D2 
receptor agents in a rodent SST paradigm (58). Human imaging studies have also shown 
that the dorsal striatum is functionally associated with SST inhibition (107). It is thought 
that dopamine acting at the D1 mediated ‘direct pathway’ in the striatum effectively 
promotes action as the competing inhibitory process of the ‘indirect pathway’ is slowed, 
thus allowing action completion (58). In contrast, dopamine acting on the D2 mediated 
‘indirect pathway’ facilities action cancellation due to the inhibitory process completing first 
(58). Therefore any change in the relative availability of dopamine at these postsynaptic 
striatal dopamine receptors could significantly affect the expression or cancellation of 
action.  
 
To further probe D2 receptor mediated effects during action cancellation, a D2 receptor 
agonist, cabergoline, was administered during the SST and subsequently found to improve 
inhibitory performance (Chapter 4). Like methylphenidate, cabergoline has been shown to 
be functionally active in the striatum (198), supporting the hypothesis that modulation of 
the D2 mediated indirect pathway contributes to enhanced action cancellation behaviour. 
Dopamine receptor expressing striatal interneurons may also play an important role in 
regulating direct and indirect pathway neurons (199). One such population, fast spiking 
parvalbumin GABAergic interneurons (FSIs), respond to glutamatergic inputs from cortical 
pyramidal neurons by inhibiting activity in striatum (200). Rodent studies have shown a 
preferential connection of FSIs to direct pathway SPNs thus allowing a top down signal to 
‘cancel’ commenced action (201). D2 receptor agonists have been shown to depress the 
GABAergic input to such FSIs to facilitate their activity (202), which may further explain our 
cabergoline SST results. Our cabergoline result is similar to that seen in a rodent study in 
which quinpirole and sumanirole, selective D2 agonists, reduced impulsive behaviour 
(203). At the doses employed in our study, cabergoline is an effective treatment for the 
dopaminergic lesions of Parkinson’s disease (204) and functionally active at central D2 as 
evidenced by its clinical usage for inhibiting prolactin secretion, which is mediated by 
pituitary D2 (205). During a reversal-learning task, cabergoline increased BOLD activations 
in the cingulate cortex and striatum (206). A very recent positron emission tomography 
study has shown that human SST inhibitory performance is mediated by striatal D2 and the 
authors conclude that their imaging results corroborate the cabergoline behavioural 
findings from Chapter 4 (207). Earlier imaging studies had also shown that striatal D2 
availability is correlated with human response inhibition neural activations (208). In vitro 
studies show that cabergoline binds to rat striatal D2 receptors more strongly than D1 
receptors (3 versus 11 nmol/L, IC50) and has almost no affinity for rodent serotonin -1 and -
2 receptors (170 and 1000 nmol/L, IC50) (205). Although Sharif et al. demonstrated that 
cabergoline is a potent D2 agonist [0.4n (196)], we cannot entirely discount the possibility 
that its moderate α2A [132nM, (196)] binding might be contributing to our SST results via 
noradrenergic mechanisms.  
  
Nonetheless, guanfacine, a significantly more potent α2A receptor agonist than cabergoline 
[20 nM; (209)], was unable to influence either GNG or SST performance in a study 
population similar to our own (161). In addition, cabergoline proved unable to influence go 
RT variability, an indirect measure of top-down attentional control, or influence subjective 
measures of attention on the VAS. Noradrenergic mechanisms have previously been 
 
Neurochemical and neurophysiological bases of executive control 
L. Sanjay Nandam 
 
Page 33 of 62 
 
linked to attentional processes (210) and cabergoline’s inability to modulate our measures 
of attention further argues against our results being exclusively α2A driven.  
 
Cabergoline is also able to influence a range of serotonergic receptors (196) but again it 
seemed unlikely that serotonergic mechanisms could underlie our results, particularly 
when citalopram proved unable to affect SST. Indeed our null result with citalopram is 
consistent with several studies that were unable to influence action cancellation with 
serotonergic manipulations (70, 75, 85, 211). Collectively, these suggest that the serotonin 
system only plays a marginal role during action cancellation (2, 3) and again supports that 
our cabergoline effects were D2 mediated. Nonetheless, this interpretation of the 
cabergoline SST results as primarily D2 receptor driven has been challenged (3).  
 
Our null finding for atomoxetine during the SST is at odds with an earlier influential work by 
Chamberlain et al., in which an acute dose of atomoxetine 60 mg improved SST 
performance (70). In small cohorts it is possible that baseline genetic differences between 
subjects, such as noradrenaline polymorphisms, might have led to different performances 
with the same atomoxetine dose (212). Performance improvement with atomoxetine is 
governed by a narrow inverted-U shaped dose response curve (213) and even closely 
matched laboratory primates display marked variation in individual dose response curves 
during PFC dependent behavioural tasks (213). In our study’s relatively small cohort of 
men aged 20 to 35 a standard dose of atomoxetine 60mg may not have been optimal for 
every subject. The modest Cohen’s d effect sizes of 0.37 and 0.32 seen in Chamberlain et 
al. and Chapter 1, respectively, further supports that non-replication is likely. The 
narrowness of the atomoxetine dose response curve in healthy subjects is also illustrated 
by the finding that atomoxetine 80mg, which is still well within the routine clinical dose 
range for adult ADHD of up to 120mg a day (214), impaired rather than improved GNG 
performance (190). In clinical studies of atomoxetine for adult ADHD differing individual 
dose response curves are controlled for by protocol-driven dose titration based on clinical 
response (214, 215). This may in part explain why the beneficial effects of atomoxetine 
take weeks to emerge in these studies, presumably, as each individual’s optimal dose is 
slowly determined. There was also at least one significant difference in SST design 
between the two studies. In Chamberlain et al. the stop stimulus was an auditory signal 
(70), whereas in Chapter 1 both the go and stop stimuli were visual. Intriguingly, in healthy 
volunteers a single dose of atomoxetine 60mg has been shown to increase cortical 
excitability in response to paired visual stimuli (216), which might be relate to why our 
subjects found it harder to inhibit action when both the go and stop cues were presented 
via visual cues in close succession. Despite these task design differences the placebo 
condition of the two studies yielded similar results (Chamberlain: SSRT: 278 msec; 
Nandam et al.: SSRT: 275 msec), suggesting that dose response variability in the samples 
under study rather than task design differences were the more likely reason for non-
replication.  
Action restraint 
The neurochemical and imaging correlates of action restraint were explored in Chapter 2. 
We found that during GNG inhibition methylphenidate and atomoxetine, but not citalopram 
or placebo, activated similar cortical areas including the RIFG and middle frontal gyrus, 
which is consistent with the so-called ‘response inhibition network’ (97).  
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Earlier studies (34, 217) identified several cortical regions associated with citalopram and 
GNG inhibition, including the occipital cortex activation as seen in our study, yet it remains 
unclear how this relates to existing theoretical frameworks linking serotonin and action 
restraint (2). Our limited findings with citalopram may be related to finding that single 
doses of citalopram’s active enantiomer, escitalopram, actually decrease central serotonin 
concentration in humans, presumably by stimulation of presynaptic serotoninergic 
autoreceptors (218). Despite this, we did not observe the orbitofrontal cortex activations 
seen during response inhibition after tryptophan depletion in earlier studies (93).  
 
Atomoxetine has previously been shown to modulate the RIFG during response inhibition 
in healthy subjects (219). In addition, the magnitude of RIFG activation correlates with 
individual response inhibition differences in both healthy adult and ADHD populations 
(220, 221). The RIFG has been associated with several executive processes that could 
assist GNG inhibition including resolution of stimulus conflict (222), rapid adaptation of 
response (223) and attentional control (191). The latter process is likely controlled by 
cortical noradrenergic mechanisms, which methylphenidate and atomoxetine are well 
placed to influence. The middle frontal activations we observed are consistent with 
atomoxetine and methylphenidate’s ability to block prefrontal noradrenaline transporters 
and raise catecholamine levels (71). Increased levels of dopamine and noradrenaline are 
thought to then modulate D1 and α2A receptors, respectively, which fine-tune neuronal 
activity to produce changes in the frontal signals that control lower level structures (213). 
The overlapping activations for methylphenidate and atomoxetine suggest that they recruit 
similar cortical regions during action restraint in the EAT. Nonetheless, methylphenidate 
was dissociable from atomoxetine, as well as citalopram and placebo, by additionally 
modulating dACC (pregenual cortex) and caudate activity during action restraint stop trials.  
 
Activation of the dACC has previously been demonstrated in response inhibition imaging 
studies (105, 106). During the EAT dACC activation might reflect conflict monitoring (114, 
224) and working memory (115) processes, which facilitate EAT colour and repeat no-go 
trials, respectively. Methylphenidate may promote dACC activity via modulation of 
dopaminergic projections that project from ventral tegmental to medial frontal areas (225). 
Methylphenidate’s ability to increase noradrenergic tone may also be relevant considering 
the reciprocal connections between the PFC, dACC and LC (226). Modulation of the 
caudate by methylphenidate during GNG is consistent with the proposition that cortical 
regions transmit stop commands to the basal ganglia to ‘intercept’ the prepotent go 
response (3). Lesion, microstimulation and imaging work support that the caudate is 
implicated in the selection of goal-relevant motor behaviour (49, 227, 228). 
Methylphenidate has previously been shown to modulate dopaminergic activity in the 
caudate (229). Whether such modulation results in an up or down regulation of caudate 
activity likely depends on population baseline dopamine characteristics, as detailed below. 
In healthy adults, such as in our study, methylphenidate 60mg is able to inhibit 60–70% of 
striatal dopamine transporters (229), which could translate into the observed reduction of 
fMRI (230).  
Comparative neuropharmacology of methylphenidate and atomoxetine 
Much of this thesis has contrasted the results of methylphenidate and atomoxetine hence 
a detailed examination of their comparative neuropharmacology is warranted. Atomoxetine 
and methylphenidate initially appear to be similar in that they both influence dopamine and 
noradrenaline reuptake. Yet, as has been seen in the results of this thesis, they can 
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produce significantly different effects following acute dosing. In a similar manner, 
atomoxetine only ameliorates ADHD symptoms after weeks of treatment, whereas 
methylphenidate can produce beneficial effects after a single dose (231). The acute effects 
seen with methylphenidate are also seen with the structurally similar phenethylamine, 
amphetamine (232), which is also used to treat ADHD via acute dosing regimes (231). 
Besides being able to reliably affect core ADHD symptoms after acute dosing, 
psychostimulants also produce euphoric effects that do not occur with atomoxetine (232). 
Noting that acute administration of psychostimulants can induce both improvements in 
executive control and euphoria, albeit at different doses with high doses producing 
euphoria and lower does favouring cognitive effects (232), we conjectured that a common 
neurobiological mechanism might underlie these phenomena and would differentiate them 
from atomoxetine and other catecholamine reuptake inhibitors.  
 
Blockade of the dopamine transporter (DAT) alone cannot explain psychostimulant acute 
dosing effects. For example, acute doses of a range of highly specific dopamine reuptake 
inhibitors (DRIs), including bupropion, vanoxerine and silbutramine, do not produce 
euphoric effects in healthy volunteers (232-234). Additionally, Volkow et al. showed that 
although a first dose of methylphenidate was still occupying >80% of striatal DAT, a 
second methylphenidate infusion 60 minutes later produced an additional wave of 
euphoric feelings, suggesting that another mechanism beyond DAT blockade was 
operating (235). Similarly, ADHD patients need to take repeated doses of methylphenidate 
to sustain the temporary beneficial effects on executive control (231). Neither can the 
euphoric effects be stopped by blockading DAT, as prior bupropion administration failed to 
prevent the euphoric effects of acute dose methylphenidate (236). Underlining the 
possibility of additional mechanisms beyond DAT blockade, microdialysis experiments in 
rodents have shown that extensive blockade of DAT has little to no effect on 
psychostimulant-induced rises in central dopamine levels (237). Similarly, the acute 
euphoric and executive control effects of the psychostimulants are not explained by their 
potency of DAT blockade. Methylphenidate Ki values for blocking DAT range from 17-
185nM, which is similar to amphetamine’s range of 34-400nm, placing them as moderate 
to weak DRIs (232). In contrast the much more potent DRI vanoxerine (Ki range 0.3-4 nM) 
does not produce euphoric effects (234). Bupropion, despite having a comparable DAT 
affinity to methylphenidate and amphetamine (Ki range 55-409nM), was also unable to 
induce euphoria or improve in executive control in healthy volunteers (57, 232). 
 
The above suggests that the behavioural effects of psychostimulants are driven by a 
mechanism that is “much faster than inhibition of dopamine reuptake” (232). Indeed, 
methylphenidate is able to produce far higher levels of dopamine efflux from rodent striatal 
slices than highly potent DRIs such as vanoxerine (232). To explain this, Heal et al. 
propose that methylphenidate allosterically modifies the conformation of DAT to allow the 
reverse-transport of dopamine out of the neuron into the synapse (232). This “inverse 
agonism” reverses the usual one-way inward flow of the DAT as dopamine moves down 
the concentration gradient from the neuronal cytosol into the synaptic cleft through the 
open transporter channel (232). DAT inverse agonism has also been shown to occur 
under physiological conditions in the absence of psychostimulants but its purpose is only 
poorly understood (238, 239). Methylphenidate is thought to facilitate inverse agonism via 
binding to an extra neuronal site that, unlike amphetamine which binds to an intracellular 
location, prevents methylphenidate from accessing the dopamine within intracellular 
vesicular storage (232). Soon after binding, the resultant efflux of cytosolic dopamine 
 
Neurochemical and neurophysiological bases of executive control 
L. Sanjay Nandam 
 
Page 36 of 62 
 
through the open channel quickly displaces methylphenidate allowing the channel to return 
to the closed position (232). By rapidly increasing extracellular concentrations of 
methylphenidate, such as through additional dosing, the channel will reopen facilitating 
further dopamine efflux and the process repeating (232). Interestingly, methylphenidate’s 
inverse agonist properties at DAT also appear to apply to it’s action on the structurally 
similar noradrenaline transporter (240). In addition to differentiating from other 
catecholamine reuptake inhibitors, inverse agonism provides a plausible mechanism as to 
why the euphoric and executive control effects of methylphenidate arise and fade relatively 
quickly yet can be quickly re-established with subsequent dosing. 
Methylphenidate and dopaminergic neuronal signalling 
The effects of methylphenidate-induced dopamine efflux on the firing rates of 
dopaminergic neurons is complex and remains poorly understood due to a lack of 
electrophysiological data from conscious free-moving animals (232). In the forebrains of 
anaesthetised rats, however, cocaine, a psychostimulant similar to methylphenidate in 
pharmacological and behavioural effects (232), produces increased striatal dopamine 
efflux in response to electrical stimulation without impairing synaptic clearance (241). 
Dopaminergic neurons have two distinct modes of firing, a basal tonic single-spike activity 
and a transient activated phasic burst-spike firing mode (242, 243). In the striatum phasic 
activation follows top-down afferent signalling that produces transient, high amplitude 
synaptic dopamine release in selected areas (244). Dopamine released into the synapse is 
then immediately subjected to powerful reuptake by DAT, which returns the neuron to tonic 
mode (245). The transition from tonic to phasic firing modes is known to occur during 
certain executive function tasks including error prediction and incentive salience (246). 
Methylphenidate’s inverse agonism mechanism could allow for the ‘dynamic range’ of 
synaptic dopamine to be increased, enhancing the transition from tonic to phasic mode in 
response to top-down cortical inputs (247). Such a mechanism might underlie the 
augmented executive control seen following acute dosage methylphenidate (247). This is 
consistent with the observation that methylphenidate produces the largest performance 
gains in those with low baseline performance (2), that is, those with the presumably 
poorest baseline differentiation between ‘signal’ (phasic mode) and ‘noise’ (tonic mode). 
Just such an abnormality has been noted in a subpopulation of ADHD patients who have 
the Val559 coding variant of the dopamine transporter gene (DAT1) (248). In this DAT1 
variant, anomalous dopamine efflux is thought to diminish the signal to noise ratio of 
striatal dopaminergic neurons with associated impairments of executive control (248). 
These behavioural abnormalities can be ameliorated by amphetamine, presumably 
through an optimisation of signal to noise similar to that described above (248).  
 
The fact that low dose methylphenidate does not hamper the removal of dopamine from 
the synaptic cleft by DAT, even after massive efflux (247), is essential to improving signal 
to noise ratio (232). This is because effective phasic firing relies on high, but transient, 
synaptic dopamine concentrations (247). Psychostimulants only completely block DAT at 
high dose and, crucially, the lower doses used in cognitive studies and ADHD treatment 
does not impair DAT function (249). With its reuptake function preserved DAT can rapidly 
remove dopamine from the synaptic cleft thus allowing for the precise matching of phasic 
bursts to time-critical afferent signals and the prevention of dopamine spreading to extra 
synaptic locations where it could affect basal tone (243). Indeed, DAT1 knockout mice 
show reduced phasic and elevated tonic signalling due to their inability to efficiently clear 
dopamine from the synapse (250). In association with these changes to dopaminergic 
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signalling, DAT1 knockout mice also show impairments of executive control (251). 
Accordingly, methylphenidate’s ability to facilitate rapid dopamine efflux without hampering 
reuptake clearance preserves temporal matching to time-critical cortical inputs and fidelity 
by restricting phasic transitioning to specific synapses, respectively (252). This ability to 
fine-tune dopaminergic phasic signal to noise is not possible with indiscriminate elevators 
of dopamine and might explain why L-DOPA and bupropion do not improve action 
cancellation (56, 57). As discussed earlier, the subcortical target of methylphenidate’s fine-
tuning of dopamine efflux is likely striatal indirect pathway postsynaptic D2 receptors, which 
then facilitate action cancellation as the inhibitory process completes first and ‘braking’ is 
expressed (58). Whilst the decision to cancel action is likely instantiated within the PFC 
(2), phasic modulation of striatal postsynaptic D1 and D2 receptors appears crucial in 
controlling the speed of the behavioural output of that decision (58). Considering that both 
drugs are active in the striatum (43, 187), this may explain how methylphenidate and 
cabergoline specifically improved SSRT, which measures the speed of the inhibitory 
process during action cancellation, without affecting mean reaction time. Crucially, 
information transfer within the striatum has been shown to be sufficiently rapid to support 
the tens of milliseconds differences seen in our results (253, 254).  
 
In contrast to phasic firing, tonic activity within striatal dopaminergic neurons is highly 
dependent on dopamine concentration in the extra-synaptic space (255). Changes in 
dopaminergic tone have bi-directional effects on PFC inputs, with increased tonic D2 
stimulation attenuating PFC inputs and decreased tonic D2 stimulation facilitating PFC 
inputs (252). Tonic activity has also been matched to some aspects of PFC-driven 
executive function behaviour, with decreased tonic D2 stimulation associated with 
switching to a new response in an animal model (252). The relationship between specific 
dopamine receptor manipulations, tonic activity and other behavioural paradigms has only 
received scant attention (252). Predicting net tonic activity can, however, be difficult due to 
the complexity of interaction between pre- and postsynaptic dopamine receptors (43), and 
interplay with noradrenergic systems (249).  
 
The PFC projection cells lack mRNA coding for D2 presynaptic autoreceptors (256). 
Accordingly, dopamine release in the PFC activates postsynaptic D2 receptors that 
enhance response-related phasic firing (192). This provides a plausible dopaminergic PFC 
mechanism for both our methylphenidate and cabergoline results. The cabergoline result 
is also consistent with work showing that the D2 agonist bromocriptine, which is 
pharmacologically similar to cabergoline, increases response-related BOLD signal in PFC 
(257). Arnsten has suggested that postsynaptic D2 mechanisms “may regulate the 
amplitude of PFC communication with subcortical structures mediating motor responses 
as well as pathways involved in updating” (192). Updating information, such as the 
decision to cancel action in response to a stop signal, and then responding via rapid motor 
adjustments are crucial for success in the SST. Methylphenidate and cabergoline may be 
facilitating the former requirement via stimulation of PFC postsynaptic D2, which then 
relays to subcortical structures to execute the motor component. 
 
In the striatum, stimulation of presynaptic D2 receptors, such as by cabergoline, diminishes 
synaptic dopamine (43). When affecting rapid motor cancellation, cabergoline-induced 
reductions in dopamine availability would constrain activity at direct pathway D1 receptors 
thus slowing the completion of action. Simultaneously, cabergoline could positively 
modulate indirect pathway postsynaptic D2 allowing the PFC determined inhibitory 
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cancellation to complete first. This proposed mechanism appears consistent with the 
finding that the D2 antagonist sulpiride specifically impaired action cancellation in a rodent 
SST model (58). Similar striatal dopamine receptor effects would be expected with the low 
dose methylphenidate used in our experiments. D2 receptors have higher affinity for 
dopamine than D1 receptors (199) and mild transient elevations in dopamine preferentially 
activate them. Accordingly, following a methylphenidate-induced rise in dopamine, 
stimulation of higher affinity presynaptic D2 would restrict further dopamine availability 
leaving postsynaptic D2 receptors with a competitive advantage over D1 allowing indirect 
pathway transmission to complete first to affect action cancellation. 
Methylphenidate and noradrenergic neuronal signalling 
Methylphenidate’s ability to boost noradrenaline, and to a lesser extent dopamine, in the 
PFC also appears to be important to its cognitive enhancing effects (249). In the PFC, 
DAT is sparse and the noradrenaline transporter (NET) clears both noradrenaline and 
dopamine from the synapse (258). PFC noradrenergic neurons projecting from the locus 
ceruleus (LC) also display phasic and tonic modes of firing, which are mediated by 
synaptic and extrasynaptic noradrenaline concentrations, respectively (249). In terms of 
behaviour, phasic LC firing is broadly associated with decision and action, whereas tonic 
firing is associated with arousal and responsiveness to sensory input (259, 260). Following 
acute low dose administration in a rat model (0.5mg/kg intraperitoneal), methylphenidate 
increased the phasic responsiveness of PFC noradrenergic neurons to afferent signals 
whilst having minimal affect on tonic discharge rates (261). Importantly, the augmented 
phasic response was to both excitatory and inhibitory inputs (261). For PFC dependent 
tasks, performance improvements with methylphenidate only occur across a narrow dose 
range yielding an inverted U dose-performance curve (249). Interestingly, different 
cognitive tasks appear to produce different shaped dose-performance curves, with 
sustained attention tasks resulting in broader right-shifted curves and response inhibition 
paradigms resulting in narrower ones (249). That low dose methylphenidate is able to 
improve phasic transmission without affecting tonic firing may explain the narrow dose-
performance curves seen during response inhibition, whereas higher dose 
methylphenidate progressively induces tonic noradrenergic firing and diminishes phasic 
signal biases function to tasks that require sustained vigilance (249).  
 
With respect to noradrenergic receptors, postsynaptic PFC α2 receptor activation, 
particularly α2A, enhances delayed-response task performance and boosts phasic input to 
PFC neurons (261). In contrast, α1 agonism produces stress-like performance 
impairments, whereas α1 antagonists are stress protective (262). Primate studies have 
shown that α2 receptors have a significantly higher affinity for noradrenaline than α1 and β 
receptors (263). As seen for DAT, methylphenidate is thought to influence NET via inverse 
agonism, that is, low doses cause a rapid efflux of cytosolic noradrenaline into the synapse 
that is promptly removed by the still functional transporter (232). This transient, high 
concentration, noradrenaline efflux then preferentially engages higher affinity postsynaptic 
α2 receptors to induce phasic signalling and promote PFC functions (249). In contrast, 
following prolonged high synaptic noradrenaline concentrations, as seen with high dose 
methylphenidate or stress, lower affinity α1 receptors become progressively engaged 
contributing to a dose-dependent impairment in executive control (262). This differential 
activation of postsynaptic α2 versus α1 receptors across the noradrenaline concentration 
gradient also aligns with the methylphenidate’s inverted U dose-performance curve (249). 
Interestingly, high dose α2 receptor antagonists can block the beneficial effects of both 
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methylphenidate and atomoxetine during executive control tasks suggesting a common 
receptor mechanism in the PFC (264). Similarly to dopamine, the relationship between 
noradrenergic receptors and cognitive function remains likely to be task specific as rodent 
sustained attention is enhanced rather than impaired by α1 agonists (264). This result 
highlights the importance of increased tonic firing, such as when stress produces high 
levels of noradrenaline that stimulate postsynaptic α1, to sustained attention (249).  
Finally, the finding that α2 and α1 receptor antagonists can increase and decrease 
dopamine in the mPFC, respectively (265, 266), raises the possibility of synergistic 
catecholamine mechanisms during executive control.  
 
Indeed, there is experimental evidence of the fine-tuning of neuronal signalling by co-
operative interactions between dendritic noradrenergic and dopaminergic receptors during 
cognitive tasks. Anatomically, α2 and D1 are located on separate dendritic spines of PFC 
pyramidal neurons thus enabling simultaneous inputs from distinct afferent pathways 
(267). This could allow for two forms of qualitatively different data to be simultaneously 
transmitted to the target neuron, which would then be integrated to modulate further 
signalling (249). For example, electrophysiological data in monkeys has shown that when 
a task target is in the correct area α2A mediated afferents strengthen phasic transmission 
in PFC pyramidal neurons, whereas when the target enters the incorrect area D1 mediated 
afferents reduce phasic signal (262). Similar co-operative modulations of PFC α2 and D1 
are presumed to occur with methylphenidate (249), and may have contributed to our 
imaging and behavioural results.  
 
In addition to co-operative interactions, there is emerging evidence of cross modulation 
between catecholamine receptor systems. For example, in rodent pineal cells dopamine 
dose dependently increased intracellular Ca2+ yet this effect could not be reproduced with 
a range of D1 and D2 agonists or blocked by D1 and D2 antagonists (257). In the same 
system, however, application of the α1 antagonist prazosin prevented dopamine from 
raising intracellular Ca2+ (257). Similar examples of catecholamine receptor-ligand cross 
modulation have also been described (268). These findings add yet another level of 
complexity to understanding how drugs like methylphenidate and cabergoline exert 
cognitive effects.  
 
Limitations and future directions 
The experimental paradigms used in this thesis had a number of limitations, primarily 
regarding pharmacological probes and behavioural tasks. Atomoxetine and citalopram 
were only ever deployed as single acute doses yet both compounds usually take weeks to 
achieve efficacy in clinical studies (269). Nonetheless, the comparative ability of 
methylphenidate and cabergoline to facilitate specific and measurable performance 
improvements following acute doses has relevance for better defining pharmacological 
mechanisms, drug holidays in ADHD (270) and, more controversially, cognitive 
enhancement in healthy adults (271). Another pharmacological limitation was the difficulty 
in finding highly specific receptor selective agents, particularly for specific dopamine 
reuptake, D1, and α2A, that were safe for use in humans and had not been examined 
before. Regarding behavioural task design, it has been pointed out that the EAT’s capacity 
to exclusively measure GNG inhibition may be diluted by the requirement for working 
memory during repeat no-go trials (8). The same review acknowledged, however, that 
having two classes of no-go trial increased task complexity facilitating more unaware 
errors (8). This problem of ‘impurity’ in executive function tasks remains an issue for the 
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entire field (3). Ideally, our error awareness studies would have included an additional eye-
tracking paradigm, which would have allowed interesting within-subject comparisons of the 
effect of task type under specific neurochemical conditions. With respect to imaging, it 
would have been desirable to compare the fMRI correlates of SST and GNG stopping as a 
function of drug condition, which would have allowed further comment on whether these 
forms of response inhibition are truly dissociable. There is also the possibility that the 
BOLD changes might have been influenced by drug determined hemodynamic responses, 
such as alterations to blood pressure and heart rate, which can sometimes be seen with 
methylphenidate.  
 
In the future we hope to deploy refined and optimised versions of our cognitive tasks with 
novel and specific treatments for executive dysfunction. This will include using of clonidine, 
amisulpride and idazoxan to see if selective receptor agents can modulate specific 
cognitive functions. In addition, by developing combined imaging techniques, such as 
simultaneous EEG and fMRI, we should be able to describe the temporal and anatomical 
localisation of discrete cognitive events with greater resolution.  
 
Empirical probing of the inverse agonism hypothesis of methylphenidate action will require 
an experimental paradigm that bridges the gap between animal models and human 
research. Using patient-derived induced pluripotent stem cells (iPSCs) could fulfil this need 
and such systems have already been used in schizophrenia and autistic spectrum disorder 
research (272, 273). iPSCs are somatic cells that have been reprogrammed back into an 
embryonic state that has the ability to differentiate into any cell type, including 
dopaminergic neurons (272). The particular advantage of iPSCs in this context is that 
somatic cells can be harvested not only from patients who have executive control deficits 
that are known to ameliorate with methylphenidate but also from their unaffected siblings. 
This would allow two distinct cell lines, one of which holds the genetic loading for a proven 
yet pharmacologically reversible executive control deficit, and a second genetically similar 
yet behaviourally unaffected control. If these cell lines were differentiated into 
dopaminergic neurons they would offer an excellent opportunity to study the human 
cellular action of methylphenidate in an informed context. Specifically, patch clamp 
recording might shed light on how varying methylphenidate concentrations influence tonic-
phasic transitioning. These variations could be contrasted against dopamine transporter 
polymorphisms and what is known about polymorphisms and methylphenidate response in 
clinical populations. Such information might then be speculatively compared to the 
genotype and methylphenidate dose-performance curves of individual cell donors. The 
speed and magnitude of synaptic dopamine efflux under methylphenidate could also be 
contrasted against potent dopamine reuptake inhibitors to see if the rodent model data 
supporting inverse agonism (232) can be replicated in human cell lines. Moving beyond 
methylphenidate inverse agonism studies, patient derived iPSCs might even be able to be 
used as screening systems for novel compounds that seek to replicate methylphenidate’s 
cellular effects before progression to human studies.   
 
In the medium term it is hoped that the results from this thesis will contribute to greater 
precision in describing cognitive deficits that are better matched to specific neurochemical 
systems and modulation possibilities. To some degree, this is already available when 
trying to treat clinical disorders that emphasise emotional symptoms, for example, in major 
depression the detection of melancholia or interpersonal rejection sensitivity point to 
specific pharmacological approaches (274). Similarly focused treatments for executive 
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dysfunction as yet remain unavailable despite their widespread prevalence in psychiatric 
disorder and substantial economic burden to society (275).  
  
 
Neurochemical and neurophysiological bases of executive control 
L. Sanjay Nandam 
 
Page 42 of 62 
 
Appendices 
General Methods 
Participants 
In this thesis two cohorts of participants were studied. Chapters 1, 2 and 3 examined the first 
cohort of 24 participants, whereas in Chapter 4 a second cohort of 25 participants was studied. 
The recruitment, inclusion and exclusion processes for both cohorts were identical.  
 
All participants were 18 to 35 year old, right-handed, non-clinical, Caucasian male volunteers 
recruited by advertisement at the University of Queensland, Australia. Participation was restricted 
to those of Caucasian ethnicity (all four grandparents had to be Caucasian) to minimise potential 
variations in drug metabolism. Candidates were then interviewed by a consultant psychiatrist (LS 
Nandam) and excluded if they reported history of psychiatric or neurological disorder including 
head injury, previous usage of psychiatric medication, or significant illicit drug use (significant was 
defined as [a] use of any illicit substances within the last month; [b] >5 lifetime intake of any illicit 
drug except cannabis; [c] more than monthly cannabis intake, smoking [>5 cigarettes/week], or 
alcohol dependence [>24 units/week]). They were also excluded if they had contraindications to 
the study drugs. The consultant psychiatrist also reviewed results from the M.I.N.I. Screen (276) 
and the Kessler K10 (277) to corroborate the interview findings. Participants completed the 
Connersʼ Adult ADHD Rating Scale (20) and the Barratt Impulsivity Scale (20). Blood pressure 
(BP), heart rate, weight, and height were recorded. 
 
The cohort studied in Chapters 1, 2 and 3 was tested at the same time and on the same day for 
four consecutive weeks. At each testing session the participants were given (in a double blind and 
randomised order) a single blue gelatine capsule that contained either methylphenidate 30mg, 
atomoxetine 60mg, citalopram 30mg or dextrose placebo. Accordingly, over the four weeks each 
participant received all drug conditions. Participants were required to fast for at least one hour 
before drug administration and caffeine was not to be taken on test days. After drug administration, 
participants rested in a quiet room for 90 minutes before commencing the SST and then the EAT, 
with the latter task being done whilst the participants simultaneously underwent fMRI. Participants 
also completed visual analogue scales (VAS) to assess possible acute drug effects on mental state 
(30). The sixteen opposing subjective states in the VAS were rated at baseline, +90 and +180 
minutes after capsule administration. A log transformation was applied to the items. VAS factors of 
‘alertness’, ‘contentedness’ and ‘calmness’ were calculated by taking the mean transformed score 
across items for each time point. Each factor was then subject to a 4(drug) by 3(time) repeated 
measures ANOVA. There were no significant drug × time interactions [alertness: F(6,132) = 1.65, p 
> 0.05; contentedness: F(6,132) = 1.62, p > 0.05; calmness: F(6,132) = 1.82, p > 0.05]. Blood 
pressure was also recorded at baseline and then again at time-points +60 and +180 minutes. 
There were no significant drug by time-point interactions for either systolic (drug×time: F(6,132) = 
2.00, p > 0.05) or diastolic (drug×time: F(6,132) = 1.18, p > 0.05) blood pressure. 
 
The Chapter 4 cohort was tested at the same time and on the same day for two consecutive 
weeks. At each testing session the participants were given (in a double blind and randomised 
order) a single blue gelatine capsule that contained either cabergoline 1.25mg or dextrose placebo. 
Accordingly, over the two weeks each participant received both drug conditions. Participants were 
required to fast for at least one hour before drug administration and caffeine was not to be taken on 
test days. After drug administration, participants rested in a quiet room for 90 minutes before 
commencing the SST and then the EAT. There was no imaging component for the Chapter 4 
cohort. They also completed the VAS and blood pressure readings at baseline, +90 and +180 
minutes after capsule administration, There were no significant drug × time interactions for the 
three VAS factors [calmness: F(2, 48) = 1.05, p > .05; alertness: F(2, 48) = .14, p > .05; 
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contentedness: F(2, 48) = 2.53, p > .05]. There were no significant drug by time interactions for 
systolic blood pressure, F(2, 48) = .74, p > .05, or diastolic blood pressure, F(2, 48) = 1.59, p > .05. 
 
The Stop Signal Task 
In this thesis, action cancellation was assayed via the stop signal task (SST). The SST 
consisted of 512 go trials where either ‘X’ or ‘O’ appeared on a computer. Each trial 
commenced with a small ‘+’ as a visual fixation point of 500msec duration, which was 
replaced with a blank screen for 100msec before the letter appeared (See Figure 2). 
Participants were instructed to rapidly press either a right button in response to the X, or a 
left button in response to the O. The stop stimulus (or stop signal) consisted of a red box 
that would appear around the go stimulus on 25% of trials (See Figure 2). Upon 
appearance of the stop signal, which always came after a go stimulus, the participant was 
instructed to withhold the button press. The delay between the stop signal and go stimulus 
is known as the stop signal delay (SSD). At the commencement of the task the SSD was 
set to 250msec but was then dynamically adjusted in increments of 50msec dependent on 
the participant’s inhibitory performance. Successful withholding in response to a stop 
signal resulted in an increase of the SSD, whereas unsuccessful withholding produced a 
decrease in SSD facilitating inhibitory success. This dynamic adjustment of the SSD 
meant that participants eventually successfully withheld on approximately 50% of stop 
trials. Accordingly, we were able to derive the stop signal reaction time (SSRT) at a 50% 
inhibition threshold by calculating [mean reaction time to go stimuli] – [SSD]. We used the 
SSRT as a key dependent variable in measuring the efficacy of action cancellation with 
shorter SSRTs indicating better inhibitory performance. We also measured variability of 
mean reaction time to go stimuli as a marker of attention.  
 
 
Figure 2 The Stop Signal Task (SST). [A] Go trial [B] Stop trial showing the stop signal delay (SSD)  
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The Error Awareness Task 
In this thesis motor action restraint and the conscious detection of errors were assayed via 
a Stroop motor GNG paradigm, the Error Awareness Task (EAT). During the EAT go trials 
consisted of a stream of single colour words in incongruent colour font (such as the word 
‘RED’ written in a blue font). Each word was presented to the participant for 800msec 
followed by a 700msec inter trial period. Participants were instructed to respond to each go 
trial with a single button press using their right index finger but to withhold this response if 
either of two no-go conditions occurred.  
 
The first no-go condition was when the same word appeared on two sequential trials 
regardless of its font colour; this is known as a ‘repeat no-go’. For example, Figure 3 
shows a repeat no-go where the word ‘BLUE’ occurs twice in the sequence (first in green 
font and then again in red font). To make the correct response, the participant would have 
needed to withhold their prepotent go trial button press when the second ‘BLUE’ appeared.  
 
The second no-go condition was when word colour and font colour were congruent; this is 
known as a ‘colour no-go’. For example, Figure 3 shows a colour no-go when the word 
RED appears with matching red font colour. To make the correct response, the participant 
would have needed to withhold their prepotent go trial button press when RED in ref colour 
font appeared (see Figure 1).  
 
 
 
 
Figure 3 The Error Awareness Task showing the two no-go conditions  
 
The requirement to monitor for these two classes of no-go was intended to make the task 
harder and thereby produce greater errors of commission. In the EAT, an error of 
commission consists of inadvertently pressing the go trial button when one of the two no-
go conditions has occurred and the correct response would have been to withhold. For 
example, in Figure 1 a repeat no-go has not been detected and the participant has 
inadvertently pressed the L(left) button thereby making an error of commission.  
 
If the participant detected they had made such an error, they were instructed to forego the 
usual go trial button press (L in Figure 1) on the trial immediately following the error and 
instead press a second button (R, right, in Figure 1). Pressing the second button indicated 
that they were ‘aware’ they had made a commission error.  
 
Accordingly, we were able to differentiate between undetected (unaware) and detected 
(aware) errors of commission for GNG behaviour (as shown in Figure 1),  
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FIGURE 1 | The Error Awareness Task (EAT). The EAT presents a serial
stream of single color words in colored fonts. Participants were trained to
respond to each of the words with a single “Go trial” butt press, and to
withhold this response when either of two different circumstances arose. The
first was if the same word was presented on two consecutive trials (Repeat
No-go), and the second was if the word and font of the word matched (Color
No-go). To indicate “error awareness” participants were trained to forego the
regular go trial button response and instead to execute the alternative “error
awareness” response following any commission error. Past studies have
demonstrated that error-related BOLD signal is uni fluenced by the
awareness response itself (Hester et al., 2005). Although levels of awareness
undoubtedly vary on a continuum, we made a qualitative distinction between
“Aware” and “Unaware” errors to facilitate our event-related fMRI analysis.
Figure reproduced from Hester and colleagues (2012).
Color names, printed in colored font, were presented in a serial
stream. The three samples completed versions of the task that
differed slightly in the stimulus presentation and inter-stimulus
interval duration, 900/600ms (Hester et al., 2005, 2009a) or
800/700ms (Hester et al., 2012). Participants were instructed
to respond to the presentation of each stimulus with a but-
ton press (a “Go” response) unless the stimulus was a “lure,”
in which case they were to withhold their response (“No-go”
response). Lures could take two forms: a “Repeat lure” in which
the same word was presented on two consecutive trials; and a
“Color lure” defined by the congruence of the color name and
the font color. Color lures were defined by incongruence between
the color word and the font in the two earlier studies (Hester
et al., 2005, 2009a); and by congruence in the third study (Hester
et al., 2012). Adopting competing inhibition rules exploits the
different strengths of the stimulus-response relationships such
that the overlearned behavior of reading a word would make the
Repeat rule more salient than the Color rule. Previous research
has suggested that this may cause the Color rule to be sup-
pressed, producing more Color errors than Repeat errors and
potentially affecting participants’ awareness of the errors (Hester
et al., 2005, 2009a). Participants were instructed to execute an
alternative “error awareness” response on the “Go” trial following
an error.
The 2005 and 2009 studies presented five blocks of 225 trials
during fMRI data acquisition with lure trials pseudo randomly
distributed across the 1125 experimental trials. The 2012 study
presented six blocks of 225 trials. There were minor differences to
the ratio of No-go: Go trials across the three experiments, with
128 lures presented in the earlier study (Hester et al., 2005) and
125 and 150, respectively, in the two later studies (Hester et al.,
2009a, 2012). On average, a lure was presented every 8.95 trials,
corresponding to an average inter-lure interval of 13.42 s. While
some other variations in the design of these tasks existed, only
the commission errors made during the aforementioned design
were considered, with the assumptionmade that the event-related
analysis would minimize the influence of unrelated task variance.
SCANNING PARAMETERS AND DATA ANALYSES
Scanning for the original study (Hester et al., 2005) was con-
ducted using contiguous 5mm sagittal slices covering the entire
brain from a 1.5 T Siemens Vision scanner using a single
shot, T2*-weighted echo-planar pulse sequence (TE = 50ms;
TR = 2000ms; FOV = 256mm; 64× 64 matrix). High resolu-
tion T1-weighted structural MPRAGE images (FOV = 256mm,
thickness = 1.0mm isotropic with no gap) were acquired prior
to functional imaging to allow subsequent activation localization
and for spatial normalization. Stimuli were delivered using an
IFIS-SA stimulus-delivery system (MRIDevices Corp.,Waukesha,
Wisconsin), which was equipped with a head-coil-mounted
640× 480 LCD panel. This shielded LCD screen is mounted
on the head-coil, directly in the subjects’ line of vision. Foam
padding was used to limit head movements within the coil.
Scanning for the second study (Hester et al., 2009a) was con-
ducted using a 3T Philips Achieva scanner in which foam padding
was used to restrict head movements. Contiguous 3.5mm
sagittal slices covering the entire brain were collected using a
gradient-echo echo-planar imaging (EPI) sequence (TE = 35ms;
TR = 2000ms; FOV = 224mm). High resolution T1-weighted
structural MPRAGE images (FOV = 256mm, isotropic 0.9mm
voxels) were acquired following functional imaging to allow sub-
sequent activation localization and spatial normalization. Stimuli
Frontiers in Human Neuroscience www.frontiersin.org June 2012 | Volume 6 | Article 177 | 3
 
Neurochemical and neurophysiological bases of executive control 
L. Sanjay Nandam 
 
Page 45 of 62 
 
 
 
Figure 1 The EAT with undetected (unaware), detected (aware) errors and correct no-go responses  
 
Key dependent variables during the EAT included percentage of commission errors on no-
go trials (showing efficacy of action restraint) and the mean correct go time (which allowed 
examination of whether there was a relationship between speed of responding and 
commission errors and reaction time variability). Percentage of aware versus unaware 
errors was also recorded. Seeing whether any of these parameters could be influenced via 
neurochemical modulation was a key objective of this thesis.  
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the font color. Color lures were defined by incongruence between
the color word and the font in the two earlier studies (Hester
et al., 2005, 2009a); and by congruence in the third study (Hester
et al., 2012). Adopting competing inhibition rules exploits the
different strengths of the stimulus-response relationships such
that the overlearned behavior of reading a word would make the
Repeat rule more salient than the Color rule. Previous research
has suggested that this may cause the Color rule to be sup-
pressed, producing more Color errors than Repeat errors and
potentially affecting participants’ awareness of the errors (Hester
et al., 2005, 2009a). Participants were instructed to execute an
alternative “error awareness” response on the “Go” trial following
an error.
The 2005 and 2009 studies presented five blocks of 225 trials
during fMRI data acquisition with lure trials pseudo randomly
distributed across the 1125 experimental trials. The 2012 study
presented six blocks of 225 trials. There were minor differences to
the ratio of No-go: Go trials across the three experiments, with
128 lures presented in the earlier study (Hester et al., 2005) and
125 and 150, respectively, in the two later studies (Hester et al.,
2009a, 2012). On average, a lure was presented every 8.95 trials,
corresponding to an average inter-lure interval of 13.42 s. While
some other variations in the design of these tasks existed, only
the commission errors made during the aforementioned design
were considered, with the assumptionmade that the event-related
analysis would minimize the influence of unrelated task variance.
SCANNING PARAMETERS AND DATA ANALYSES
Scanning for the original study (Hester et al., 2005) was con-
ducted using contiguous 5mm sagittal slices covering the entire
brain from a 1.5 T Siemens Vision scanner using a single
shot, T2*-weighted echo-planar pulse sequence (TE = 50ms;
TR = 2000ms; FOV = 256mm; 64× 64 matrix). High resolu-
tion T1-weighted structural MPRAGE images (FOV = 256mm,
thickness = 1.0mm isotropic with no gap) were acquired prior
to functional imaging to allow subsequent activation localization
and for spatial normalization. Stimuli were delivered using an
IFIS-SA stimulus-delivery system (MRIDevices Corp.,Waukesha,
Wisconsin), which was equipped with a head-coil-mounted
640× 480 LCD panel. This shielded LCD screen is mounted
on the head-coil, directly in the subjects’ line of vision. Foam
padding was used to limit head movements within the coil.
Scanning for the second study (Hester et al., 2009a) was con-
ducted using a 3T Philips Achieva scanner in which foam padding
was used to restrict head movements. Contiguous 3.5mm
sagittal slices covering the entire brain were collected using a
gradient-echo echo-planar imaging (EPI) sequence (TE = 35ms;
TR = 2000ms; FOV = 224mm). High resolution T1-weighted
structural MPRAGE images (FOV = 256mm, isotropic 0.9mm
voxels) were acquired following functional imaging to allow sub-
sequent activation localization and spatial normalization. Stimuli
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